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Abstract 
 
The main aim of my research, presented here, is to develop proteomic research techniques, 
for their use in biomarker discovery and identification. This is broken down into three 
main chapters: 
• Biomarker Identification in Stroke Brain guided by MALDI-imaging. 
• Evaluation of the Effectiveness of Heat Treatment for Prevention of Proteomic 
Sample Degradation using Label Free Relative Quantitation. 
• Discovery and Identification of Biomarkers for Hypertension  
Within these chapters special attention is paid to sample preparation, development and 
assessment of new methods for biomarkers discovery and identification, the importance of 
experimental design and the application of relevant and useful statistical methods to enable 
the mining of useful information from rich datasets. The biological changes in stroke 
induced mouse brain tissue are studied, the prevention of degradation to tissue samples by 
a novel heat treatment method and changes to plasma samples from hypertensive, wild 
type and a congenic strain of rat are also studied. The outcomes of this work are multiple, 
namely: 
• The identification of a possible marker for stroke from mouse brain tissue 
• The effect of a new heat treatment device on proteomic data obtained from mouse 
brain tissue 
• The novel application of a statistical analysis to a new type of dataset (LC-MS and 
label free quantitation of biological samples) 
• The identification of possible biomarkers for hypertension in rat plasma using this 
method 
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1 Introduction 
Proteomics is a field that has emerged in the post-genomic era (1). The sequencing of the 
human genome revealed that we have around 40 000 genes (2). Subsequently this number 
was reduced to 20 000 to 25 000 (3). Each human gene may encode several different 
proteins, resulting in a huge combination of different proteins in the human body. This 
means that studying genes alone cannot solve the many different mysteries of disease. If 
DNA is the blueprint of life then proteins are the building blocks from which life is 
constructed, and understanding their functions, expression and interactions is vital in the 
quest for information regarding life and disease. 
Proteomics is essentially the study of the complete set of proteins in a cell, organ or 
organism (4), and the phrase was first coined in 1995 by Wasinger et al (5). While the 
genome is static, the proteome is dynamic and ever changing, either as a reaction to 
environment or due to development. Understanding these dynamic processes will be 
important in understanding mechanisms of disease, and one of the most important 
applications of proteomics is the discovery and identification of biomarkers for disease (6). 
Additionally, proteomics encompasses expression patterns, interactions and functional 
states of proteins present in a cell, organism or organ. Problematically the increased 
importance of proteomics has not been accompanied with an improvement in analytical 
tools and methods, in particular if compared to the tools available for the study of 
genomics such as sequencing techniques and expression microarrays. There are many 
challenges and issues to overcome in the study of proteomics. This review of the literature 
concentrates on the technologies and tools used in the research presented here, including 
liquid chromatography, mass spectrometry and label free relative quantitation, as well as 
alternative proteomic methods, such as differential gel electrophoresis, capillary 
electrophoresis and isotopic labelling for quantitation. The theory behind these 
technologies is also covered, as well as the thought process behind biomarker discovery 
and identification. The diseases studied and more specific techniques used are covered in 
the short introduction at the start of individual chapters. 
1.1 Biomarker Discovery 
Diagnosis is one of the most important stages in treating disease, and is the first line of 
defence available to a clinician. Sometimes diagnosis will be visual, or may be the result 
of, for instance, a biopsy. Early diagnosis and selection of appropriate treatment can be 
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critical, and mean the difference between a failing or successful treatment for certain 
diseases. There are many treatments which have been developed, that are not always 
successful due to late diagnosis. It is thought that biomarkers in body fluids may be one of 
the solutions to this problem. 
A biomarker is a something which can be measured and used to diagnose or classify 
disease and also to measure progress and therapeutic response of disease. Body fluids pass 
through tissues, including diseased tissues, and collect biomolecules, including peptides 
and proteins, that can indicate the status of health. If these biomolecules can indicate the 
presence of a disease they are a type of biomarkers. The ideal marker, in the context of this 
work, is a biomolecule that is present only in diseased patients and absent in healthy 
controls, or vice versa. In reality a biomarker will most likely be detected as a change in 
abundance of the marker or relative abundance between markers. Additionally, markers 
can also occur as more than one biomolecule, for instance a disease could be characterised 
by the presence of a set of markers. This means that it is important to characterise as many 
biomolecules as possible, with high accuracy and resolution (7). Biomarkers can be 
detected in different body fluids such as blood, urine, cerebrospinal fluid and saliva. 
Biofluids such as plasma and urine, do not have an associated genome or transcriptome, 
meaning that gene expression measurement is not possible (8). This is why proteomics, as 
well as metabolomics, is such an important field for biomarker discovery in biofluids (9). 
Urine has been an attractive fluid for the study of biomarkers as it is non-invasive to obtain 
in large quantities and is less complex than blood or plasma, due to the much lower protein 
concentration (10). Repeated sampling from the same individual is also commonly 
achievable. A further attractive quality of urine for biomarker discovery is that it contains 
proteins and peptides in their native state that are of a relatively low molecular mass and 
are highly soluble. This means they can be analysed in their natural state with little 
manipulation (11). Urine is also a relatively stable fluid, and the urinary proteome has been 
shown to be stable at 4 ºC for up to 3 days or at room temperature for up to 6 hours. It is 
thought that this is due to its storage for several hours in the bladder, meaning that 
proteolytic degradation by endogenous proteases is complete by time of voiding (11). 
Urine can be especially useful for diagnosis of kidney disease (12). However, urine does 
have certain disadvantages as a fluid for biomarker discovery. Urine samples have a wide 
variation in protein concentration, due to fluid intake of the individual. This can be 
normalised using creatinine concentration (13) or other peptides present in urine (14) but 
this does add an additional complication to the analysis. Urine samples also have 
inconsistent pH levels that can alter protease activity, leading to greater sample variability 
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(15). There are also clear differences between early and mid-stream urine samples (16), 
meaning that sample collection must be well controlled (17). 
Plasma, or serum, is commonly studied with regards to cardiovascular disease (18-23) and 
cancer (24-28), as the biomolecules found in blood directly reflect the health of an 
individual and can indicate the presence and stage of disease. Serum represents the soluble 
fraction of blood that remains following clotting and is therefore simpler than plasma, 
which contains clotting factors. Plasma is obtained from blood following the addition of an 
anti-coagulant, such as heparin or EDTA, in the presence of an inert powder, such as glass 
beads. The advantage of using serum over plasma is its reduced complexity and lower 
protein concentration, however the clotting process is not uniform, unlike the preparation 
of plasma, and interesting proteomic and metabolomic features may be lost with the 
insoluble blood clot (8). Additionally, an array of proteases are activated when clotting 
occurs, generating degradation products, meaning that the protein profile of serum is quite 
different from that of plasma. As a consequence of this the Human Proteome Consortium 
has recommended that plasma is the fluid of choice, as opposed to serum, for proteomic 
studies (29). Plasma potentially contains elements of all proteins in the body meaning 
plasma has a high potential for biomarker discovery. Plasma is studied in the research 
presented here, specifically in Chapter 4, “Discovery and Identification of Biomarkers for 
Hypertension”. 
Cerobrospinalfluid is another alternative for biomarker discovery, particularly with regards 
to neurodegenerative diseases (30). 
Tissue samples are also studied in this work in Chapter 2, “Biomarker Identification in 
Stroke Brain Guided by MALDI-imaging” and in Chapter 3, “Assessment of Denator Heat 
Treatment for Prevention of Proteomic Sample Degradation using Label Free Relative 
Quantitation”.  
The local concentration of any biomarker will be high in the vicinity of the diseased tissue 
itself, particularly with regards to diseases such as cancer or stroke, where a clear site of 
disease is present. Fine-needle aspiration biopsy is a method used to obtain samples from, 
for example, cancerous tumours (31). An obvious disadvantage of this is the invasive 
nature of this procedure. Also, there may be many different classes of cell types present in 
biopsies of this type, hence the development of laser microdissection (LMD) techniques. 
LMD is used to rapidly separate populations of cells from tissue, which has been thinly 
sliced using a cryostat device, for further analysis (32). However, LMD can subject 
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samples to subjective sample processing; both at the selection of relevant cell types and 
also during the dissection process itself. It should be taken into consideration that this can 
have an impact on the quality and results of subsequent studies (33). Formalin-fixed, 
paraffin-embedded (FFPE) tissue is a commonly encountered clinical sample from biopsy 
samples or samples of a surgical origin and can be a valuable resource. Unfortunately the 
protein cross-linking, due to the formalin fixing, makes protein profiling by western blot 
and protein microarray analysis difficult (34;35). Currently, immunohistochemistry is the 
most routinely used method for analysis of FFPE tissue, which is a guided technique, 
whereby a particular protein is stained using tagged antibodies. There remains a lack of 
data about protein expression in normal and cancerous cells, due to the difficulties 
associated with dealing with these samples (36;37). It has been shown to be possible to 
disrupt the cross-linked proteins in FFPE tissue for protein identification using mass 
spectrometry (36), meaning it may be possible to unlock the data potential from these types 
of samples. 
Biological samples and proteins, protein complexes and biomarkers in particular are often 
very complex. This means that an effective, unbiased proteomic profiling approach, 
without any pre-selection, may require a multi-discipline approach to accomplish protein 
identification and quantitation. This means that there are several optimisation steps in 
method and technology development, including sample collection, storage and preparation, 
protein and peptide separation, protein and peptide identification and quantitation, 
including statistical analysis, and finally independent confirmation and validation. These 
steps are discussed further in following sections. 
Clinically relevant biomarkers (i.e. markers that can be measured in a clinical sample, such 
as plasma or urine) can provide a “snap shot” view of a specific stage of disease. Therefore 
it is important to identify specific plasma proteins without complication by the presence of 
abundant plasma proteins. This is discussed in more detail in section 1.10 and additionally 
in Chapter 4, “Discover and Identification of Biomarkers for Hypertension”. Valuable, 
usable biomarkers are specific, sensitive and reproducible. It is worth noting that the 
majority of FDA approved biomarkers for cancer are single proteins found in serum, 
CA19-9 for pancreatic cancer, CA125 for ovarian cancer and PSA for prostate cancer 
(38;39).  
In my work, presented here, an unguided proteomic method is developed and used for 
biomarker discovery, assuming no prior knowledge of disease. This means that not only 
can possible biomarkers be unearthed, but possibly mechanisms of disease can be 
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understood and previously unknown functions of disease discovered. This method has been 
utilised by Kiga et al (40) for the identification of stroke plasma biomarkers in 
spontaneously hypertensive stroke prone rats, which is the same genetic model used in 
chapter 4 of the work presented here. Kiga et al used an unguided biomarker discovery 
method and successfully identified haptoglobin as a biomarker candidate for stroke. This 
identification was validated using traditional biochemical methods. Similarly, Silbger et al 
(41) have used an unguided biomarker discovery method for human myocardial infarction 
plasma samples. The combination of mass spectrometry with bioinformatic methods 
enabled the identification of potential biomarkers. The use of these methods is discussed in 
more detail in the introduction to chapter 4 “Discovery and Identification of Biomarkers 
for Hypertension”. 
1.2 Sample Collection and Storage 
As sample collection and storage is the initial step in any study it is vital that it is 
performed correctly. It has been shown that sampling procedures have the greatest effect 
on proteomic data from plasma samples, whereas handling and storage have relatively 
small effects (42). However, it is still important that standardised protocols for sample 
handling and storage are developed and adhered to, if results are ever to become 
comparable between laboratories (43). Studies have also shown that the standardisation of 
sample tubes is important for reliable plasma analysis (44). It should be considered that 
commercially available blood collection tubes contain many components, including 
silicones, PEGs and polymers, which may interfere with mass spectrometric analysis (45).  
Additionally, the sample tubes used will influence adsorption of plasma protein onto the 
inner surfaces of the tubes. For instance, significant differences have been seen in the mass 
spectrometric data from serum samples collected in glass tubes containing no anticoagulant 
in comparison with plastic serum separator tubes (46). 
A further consideration is the anti-coagulant used, as this can also influence the proteomic 
data obtained from the plasma samples (47). Platelets tend to be more stable in citrate anti-
coagulants, but this is often used in liquid form which dilutes the plasma samples. Heparin 
is used to enhance the activity of antithrombin III, but it also binds to other proteins (48). 
EDTA can lead to platelet clumping and aggregation, meaning that plasma protein profiles 
from samples treated with EDTA are most different from those obtained from samples 
treated with citrate or heparin (42;49). 
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Plasma samples are also affected by storage conditions, with minimal changes detected 
within 6 hours at room temperature, but noticeable changes detected after 8 hours at room 
temperature, with even more pronounced changes after 24 hours (50). For plasma or serum 
stores at 4ºC minimal changes were seen after 24 hours, but more significant changes were 
seen after 48 and 96 hours (51). Samples stored at -20 ºC, -80 ºC or in liquid nitrogen show 
no significant changes, even with long term storage (43;51), however freeze/thaw cycles 
can change sample composition, due to protein precipitation, aggregation and surface 
adsorption (46;47). 
As there are many steps in sample collection and storage that can influence sample 
composition and proteomic profiles it is vital that these steps be kept constant across a 
study, if data is to be in any way comparable. Ideally, universally used standardised 
protocols would be accepted, creating comparable datasets between laboratories.  
The sample collection and preparation methods used in my research will be discussed 
further in the introduction to each chapter. 
1.3 Mass Spectrometry 
Recent advances in mass spectrometry (MS) have been one of the major driving forces 
behind progress in proteomics (52). A mass spectrometer is able to determine the 
molecular weight of chemical compounds by ionising, separating, and measuring ions 
according to their mass-to-charge ratio (m/z). The ions are generated in the ionisation 
source by inducing either a positive or negative charge. Once the ions are formed in the gas 
phase they can be directed into a mass analyser, separated according to mass and finally 
detected. The result of ionisation, ion separation, and detection is a mass spectrum that can 
provide molecular weight or even structural information. 
In the research presented here, an electrospray quadrupole time-of-flight mass 
spectrometer is the main instrument used. This is the main focus of the introduction to 
mass spectrometry discussed here. 
The mass-to-charge ratio of the ions can be determined in several ways, including the exact 
time taken for the ion to reach the detector (used in time-of-flight mass analysers, TOF), or 
by trapping the ions in an electric or magnetic field and sequentially filtering them out 
based on size (with the smallest first) by scanning the rf-voltage making ion trajectories 
sequentially unstable (used in trap analysers). This can then be used to identify an 
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unknown sample, by the mass of the molecule and of the fragments created. The six 
primary components of any mass spectrometer are the vacuum system, sample introduction 
device, ionisation source, mass analyser, ion detector and data collection and storage.  
Until the early 1980’s mass spectrometry was not routinely applied to proteins, as proteins 
were too fragile and of too large a size to withstand the processes of ionisation. 
Developments of ‘soft’ ionisation techniques (53), such as electrospray mass spectrometry 
(ESI-MS) and matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) 
have overcome these problems, allowing the detailed analysis of proteins. Mass 
spectrometry has now become an important tool for characterisation and identification of 
proteins and peptides from biological samples and advances in this area have enabled the 
identification of proteins with an unprecedented speed and sensitivity. 
1.3.1 Time-of-flight Mass Spectrometry 
The significance of TOF mass analysers has grown over the last 20 years, especially in the 
biomedical fields. The TOF mass analyser was originally described in 1946 by Stephen 
(54). By 1951 Goudsmit et al (55) were using the TOF mass spectrometry to measure the 
time of flight of ions for a number of complete revolutions in a magnetic field allowing, in 
particular, the mass of heavier elements to be determined. 
In a TOF analyser, ions are separated by differences in their velocities as they move in a 
straight path toward a collector in order of increasing mass-to-charge ratio. The first 
commercial instrument was marketed by the Bendix Corporation in 1955, and was based 
on a design by Wiley and McLaren (56). 
Put in the simplest terms, time-of-flight analysis works by accelerating a set of ions to a 
detector with the same amount of energy. As the ions have the same energy but a different 
mass, the ions reach the detector at different times. The lower mass ions reach the detector 
first because of their greater velocity and the higher mass ions take longer. 
The arrival time of an ion at the detector is dependent upon the mass, charge, and kinetic 
energy of the ion. The TOF analyser consists of a field free drift region, D, which is held at 
constant electrical potential, and a source region, S, where a gradient in electrical potential 
exists, Vs.  Ions which are present in the short source region are accelerated into the drift 
region by the action of the electric field, Es.  Analysis is based on the principle that ions of 
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different m/z values will have been accelerated to the same kinetic energy, EK, in the 
source:  
SK zeEE =    (1.3.1) 
 
where e is the charge on an electron in coulombs and z is the number of charges. However, 
ions of different mass will exhibit different velocities (v):   
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where m is the mass of the ion.  The time, t, taken for ions to traverse the length, d, of the 
drift region is also dependent on the mass of the ions: 
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Thus, the time that is required for each ion to traverse the drift region is different: high 
mass ions take longer to reach the detector than low mass ions.  The basic formula by 
which the time spectrum can be converted to a mass spectrum is given in the equation 
1.3.4: 
( )22 dteEzm S=   (1.3.4) 
A major limitation in achieving higher resolution in TOF mass analysers is the 
consequence of the distribution in time, in space and in kinetic energy of the initial ion 
packet.  It must be assumed for the purposes of calculation that all the ions will be 
accelerated from the same position and have the same EK.  However, this is not the case as 
there are a number of sources producing inaccuracy associated with ion formation and 
acceleration (57). 
1.3.2 Quadrupole Mass Spectrometry 
The quadrupole mass filter was first developed in the 1950s by Paul et al (58). Paul shared 
the Nobel Prize in Physics in 1989 for his work on ion trapping. In a quadrupole device, a 
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quadrupolar electrical field (comprising radiofrequency and direct-current components) is 
used to separate ions (59;60). Another instrument that Paul developed was the quadrupole 
ion trap, which can trap and mass-analyse ions using a three-dimensional quadrupolar 
radiofrequency electric field. The first commercial ion trap system was introduced in 1983 
by Finnigan MAT (San Jose, CAL, USA.), originally as a gas chromatography detector. 
More recently, ion trap instruments serve not only as gas chromatography detectors but 
also as liquid chromatography detectors and stand-alone mass spectrometers (61).  
Quadrupoles are made up of four parallel rods with a direct current (DC) voltage and a 
superimposed radio-frequency (RF) potential. Consequently, adjusting the RF potential 
and the level of the DC field component can effectively scan a mass range. Quadruples are 
tolerant of relatively poor vacuums and this makes them well-suited to electrospray 
ionisation, as the ions are produced under atmospheric pressure conditions.  Quadrupoles 
are now capable of routinely analysing up to a m/z of 3000. This is useful because 
electrospray ionisation of proteins and other biomolecules commonly produces a charge 
distribution below a m/z of 3000. Additionally, the relatively low cost of quadrupole mass 
spectrometers makes them attractive as electrospray analysers.  
Another type of mass spectrometer used in my research is the ion trap. The physics behind 
the quadrupole mass analyser and the quadrupole ion trap mass analyser is very similar. In 
an ion trap the ions are trapped in a radio frequency quadrupole field. One method of using 
an ion trap for mass spectrometry is to generate ions externally before injecting them into 
the trapping volume. The ions are then ejected and detected as the radio frequency field is 
scanned. It is also possible to isolate one ion species by ejecting all others from the trap. 
The isolated ions can subsequently be fragmented by collisional activation and the 
fragments detected to generate a fragmentation spectrum. The primary advantage of 
quadrupole ion traps is that multiple collision-induced dissociation experiments can be 
performed without having multiple analysers. Other important advantages include its 
relatively small size and the ability to trap and accumulate ions to increase the signal-to-
noise ratio of a measurement. Quadrupole ion traps have been utilised in many 
applications, mainly for the analysis of peptides and small molecules. 
MS can be used for peptide mass fingerprinting (PMF) (62). This is a technique that is 
used to identify proteins by matching the masses of the fragments to the theoretical peptide 
masses obtained from a protein database. Specific proteases, such as trypsin, cleave 
proteins at certain points in the amino acid chain. This means that it is possible to 
theoretically digest a protein, and predict the peptides that will be produced. As the masses 
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of amino acids are accurately known, a list of predicted peptide masses can be produced. 
This peptide mass information can be used to produce a unique ‘peptide mass fingerprint’ 
for the protein, which can then be used for fast identification of unknown proteins in a 
sample. Different databases have been developed which contain vast amounts of protein 
data and predicted peptide masses. These can be used to search mass spectrometric data 
against, and therefore identify proteins quickly and uniquely. A statistical scoring system is 
used to determine the accuracy of identifications. 
1.3.3 Tandem Mass Spectrometry 
In tandem mass spectrometry (MS-MS) the ions initially produced are then fragmented and 
analysed further. Tandem in space instruments, such as the Q-TOF, requires more than one 
analyser. The first is required for analyte isolation. The ions then pass through a collision 
cell where they are fragmented with an inert gas such as argon or nitrogen, and a second 
analyser is used for detection of the fragment mass to charge ratios. Quadrupole mass 
filters work well for MS-MS analysis as they can be used to allow only ions in a pre-
defined mass range to pass through the quadrupole, enhancing the sensitivity of the 
technique. 
Additionally, MS-MS can be used in a targeted manner. For instance, if certain features are 
of a particular interest, their masses can be chosen for preferential fragmentation, in order 
to attempt to ensure identifications are made. This method is used in my research presented 
here, namely in chapters 3 and 4.  
One of the major problems with biological samples, such as blood or urine, is that they can 
be extremely complex. This means that a separation technique or pre-fractionation method 
is needed prior to analysis by mass spectrometry. Commonly technologies such as high 
performance liquid chromatography (HPLC) and capillary electrophoresis (CE) are used to 
separate samples. This has resulted in particular interest in the development of methods for 
interfacing liquid separation techniques directly to mass spectrometry. This introduces the 
complication of attempting to maintain a high vacuum within the mass spectrometer, with 
various flow rate interfaces. Capillary electrophoresis uses flow rates of around 100 
nL/min whereas HPLC can use flow rates of over 1 mL/min. An additional consideration is 
the need to vaporise the eluent prior to ionisation.  
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1.3.4 Ionisation for Mass Spectrometry 
There are many different techniques used for ion production in mass spectrometry. These 
include amongst others: electrospray ionisation (ESI) (63-66), micro-electrospray 
ionisation (micro-ESI) (67;68), nano-electrospray ionisation (nESI) (69;70), fast atom 
bombardment (FAB) (71), atmospheric pressure chemical ionisation (APCI) (72), plasma 
desorption (73), laser ablation/desorption ionisation (LA, LDI) (74;75), and the workhorse 
of many biological studies, matrix assisted laser desorption ionisation (MALDI) (76). 
MALDI mass spectrometry is a form of laser desorption mass spectrometry, where sample 
molecules are laser-desorbed from a solid or liquid matrix containing a highly UV-
absorbing substance. The matrix protects the biomolecules from being destroyed by the 
laser beam and also facilitates vaporisation and ionisation, making it a widely used 
technicue in biological analysis. Additional advantages of MALDI mass spectrometry are 
that it is a sensitive technique with low sample consumption and is fairly quick and simple 
to use. 
Electrospray ionisation mass spectrometry (ESI-MS) techniques have had an influential 
impact on the ability to use mass spectrometry for the study of large biomolecules. 
Electrospray has become the most widely used LC-MS interface technique in modern mass 
spectrometry as it is a versatile mode for the production of gas phase analyte ions from 
solutions and is almost ideal for biological analytes.  Chapman may have used some of the 
initial elements of ESI with work performed in 1937 (77). However, it was research by 
Dole and colleagues in the 1960s that is usually credited as the birth of electrospray 
ionisation (78). It was not until the mid 1980s that its use as an interface for mass 
spectrometry was demonstrated by Fenn, revealing the power of the technique (79;80) and 
winning Fenn the Nobel prize for Chemistry in 2002.  
In ESI-MS, highly charged droplets dispersed from a capillary in an electric field are 
evaporated and the resulting ions are drawn into a mass spectrometry inlet. The charged 
droplet travels through the ambient air for a few milliseconds (81). During this time the 
radius of the droplet decreases due to solvent evaporation and the droplet approaches the 
point where the forces of surface tension and the Coulomb repulsion counterbalance each 
other. It then suffers what is commonly referred to as ‘Coulomb explosion’ or ‘Rayleigh 
fission’, after Lord Rayleigh (1882).  
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It has been shown that, under the influence of aerodynamic forces corresponding to ESI-
MS conditions, droplet fission occurs already at charge states of about 80% of the Rayleigh 
limit, where the forces of surface tension and the Coulomb repulsion counterbalance each 
other. All experimental investigations have shown that there was no ‘explosion’ of the 
droplet, but that the droplet surface formed a cone-like shape, from which a number, 
approximately 20, of smaller droplets are ejected (82;83). The primary droplet loses about 
15% of its charge and about 2% of its mass (84). From the primary droplet there are two or 
three successive uneven fissions until the charge state of the droplet becomes too low for a 
further fission. Following the evaporation of the remaining solvent the contents, analyte 
and electrolyte molecules and some additional ions, end up as a lowly charged residue. The 
daughter offspring droplets, however, undergo further fissions following the method of 
evaporation and fission just described. 
Finally, the evaporation of the remaining solvent leads to a ‘charge condensation’ on the 
analyte molecule and hence to a gas-phase analyte ion. It is thought that the resultant 
analyte molecules transferred to the gas-phase are not ‘dry’ gas-phase ions. This is due to a 
gradual transition from a very small charged droplet via a charged solvent-analyte cluster 
to a gas-phase molecule to which a number of charges, are attached (85). This is 
particularly believed to be the case for large biomolecules (86). 
Impurities may also be attached if they are present in the droplet. However, it has been 
reported that when proteins or peptides are the analyte, the impurity must be present in 
orders of magnitude higher concentration before complete suppression of the analyte ion is 
obtained in the mass spectrum. A possible explanation for this fact is that an influence of 
the analyte surface activity may lead to enrichment of analyte molecules in the offspring 
droplets, which are then preferentially released as ions, while the non-surface active 
impurities are more likely to remain in the lowly charged residue (87). 
Following repeated cycles of solvent evaporation and coulombic fissions by the droplets 
the gas-phase ions generated are guided to the counter electrode. The process by which 
gas-phase ions are generated is still under considerable debate with two main theories 
proposed; namely the ion evaporation model and the charge residue model. 
The charge residue model relies on the formation of extremely small droplets, radius of 
approximately 1 nm, which contain only a single ion. Solvent evaporation from the droplet 
will lead to the conversion of the droplet to a gas phase ion. Such a model was assumed to 
be the case by Dole et al (78) who first investigated gas-phase ion production by 
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electrospray. This charge residue model for gas-phase ion generation is now also known as 
the single ion droplet theory (SIDT).  
The ion evaporation model assumes that before the droplet reaches this ultimate stage prior 
to gas-phase ion generation, the field on the droplets surface becomes strong enough to 
overcome solvation forces and lifts a solute ion from the droplet surface into the gas-phase. 
This model was first introduced by Iribarne and Thomson (88) in 1976. Typically the 
droplets from which ion emission/evaporation becomes competitive with Rayleigh fission 
have a radius of R ≈ 8 nm and N ≈ 80 charges (88). It is proposed that under such 
conditions the droplet no longer undergoes further fission but emits gas-phase ions. Also as 
the charge, N, decreases emission can continue as the droplet radius, R, also decreases 
from further solvent evaporation. This model therefore allows the gas-phase ion production 
without the formation of extremely small droplets, R ≈ 1 nm, which contain a single ion. 
Also such emission can occur even when the droplet contains other solutes such as charge-
paired-electrolytes (89). 
At present the general consensus is that neither the charge residue model nor the ion 
evaporation model can account for all the experimental observations, and it has therefore 
been speculated that the two models describe different aspects of the observed process of 
gas-phase ion formation (90). 
In the mid 1990s Wilm and Mann described a revolutionary development to electrospray 
ionisation, which they described as microelectrospray (91). The idea they used was to 
apply a narrow, fused-silica capillary as an ESI emitter, instead of the routinely used, 
relatively wide, steel or fused silica capillaries. This reduced the internal diameter of the tip 
from 100 µm to 20 µm, leading to a decrease in the initial size of liquid droplets. In turn 
this reduced sample consumption and increased the ionisation yield, resulting in higher 
sensitivity of the system. Around the same time, in 1994, Caprioli et al reported a modified 
electrospray ion source, where the fused-silica capillary filled with the reverse phase 
material was used as the emitter needle (92). The same group then reported the sensitivity 
of the nanospray device, demonstrating a successful analysis of a peptide at a concentration 
of 500 zmol/L (93). 
There were further improvements to the nanospray system by Davis et al (94) and Gatlin et 
al (95). These were based on the integration of column packing with the emitter tip, 
resulting in a system free from the after-column void volumes. Reduction of these void 
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volumes to a minimum plays an important role in micro and nanoscale liquid 
chromatography. 
Furthermore, following the development of nanospray electrospray ionisation (nESI) 
greater insight has been gained due to the decreased size of the primary droplet. In 
conventional ESI, with μL/min forced-flow rates, the droplets formed are in the μm range. 
However, for nESI, where the ESI capillary outlet is replaced with a tapered glass pipette 
with a small orifice, within the region of 5 to 15 μm, the resulting flow rate is 
approximately 50 nL/min. In this case the droplet diameter has been estimated at 180 nm 
(91;96). 
The low surface activity of analytes is therefore less problematic when dealing with 
nanospray, as gas-phase ions can be produced directly from primary droplets, unlike ESI 
for which gas-phase ions are produced almost exclusively from offspring and satellite 
droplets. The ionisation efficiency is also greatly increased as there is sufficient time for 
the primary and residue droplet ions to be entirely transferred to the gas-phase, due to their 
very high surface-to-volume ratio. 
There is an increased tolerance to salt contamination when using nESI. This can be 
explained by the theory that the formation of droplets with a diameter one order of 
magnitude smaller means that fewer fission events are necessary before ions are released, 
and each additional fission event results in an increase in salt concentration. 
However, one of the challenges with the development of nESI was that the system could 
not be connected to the typical, analytical HPLC system due to the much higher flow rate 
of the mobile phase. This will be discussed further in the following section. 
To summarise, the ion evaporation model is believed to be the process for gas-phase ion 
formation for small ions (e.g. salt ions); however, the complications of experimental study 
at such small droplet size and charge prevent sufficient empirical results. For macro ions 
(for instance proteins larger than 6500 Da) the charge residue model is more likely (84;96).   
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1.4 Separation Techniques 
1.4.1 Liquid Chromatography 
Liquid chromatography (LC) is an analytical technique, used for separating mixtures of 
many types. In this work it will be applied to body fluids, which can essentially be thought 
of as complex mixtures of biomolecules. Liquid chromatography involves passing a 
sample, in a solution known as the ‘mobile phase’ over a solid ‘stationary phase’, which is 
packed into a column (97). The stationary phase retards the movement of the sample 
selectively. Each sample component has a characteristic time of movement through the 
column, known as the ‘retention time’. In High Performance Liquid Chromatography 
(HPLC) the analyte is forced through a column, containing the stationary phase, at a high 
pressure. Normal phase liquid chromatography was the first HPLC method, which uses a 
polar stationary phase, and a non-polar mobile phase. It is not commonly used now as 
water can alter the hydration state of the chromatographic media, causing problems with 
reproducibility of retention times. Reverse phase (RP) HPLC is now more commonly used. 
RP-HPLC uses a non-polar stationary phase, such as a silica surface modified with long 
chain hydrocarbons, and a polar mobile phase, such as water. The separation is based on 
the hydrophobicity of a sample. The sample components will bind selectively to the 
stationary phase and their movement is slowed through the column. Strongly binding 
components will move slowly and weakly binding components will move quickly. The 
mobile phase is initially a high water content solution. This allows strongly binging 
components to bind to the stationary phase, and weakly binding components to be 
separated. The organic content of the mobile phase is gradually increased, which slowly 
displaces bound components off the column. This ‘gradient’ technique increases the 
resolution, and lowers the peak broadening effects.  
It is well recognised that peak broadening originates from three main sources: 
• Multiple path of an analyte through the column packing 
• Molecular diffusion 
• Effect of mass transfer between phases 
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In 1956 Van Deemter introduced an equation (98) which combined all three of these 
sources. It represented them as the dependence of the theoretical plate height (HETP) on 
the mobile phase linear velocity.  
The plate model supposes that the chromatographic column contains a large number of 
layers, called theoretical plates. There are separate equilibriums of the sample between the 
stationary and mobile phase, which occur on each plate. The analyte moves down the 
column by transfer of the mobile phase from one plate to the next. It is important to 
remember that the plates do not actually exist, but are a theoretical model which is used to 
understand the processes that occur in the column. The plates can also be used as a way to 
measure column efficiency, either by stating the number of plates in a column, N (the more 
plates; the more efficient), or by stating the plate height, HETP (the smaller the plates; the 
more efficient). 
If the length of the column is L, then: 
NLHETP /=   (1.4.1.1) 
The number of theoretical plates that a real column possesses can be calculated using the 
following equation: 
2
2/1
255.5
w
tN r=    (1.4.1.2) 
Where tr is the retention time of the analyte and w1/2 is the half-height peak width of the 
peak in question. As can be seen from this equation, columns have different numbers of 
theoretical plates for different analytes. 
The van Deemter equation was originally written for gas chromatography, but HPLC has 
the same physical processes and the equation also fits. This is explained as follows: 
The analyte will take multiple paths through the column. Band broadening is caused by the 
differing flow velocities through the column: 
pp dH λ2=    (1.4.1.3) 
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Where Hp is the HETP arising from the variation in the zone flow velocity, dp is the 
average particle diameter and λ is a constant, which is close to 1. This shows that Hp may 
be reduced (increasing efficiency) by reducing the particle diameter. λ depends on the 
distribution of the particle size. 
Molecules will disperse due to diffusion. Longitudinal diffusion (along the column) leads 
to band broadening. This is described as follows: 
v
D
H md
γ
2=    (1.4.1.4) 
Hd is the HETP arising from diffusion, Dm is the analyte diffusion coefficient in the mobile 
phase, γ is the factor related to the diffusion restriction by column packing and v is the 
flow velocity. It can be seen from this equation that the higher the eluant velocity, the 
lower the diffusion effect is on the band broadening. Molecular diffusion in the liquid 
phase is much lower than in the gas phase, and this effect is close to negligible at standard 
HPLC flow rates. 
Mass transfer is the third parameter of interest. This is the combination of adsorption 
kinetics and mass transfer inside the particles. Adsorption kinetic is almost negligible 
compared to diffusion inside the particles and the band broadening due to this effect is 
expressed as follows: 
v
D
d
H
m
p
m
2
ω=    (1.4.1.5) 
Where dp is the particle diameter, Dm is the diffusion coefficient of the analyte in the 
mobile phase, ω is the coefficient determined by the pore size distribution, shape and also 
particle size distribution and v is the flow velocity. It can be seen from this equation that 
the HETP has a linear dependence on the flow rate, as the slower the velocity, the more 
uniformly analyte molecules penetrate inside the particle and the less the effect of different 
penetration on the efficiency. Conversely, at faster flow rates the elution distance between 
molecules with different penetration depths will be high. 
Each term described above has an effect on the band broadening, so the sum of them all 
gives the total column plate height: 
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The liquid chromatograph can be interfaced with different detectors for analysis of the 
sample. Commonly used detection systems are UV-Visible absorption (99;100), 
fluorescence (101) and mass spectrometry for a more detailed analysis of the sample (102-
104). HPLC is probably the most commonly used separation technique, in conjunction 
with mass spectrometry and it is the method of choice in this work. 
As previously mentioned, with the development of nESI came the need for liquid 
chromatography systems with lower flow rates, and this is the type of instrument employed 
in my research.  
Initially, post column splitters were used to reduce flow rates. However, this reduced the 
sensitivity of the analysis to such a degree to render it useless. The only practical solution 
was to design capillary, high performance liquid chromatography. In theory, this is a 
simple technique. In essence the capillary HPLC system is purchased, connected to a nano-
ESI-MS instrument and sample is analysed. In reality this type of system can have many 
challenges associated with it (105).  
Typical nano-LC systems usually have flow rates ranging from 1µL/min to 10nL/min and 
use very narrow RP columns (often 75 µm internal diameter). The columns used are often 
made of fused silica, and sometimes carbon, titanium or stainless steel. The stationary 
phase is usually made up from beads with diameters of 5 µm, or smaller. An alternative to 
the traditional columns are monolithic column, which are prepared using a polymerized, 
porous filling. Such tiny columns are easily blocked, with even the submicroscopic solids 
causing problems. An additional issue is that there is no possibility to back flush these 
columns, so once blocked they are permanently damaged.  
Further issues can be encountered if the column is overloaded. This should not 
permanently damage the column, however, several blank runs may need to be used to 
‘clean’ the column and prevent contamination in the following samples. Additionally, there 
can be many problems encountered with leakages and void volumes in these tiny systems. 
LC-MS can be used in many different ways for proteomic analysis. One type of LC-MS-
MS analysis that is used in my research, in chapter 2, is known as MudPIT 
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(multidimensional protein identification technology) (106). This involves a 2-dimensional 
separation and is often used to identify proteins and peptides from complex biological 
mixtures. It can be visualised in the following way, with two chromatography steps, as 
shown in figure 1.1: 
 
Figure 1.1: Schematic demonstrating the process of MudPIT (multidimensional protein 
identification technology). It is shown here that the protein samples are digested into 
peptides. Following that there are two separation steps using a Strong Cation Exchange 
Column and also a Reverse Phase Column.  
 
This method is utilised in Chapter 2 in the research presented here. 
1.4.2 Capillary Electrophoresis 
Capillary electrophoresis (CE) has become an important bioanalytical separation 
technique, for proteins and peptides (107). Some of the advantages of CE include that it is 
of a high speed and resolution, it is sensitive and requires only a small amount of reagent, 
and is easily automated for high throughput analysis. Proteins create certain challenges 
from a separations point of view (108), as they can possess a wide range of 
physicochemical properties.  
Capillary electrophoresis is an automated analytical technique that separates sample 
components by applying a voltage across a capillary filled with a buffer solution. The ends 
of the capillary are dipped into reservoirs of the buffer, and electrodes made of an inert 
material are dipped into the buffer reservoirs to complete the electrical circuit. The buffer 
solution will conduct current through the inside of the capillary. The sample is injected into 
one end of the capillary and is separated according to its size and charge. Migration 
through the column is dependent on the electroosmotic flow. In silica capillaries, when a 
buffer solution above around pH 3 is used, the surface silanol groups are ionised forming a 
fixed anion layer on the surface of the capillary. Cations from the buffer solution then form 
a mobile layer next to the fixed anion layer. This layer of cations is pulled towards the 
cathode, pulling the buffer solution and sample with it. This is demonstrated in figure 1.2. 
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Figure 1.2 Electroosmotic Flow 
 
This means that there is little drag from the edges of the capillary giving a very high-
resolution separation. The flow profile in capillary electrophoresis is flat, as opposed to the 
laminar flow profile seen in pressure driven systems such as chromatography. 
Electroosmotic flow does therefore not contribute to band broadening, making CE a 
higher-resolution technique. 
Common modes of detection after separation by CE include UV-Visible absorbance, laser 
induced fluorescence and mass spectrometry (109). UV-Visible absorbance is probably the 
most commonly used detection method for CE and also the most simple, but it is the least 
sensitive detection method. Detection is often measured at 214 nm where absorption is 
proportional to any peptide bonds that may be present. Different types of detection cells 
are available; including the Z shaped cell and the bubble cell. These cells help to increase 
the sensitivity of the detection.  
Laser induced fluorescence (LIF) detection is more sensitive than UV-Visible absorbance, 
but is slightly more complicated to implement (110). However it is simpler to use than on-
line mass spectrometric detection. Since proteins do not produce much natural 
fluorescence, a derivatisation step is often needed, although it is possible to use native 
fluorescence from aromatic residues (such as tyrosine or tryptophan) for detection. LIF as a 
quantitative method is discussed in more detail in section 1.6. 
Mass spectrometry is the detection technique that can give most information about a 
separated proteomic sample, but interfacing between CE and MS can be challenging. CE 
can be coupled online to an electrospray mass spectrometer (111), or to a spotter for 
MALDI mass spectrometry analysis. The drawbacks of coupling CE to online mass 
spectrometry are that a relatively complicated interface is required. Sheath flow interfaces 
are the most popular. This interface implements a sheath liquid that flows around the end 
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of the capillary, therefore completing the electrical circuit and allowing the electrophoretic 
separation to take place. 
1.4.3 Biomarker Discovery using CE-MS and LC-MS 
CE-MS has been successfully used to identify biomarkers for diabetec renal disease by 
Mischak et al  (112). They showed that CE-MS is a viable technique for inspection of 
polypeptides in urine samples, with respect to identifying potential biomarkers for disease. 
A ‘normal’ urinary polypeptide pattern was established and it was shown that for patients 
with diabetic renal disease, and healthy controls, specific patterns of polypeptides could be 
seen. This allows diagnosis of diabetic renal disease from urine samples, and also the 
possibility of distinguishing between different types of renal disease with a high 
specificity.  
Wittke et al (113) have also demonstrated that it is possible to use CE-MS to distinguish 
between patients who have received a successful kidney transplant, and those whose 
bodies are rejecting a transplanted kidney. Diagnosing these conditions by analysis of 
urine, rather than the more traditional diagnosis method of kidney biopsy, has the 
advantage of being less invasive. It also makes it possible to make earlier diagnosis, 
allowing prompt remedial treatment. In addition, Kolch et al (114) have also reported on 
polypeptide patterns that have been identified in other fluids such as plasma and 
cerebrospinal fluid. 
Meier et al (115) have also used capillary electrophoresis coupled to an electrospray time-
of-flight mass spectrometer (CE-ESI-TOF-MS) to identify patterns of polypeptides in 
urine. Patterns were identified for the recognition of diabetic nephropathy. They were able 
to detect, on average, 767 polypeptides in an individual sample. Overall 5076 different 
polypeptides were detected, in the mass range 800 Da – 66.5kDa. Each one was 
characterised by its mass and its CE retention time. This study showed that the urinary 
proteome contains a greater range of polypeptides than previously recognised. A ‘normal 
polypeptide pattern’ was also established, from healthy patients urine samples. 
Ramstrom et al (116) have published work concerning analysis of human body fluids using 
LC and CE coupled to a high resolution mass spectrometry technique, known as Fourier 
Transform Ion Cyclotron Resonance (FT-ICR) mass spectrometry. LC and CE are easily 
interfaced with electrospray mass spectrometry (ESI), and this is a well-documented 
technique. FT-ICR was used because it is a high-resolution technique. Tryptic digests of 
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different body fluids were used including saliva, urine, plasma and cerebrospinal fluid. 
They found that the LC approach gives more information, and accepts a higher sample 
load, whereas the CE experiments are faster to run. It was also shown that it is possible to 
quantify the peptides seen in body fluid samples using labelling methods. It was concluded 
that neither LC nor CE is a ‘better’ separation technique, but they are complementary and 
the best results were obtained when these techniques were used in conjunction with one 
another. However, it must be noted that both technologies may not always be available to 
the researcher, and liquid chromatography remains the more commonly used technique, 
and additionally is the technique used throughout the work described in following chapters.   
1.5 Quantitation using 2D Gel Electrophoresis 
2D gel electrophoresis is a widely used and powerful technique for analysis of protein 
abundance (117), and has for many years been thought of as the ‘gold standard’ for protein 
separation. 2D electrophoresis separates proteins by their isoelectric points and in the 
second dimension by their size and charge. Unfortunately 2D gel electrophoresis is 
expensive, time consuming and labour intensive. It requires many gels to be run, as only 
one sample can be analysed on each gel, and comparisons made. Gels must be stained and 
scanned in order to visualise the protein sample. There is also a certain lack of 
reproducibility between gels. This can cause problems with distinguishing between 
variation in the gels or biological change between samples. 
1.5.1 Differential Gel Electrophoresis 
Fluorescence detection has a high sensitivity and a wide dynamic range, and is an ideal 
detection method for quantification of proteins and peptides in small biological samples. 
Fluorescence detection has previously been widely applied to 2 dimensional 
polyacrylamide gel electrophoresis (2D-PAGE) in proteomics (117).  When fluorescence 
detection is applied in this way it results in a technique known as differential gel 
electrophoresis (DIGE). Fluorescent dyes (Cy dyes DIGE fluorophores) are used to label 
different protein sample sets, and an internal standard is labelled in the same way. These 
samples are then mixed and run at the same time, on the same 2D gel. This allows spot 
matching and minimises gel-to-gel variation. The fluorescent dyes are size and charge 
matched, and are spectrally resolvable. The dyes modify the lysine residues in a peptide or 
protein, via an amide linkage. The same protein labelled with the different Cy dyes will 
migrate to nearly the same point on the 2D gel. The gel can then be scanned at different 
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laser wavelengths, to separately visualise the differentially labelled protein samples. As the 
dyes are linear, sensitive and have a wide dynamic range this makes the DIGE technique 
quantitative. The sensitivity of the Cy dyes can be down to 0.1ng of protein (118), meaning 
that this technique is more sensitive than silver staining (which has a sensitivity of 
1ng(119)). DIGE has the advantage over traditional 2D gels that the gel-to-gel variability is 
eliminated and an internal standard can be run on each gel, along with the samples.  
There are currently 2 different classes of CyDye labels available (117), minimal labelling 
dyes and saturation labelling dyes. There are 3 minimal labelling dyes, enabling analysis of 
three samples on the same gel, although typically the third dye is used for a standard 
allowing two samples to be analysed on each gel. The minimal labelling dyes are capable 
of detecting differences between protein abundance when 50 μg of total protein, or 1 μg of 
individual protein, is present. There are only two saturation-labelling dyes, but they are 
capable of detecting differences on gels when only 5 μg of total protein, or 100 pg of 
individual protein is present. 
In minimal labelling the ratio of dye to protein is kept low, so that only around 3-5% of the 
total protein in a sample is labelled. This is so that protein molecules visualized on a gel 
will be those labelled with mainly single dye molecules. Minimal labelling dyes label the 
lysine residues in a protein, via an amide linkage. This approach is possible due to the fact 
that most proteins have a relatively high lysine content. If all lysine residues in a protein 
sample were to be labelled, this would result in a large consumption of expensive dye. This 
could also lead to insolubility problems. One significant problem with minimal dye 
labelling is that the small proportion of labelled protein molecules will migrate to a slightly 
different point on the 2D gel to the unlabelled protein (120). This can cause problems if 
spot picking is required for post-gel mass spectrometric analysis, as the majority of the 
protein will not be at the points indicated by the dyes, meaning that additional post-
electrophoretic staining are required to locate the majority of the spot. As low amounts of 
protein loading is required for DIGE a sensitive stain, such as SYPRO Ruby is required. 
This adds extra expense, time and experimental complication (121). 
Saturation labelling is used to label all available cysteine residues in a protein. This means 
that a high dye-to-protein ratio must be used. Proteins generally have a relatively low 
cysteine content, meaning that it is reasonably efficient to label all cysteines that are 
present. The saturation CyDyes (see figures 1.3, 1.4) contain a maleimide reactive group 
which forms a covalent bond with the thiol group present in cysteine residues, via a 
thioether linkage. The saturation dyes have a neutral charge and are matched in molecular 
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weight, so all proteins labelled with different dyes will migrate to the same spot on a gel. 
The saturation dyes are normally used when only a very small sample is available. 
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Figure 1.3 Cy5 Saturation dye. Structures obtained from Amersham.com 
 
 
  
ON
NN
+
S
O
O
H
O
S
O
O
N
O
H
O
S
N(II)
C(III)O
H
O
H
 
Figure 1.4 Cy3 Saturation dye. Structures obtained from Amersham.com 
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2D gel electrophoresis and DIGE still have limitations. Proteins that are present at a low 
relative abundance in a sample may not be visualised, and pre-fractionation and 
enrichment technologies may still be needed. Large and hydrophobic proteins may also not 
enter the gel. DIGE also has the problem that if a protein contains a large number of lysine 
residues it may be labelled more efficiently compared to a protein will less lysine residues. 
Another point to consider is that if a protein contains no cysteine residues saturation 
labelling will not be possible. 
1.5.2 Alexa Molecule Internal Standard (ALIS) 
An alternative method to DIGE for quantitation on gel has been developed (121), using an 
internal standard method. It is as sensitive as the DIGE minimal labelling method, but use 
of post-electrophoretic stains as apposed to pre-labelling removes the problem of the 
labelled proteins migrating differentially. This method works on the principle that if all 
proteins are absorbed into the IPG strip with equal efficiency, then the incorporation of an 
internal protein standard that has been labelled with a fluorescent Alexa molecule (ALIS) 
can provide a way of quantifying the experimental variability. The sample is spiked with 
the standard prior to 2D gel electrophoresis separation. After the separation the gel is 
stained with a fluorescent protein stain, which is sufficiently spectrally separate from the 
ALIS. The ALIS and the sample protein can be visualised and quantified independently. 
The spot volumes of the total protein can then be normalised with the ALIS output. This 
means that variability between gels can be taken into account in the quantification. As the 
internal standard proteins are labelled there will be a shift on the gel in comparison to the 
unlabelled proteins, but this does not influence the normalisation, as it is not a direct 
ratiometric normalisation that is used, as in DIGE, but a global ratiometric normalisation 
method. This is when a median of a selection of spot volumes is used for normalisation. 
Fluorescent stains that can be used with this method include SYPRO Ruby, RuTBS, Sulfo-
rhodamine G and Deep Purple. One of the main advantages of ALIS to DIGE is that it has 
a much lower cost, as less expensive dye is required. 
1.6 Quantitation with CE-LIF 
Fluorescence detection has been used routinely for quantitation in DIGE, however 
fluorescence detection has not been so widely used with separation technologies such as 
high performance liquid chromatography (HPLC) and capillary electrophoresis (CE). It is 
possible to label proteins and peptides with a fluorescent dye, in the same way as proteins 
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are labelled for DIGE (117). These labelled proteins can then be separated, detected using 
laser induced fluorescence (LIF) detection and identified with mass spectrometry. LIF 
detection is more straightforward to implement than mass spectrometry as a detection 
method, but is more complicated than a UV absorbance detection system, as a 
derivatisation step is usually needed. However, LIF detection has the advantage over UV 
absorbance that it is much more sensitive (109). A LIF detector along with a CE (or 
possibly an LC) separation can be used to detect very low amounts of fluorescent analytes, 
even possibly down to the single molecule level (122-125). 
The theory of LIF is relatively simple (126). Light from a laser of specific wavelength is 
shone onto a sample, containing a known fluorophore. The laser light excites the 
fluorophore to a higher energy level. It then relaxes, emitting fluorescent light, of a longer 
wavelength. This light can then be measured, using a photomultiplier tube, or other 
detector. 
CE-LIF is already used as a powerful and sensitive qualitative tool for separation and 
detection of proteins and peptides (127), and a CE-LIF system can be relatively straight 
forward to build, see figure 1.5. Biological molecules such as amino acids and proteins can 
display native fluorescence. For peptides and proteins the native fluorescence of tyrosine 
and tryptophan residues can be used. However this native fluorescence is often low, and an 
expensive laser may be required in order to excite it in the UV region of the spectrum. This 
means that labelling will usually be necessary. Some of the common fluorescent tags used 
for labelling proteins and peptides are succinimidyl esters (128), isothiocyanates (129) and 
sulphonyl chlorides (130). Dyes such as fluorescein isothiocyante are commonly used as 
they have a relatively low cost, and can be easily excited with a common Argon laser. In 
the analysis of labelled molecules the detection of these molecules is likely to limited by 
the chemistry of the labelling reaction (such as incomplete labelling), and not by the LIF 
detection system (127). 
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Figure 1.5 Schematic showing home built CE-LIF system (127) 
 
One of the major limitations of LIF detection is that the laser wavelengths required may 
not be available, or may be very expensive, restricting their widespread use. Continuous 
wave lasers were traditionally used for CE-LIF, but alternatives have been found such as 
semiconductor lasers. A further alternative for excitation is an optical fibre and a blue light 
emitting diode (LED) (131). The LED can be used as an excitation source, and the optical 
fibre is used to transmit the light to the sample detection window. LEDs can be purchased 
with increased power and with a large range of emission wavelengths. They are of a small 
size and straightforward to use. The LED excitation system also has the major advantage 
of being much cheaper and simpler than a laser excitation source. LEDs are also 
convenient and attractive in regards to miniaturisation of the detection system. However, 
unfortunately all the light coming from an LED cannot be used for excitation. This is due 
to reflectance and scattering increasing background noise and reducing the efficiency of 
the LED excitation. Use of an optical fibre helps to reduce reflectance and light scattering, 
and therefore make the system more flexible, and easier to use. 
CE-LIF has been shown to have many biological applications, for instance it has been 
demonstrated (132) that CE-LIF can be used for quantitative nuclear and cytoplasmic 
localisation of antisense oligonucleotides, by labelling with a fluorescent molecule 
(fluorescein). CE-LIF has also been used for detection and semi-quantitative determination 
of GFAP (glial fibrillary acidic protein) mRNA (133), in mouse brain. It was shown that 
CE-LIF was a sensitive technique, but that care must be taken to remove any possible 
interfering substances prior to analysis. 
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1.7 Stable Isotopic labelling for Quantitation 
Widely used approaches for quantitative proteomics may involve protein separation by 2D 
gel electrophoresis (134), as mentioned previously in section 1.5. These techniques are 
time consuming, labour intensive and expensive. Also, as again mentioned previously, gel 
analysis is not useful for large, hydrophobic or extremely basic or acidic proteins. The gel 
techniques are also biased towards the most abundant proteins present, meaning lower 
abundant proteins are often not identified. This has encouraged the development of gel free 
and mass spectrometric based proteomic technologies, in order to obtain more information 
and decrease analysis times. 
Stable isotope labelling has become a popular method for quantitation (135). This involves 
proteins or peptides, in two, or more, different samples, being differentially labelled using 
stable isotope tags. The tags will produce specific, and known, mass shifts in the mass 
spectra for the labelled peptides. These mass shifts in the spectra can then be used as 
internal standards for relative quantitation. Different methods for stable isotope labelling 
have been developed, and some of these will be reviewed here. 
1.7.1 Isotope Coded Affinity Tags 
One of the commonly used stable isotope labelling methods is based on isotope coded 
affinity tags (ICAT) (136). These consist of three parts, a specific chemical reactivity, an 
isotopically coded linker and an affinity tag, see figure 1.6:  
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Figure 1.6 ICAT reagent (137) 
 
In the light form ‘X’ is hydrogen and in the heavy form ‘X’ is deuterium. The biotin is 
used to enrich for peptides labelled with ICAT reagent and the thiol specific reactive group 
is used to attach the tag to cysteine residues.  
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Two sets of samples are derivatised, one with the heavy reagent and one with the light 
reagent. The samples are then combined and cleaved with an enzyme to generate peptides, 
some of which will be tagged. The tagged peptides (these will be any peptides containing 
cysteine residues) are then isolated using an avidin affinity chromatography column. The 
isolated peptides are then separated using HPLC and analysed by tandem mass 
spectrometry. The quantity and the sequence information of the proteins can then be 
determined using MS-MS. To do this the mass spectrometer operates in a dual mode. It 
changes between measuring the relative quantities of peptides eluting and recording the 
sequence information. The peptides are quantified by measuring the relative peak areas for 
the pairs of identical peptides that are tagged with the light or heavy forms of the ICAT 
reagent. These differ in mass-to-charge ratio by the difference in mass between the light 
and heavy reagents. Sequence information from the tagged peptides is generated by 
selecting ions of a particular mass-to-charge ratio, for fragmentation. These peptides are 
fragmented and the masses of the fragments can be compared with masses from sequence 
databases, in order to identify the protein that the tagged peptide is from. 
One of the main principles behind the ICAT approach to quantitative proteomics is that a 
short sequence of amino acids from a particular protein (this can be between 5 and 25 
amino acids) contains enough information to uniquely identify that protein. Another 
important principle is that pairs of peptides tagged with the light and heavy ICAT reagents 
are chemically identical. This is why they can be used as internal standards for 
quantification. 
The ratio between the intensities of the heavier and lighter peaks can provide an accurate 
measurement of the relative abundance of the peptides in the original samples. This is 
because the MS intensity will be the same, regardless of the isotopic composition. 
Selective enrichment for peptides containing cysteine residues also reduces the complexity 
of the sample.  
It has also been shown (137) that ICAT coupled with three dimensional chromatography 
(cation exchange, biotin affinity, reverse-phase) of an enzymatic digestion of the tagged 
protein sample is a useful technique for analysis of low abundance proteins in proteomic 
samples. This is very useful as low abundance proteins are notoriously difficult to analyse 
using 2D gel electrophoresis coupled to mass spectrometry, as it simply lacks the 
sensitivity required. It must be remembered that the labelling reaction is concentration 
dependent (138), and also that denaturing agents will affect the labelling procedure, for 
instance urea improves the labelling (seemingly by making the sulfhydryl groups more 
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accessible) and SDS compromises the reaction. Minimal reaction time should also be used 
in order to avoid any side reactions, and the reaction can be quenched when complete. 
Despite the many advantages of ICAT there are certain disadvantages associated with this 
technique (139).  Even though the mass difference from labelling with deuterium is small, 
there is still a shift in the mobility of the deuterium labelled peptides in size or mass 
dependent separation technologies. For instance in RP-HPLC the heavy peptide may 
migrate more rapidly than the light peptide, and can elute as a separate fraction. Therefore 
in order to accurately quantify the heavy and light peptide pair, both peptides must elute 
completely, allowing integration of the ion current for each peptide. This means that the 
sequencing of the peptides must be sacrificed in order to get accurate relative 
quantification. If the peptide pair do not co-elute, they do not act as true standards. This 
can reduce the accuracy of the quantification. For instance one peptide of the pair may 
elute with a different peptide that could suppress its ionisation. 
Problems with ICAT can also occur due to the fact that electrospray ionisation mass 
spectrometry can produce peptides with different charge states. This means that the mass 
difference between peptide pairs will be altered depending on the charge state, for instance 
for doubly charged ions the mass difference will be halved, in comparison to singly 
charged ions, meaning software algorithms are needed to compensate for this. 
Since the ICAT reagents tag the thiol group in cysteine residues, peptides that do not 
contain cysteine cannot be analysed. This can be an important issue for consideration, as 
cysteine is a relatively rare amino acid. It has been described how an SH group can be 
incorporated into peptides lacking cysteine, in order to make tagging possible (140). Since 
every tryptic peptide will contain an N-terminal amino group, a simple method for 
converting peptide amino groups into sulfhydryl groups was designed. This means that the 
same ICAT reagents can be used for peptides that lack or contain cysteine.  
A second generation of ICAT reagents has been developed, known as cleavable ICAT 
reagents (cICAT) (141;142). The cICAT reagents consist of a protein reactive group, a 
linker region and a retrieval tag. Nine atoms of either 12C or 13C are incorporated into the 
linker part of the molecule, for differentiation. The samples are treated in the same way as 
the original ICAT reagents, but the biotin affinity tag can be cleaved off after enrichment 
but prior to mass spectrometric analysis. MS is then used to screen for paired isotopic 
peaks that are different in weight by 9 Da. As the biotin tag can complicate fragmentation 
patterns, cleaving it prior to analysis avoids this issue. 
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It is also possible to label an internal standard with a cICAT reagent (141), allowing 
absolute quantification to become possible. However, it must be noted that absolute 
peptide concentration must be extrapolated to absolute protein concentration, and this is 
reliant on factors such as digestion efficiency and sample handling. Therefore samples 
must be processed extremely carefully and reproducibly in order to achieve accurate 
absolute quantification. The peptide to be used for an internal standard must also be 
selected carefully. 
A further ICAT technique that has been developed is the use of visible ICAT reagents 
(VICAT) (140). VICAT reagents contain a visible tag, which allows the position of the tag 
and therefore the tagged peptides to be monitored during separation. They also contain a 
photocleavable linker, meaning that the majority of the tag can be removed prior to mass 
spectrometric analysis, avoiding problems with fragmentation. They also contain an 
isotope tag, but instead of the traditional deuterium atoms they use 13C and 15N, avoiding 
any problems caused by non-comigration of paired peptides. The VICAT reagents are 
designed so that tagged peptides can be initially separated on a gel strip by isoelectric 
focussing. The visible tag allows the position of the tagged peptide to be determined, this 
region can then be excised and the peptides analysed by RP-HPLC-ESI-MS-MS. 
1.7.2 Tandem Mass Tagging 
A different approach to quantitative proteomics, that overcomes some of the problems 
associated with ICAT is tandem mass tagging (TMT) (139). These tags are designed so 
that the same peptides labelled with different tandem mass tags comigrate in all 
separations. The tandem mass tags are peptides made up of a tagging group joined to a 
sensitisation group and a mass normalisation group. Each tag in a pair has the same overall 
mass and atomic composition. A second-generation tag has also been developed that 
contains a fragmentation enhancement group, proline. Proline is used as it enhances 
cleavage of the amide bond on its N-terminal side. When used with a Q-TOF instrument 
the first generation tag, without the proline, only gave consistent fragmentation results 
when high collision energies (70V) were used. But, using high collision energies can 
fragment ions that provide sequence information into smaller fragments, meaning little 
sequence information can be obtained, without a second lower energy scan. Therefore the 
second generation tag which allows fragmentation at lower energies (35-40V) is beneficial, 
as sequence and quantification information can be obtained in one scan. 
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The tags are designed so that when they are analysed by collision induced dissociation the 
tag is released, producing an ion with a specific mass-to-charge ratio. Each tag can also 
have a specific functionality, which can be varied allowing different types of labelling. The 
tag can also contain an affinity ligand, like biotin, as in the ICAT reagents. It is also 
possible to create more than two tags meaning that more than two samples can be 
compared, or an internal standard can be incorporated into the analysis.  
Pairs of TMT peptides have the same atomic composition, but are also identical in mass, 
unlike the ICAT tagged peptides. This means that they will exactly comigrate in 
separations, and can be used as extremely precise internal standards. This can give more 
accurate quantification, than in ICAT. Additionally the MS signal for the two sets of 
tagged peptides is not split into two peaks, giving a higher MS sensitivity. The fact that 
untagged peptides can be ignored in this technique can also help to improve data quality. 
Another advantage of TMT is that the charge state of the peptide does not affect the 
appearance of the TMT fragment after fragmentation. Therefore scanning of the spectrum 
can be done without the need for adjustments to compensate for different charge states of 
every peptide. This can be a problem in ICAT, as mentioned previously. 
1.7.3 Isobaric Tags for Relative and Absolute Quantification 
ITRAQ (143) (isobaric tags for relative and absolute quantification) is another quantitative 
technique that is similar to TMT, and was developed in 2004 (144). ITRAQ involves a set 
of amine reactive isobaric tags, which derivatise peptides at the N-terminus and at lysine 
residues. This means they will label all peptides from a tryptic digest. In MS mode the 
peptides labelled with the tags cannot be differentiated, but upon fragmentation in MSMS 
mode signature ions are produced, in the same way as in TMT. These provide quantitative 
information when the peak areas are integrated. There are four different ITRAQ reagents 
(145), that give four unique reporter ions when fragmented in MS-MS mode.  
1.7.4 Stable Isotope Labelling with Amino Acids in Cell Culture 
Another widely used approach to quantitative proteomics is the stable isotope labelling 
with amino acids in cell culture (SILAC) (134;146-149),  which was first described in 
2002 (147;150). In this simple light or heavy amino acids are incorporated into proteins in 
vivo. The different cell cultures are grown in separate light or heavy cell media. The heavy 
media can contain 2H in place of 1H, 13C in place of 12C or 15N in place of 14N. The isolated 
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proteins are the combined and digested. The samples can then be fractionated and analysed 
by mass spectrometry. As in ICAT the labelled peptides can be identified by the mass 
difference of a known amount, and the peak intensities, or areas, determine their relative 
quantities. The sample complexity is not reduced as in ICAT, but as all peptides are 
labelled the sequence coverage is greatly increased. Again the accuracy of quantitation 
depends on the abundance and signal-to-noise ratio of the peptide pair. SILAC allows 
mixing of labelled and unlabelled cells, meaning that as much care does not have to be 
taken to ensure the two sample sets are fractionated and purified in the same way, as in 
ICAT. However one of the disadvantages of SILAC is that the cell culture system must be 
able to tolerate the isotope substituted media, which can cause problems. A further 
disadvantage is that due to complete labelling being required for reliable quantification the 
method can prove rather expensive.  
A further version of SILAC that uses light, medium and heavy media can be used to 
compare three different samples (147;151). This involved mixing cell lysates that were 
derived from cells labelled with three different isotopic forms of arginine. 12C614N4-
arginine was used as the light version, 13C614N4-arginine was the medium version, and 
13C615N4-arginine was the heavy version. The reproducibility of this method was 
determined and it was found that alterations on protein abundance could be reliably 
measured reproducibly, even when the alterations were only 1.5 or 2 fold changes. 
1.7.5 18O Labelling 
A different form of stable isotope labelling that is performed subsequent to digestion is 18O 
labelling for relative quantification (152;153). As this method is performed post-digest it 
circumvents the possible issues of growing cells in certain media. One part of the digested 
sample can be analysed using MALDI-TOF-MS for fast identification of proteins, while 
the remainder of the sample can be labelled with 18O for relative quantification. This 
means that the set of samples to be compared for relative quantification does not have to be 
decided until after the protein identification stage. Samples can be separated on a gel and 
then tryptically digested, followed by trypsin catalysed 18O labelling. The labelling 
procedure can also be performed during digestion if the whole sample is to be analysed, 
rather than an aliquot used for identification. The labelled and control samples can then be 
directly mixed on a MALDI(152) plate for analysis, or analysed by LC-ESI-MS (153). 
The labelling method uses the premise that trypsin accepts the products of protein cleavage 
reactions as substrates and so catalyses the exchange of hydroxyl groups from 18O water 
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into the C-terminus of peptides until equilibrium is reached.  Two atoms of 18O are 
incorporated into the C-termini of the digested peptides, resulting in a mass shift of 4 Da 
for the labelled peptide fragments. 
18O labelling is very sensitive, and can be used to quantify proteins in the low femtomole 
range, so could be a useful technique when samples are limited. In theory, with this 
method, all tryptically-digested peptides are available for quantification, increasing the 
reliability in the measured values. A disadvantage of this technique is that the labelled and 
unlabelled peptides have only a 4 Da difference, meaning a high resolution mass 
spectrometer may be needed to distinguish the labelled products. 
1.7.6 Isotope Coded N-terminal Sulphonation 
Isotope coded N-terminal sulphonation (ICenS) of peptides is a procedure recently 
developed (154) which has a major advantage of improved peptide identification, 
facilitates de novo sequencing, as well as allowing quantitative analysis. 13C-labelled 4-
sulphophenyl isothiocyanate (13C-SPITC) and unlabelled 4-sulphophenyl isothiocyanate 
were synthesized, see figures 1.7 and 1.8 below:  
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Figure 1.7 13C-SPITC    Figure 1.8 12C-SPITC 
 
The two tags were used to label two sets of peptides independently, these were then 
combined giving a mixture of peptides where each peptide isotope pair is separated by 6 
Da. RPLC-MS-MS is then used to analyse the mixture. Due to the nature of 13C labelling 
the two sets of peptides have nearly identical retention times. As the sulphonation reaction 
is inherently incomplete, the MS spectra can be used to distinguish between sulphonated 
and unmodified peptides. The MS-MS spectra can be used to differentiate between N-
terminal fragments and C-terminal fragments by comparing the fragmentations of isotopic 
pairs. This results in improved pepdtide identification and increased confidence in de novo 
sequencing. Quantitation is performed in the same ways as mentioned previously. 
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1.8 Label Free Relative Quantitation 
In recent years quantitative proteomics without labels has become an emerging area (155), 
as an alternative to stable isotope labelling. The label free technique is appealing as it is 
simple and relatively cost effective, although purchase of software can be expensive. Label 
free quantitation is based on comparing identical proteolytically digested peptides, which 
elute with the same retention time using LC-MS-MS analysis, from different samples. The 
relative ratios of the protein can then be calculated, providing a comprehensive quantitative 
overview of many protein concentrations between different samples. This relies on the 
observation that the peak intensity, or area, is, in most cases, proportional to the 
concentration of the peptide in the sample (156-159). Systematic errors are minimised by 
normalising peak intensities across the entire analysis (160). 
Commonly the mass spectral peak intensities of the peptide ions are used for normalisation 
(161). The peak intensities have been shown to have a good parallel with protein 
abundances in complex samples. Spectral counting is an alternative method for the 
normalisation calculation (162). Spectral count is defined as the sum of all MS-MS signals 
for any peptide, including spectra that take the ion charge state into account. Spectral 
counting has been shown to have good reproducibility between replicate experiments, and 
good linearity in spectral count versus protein abundance. Spectral counting allows the 
opportunity to detect, identify and quantify more proteins compared to peak alignment and 
integration, because in spectral counting peptides in common, between datasets, are not 
required for the ratio calculations. However larger errors in protein ratios are seen in 
spectral counting than in peak area intensity measurements (160), meaning that the two 
methods are complementary to each other. It should also be taken into account that spectral 
counts will be more accurate for proteins with large numbers of spectra, and ratios from 
peak area intensities will be more accurate for proteins with more overlapping peptide ions. 
Protein ratios significant down to around 2.5 fold can be measured with high confidence 
using both methods. This is a lower sensitivity than that achieved by isotopic labelling, but 
label free methods will still be useful when labelling is difficult. It has also been shown 
(163) that linearity and reproducibility of label free protein quantitation methods can be 
improved by removing some of the most abundant proteins from complex samples.  
It is very important to have a highly reproducible nano-flow HPLC separation system, as 
retention times must be reproducible if they are to be compared between samples. An 
additional important factor to consider for label free relative quantitation is the sample 
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processing. It is vital that the sample processing does not introduce false positive or mis-
leading quantitative results. Preferably, a high resolution mass spectrometer should also be 
used, to prevent drifts in mass-to-charge ratio. Regular mass spectrometer calibration can 
also help to prevent this.  Additionally, software tools must be developed to monitor 
changes in protein abundance within complex samples, and some commercial software is 
available (for example DeCyder MS). There are several data processing steps that must be 
performed, including peak detection, peak integration, deconvolution, chromatographic 
alignment of elution profiles, normalisation and statistical analysis (164). Different types 
of statistical analysis are discussed in more detail in following chapters. 
 A typical workflow for a label free quantitation experiment is as follows. Protein extracts 
from different samples are digested, normally using trypsin, giving complex peptide 
mixtures. An aliquot of this, for each sample, is analysed with the LC-MS system for the 
initial data acquisition. Typically, for this initial acquisition, only MS data is collected, as a 
high frequency of MS spectra is required to obtain the required chromatographic resolution 
for peak detection and integration. Following the label free analysis and identification of 
features of interest, the sample aliquot is re-analysed and MS-MS data is selectively 
acquired in a targeted manner. This can cause problems with relating the two datasets, but 
has the advantage that only the features of interest are targeted for identification, due to 
their detected quantitative differences. 
One of the main advantages of label free quantitation is that there is no limit to the number 
of samples analysed, whereas stable isotope labelling methods will always be limited by 
the number of labels available to the researcher (165). There has already been work 
published, where label free quantitation has been used for biomarker discovery in different 
fields. These include breast cancer (166;167), Gaucher disease (168), proteinurea (169), 
schizophrenia (170) and diabetes (171). 
Ru et al (166) developed a label free quantitation method for analysis of breast cancer 
samples. They investigated 120 human sera samples with 49 from invasive breast 
carcinoma patients, 26 from non-invasive breast carcinoma patients, 35 from benign breast 
disease patients and 10 from normal controls. The samples were analysed using a 2D-LC-
MS method. The quantitation method used was a semi-quantitative peptide profiling 
method which was based on comparisons of normalised relative ion intensities. The data 
was analysed using two techniques, known as hierarchical clustering analysis and principal 
components analysis. It was concluded that the method developed has the potential to be 
scaled up for a larger clinical study. 
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Patwardhan et al (167) also used a label free quantitation method to study breast cancer 
samples, however cell lines were the samples used here. The technique employed in this 
case is known as an accurate mass and time strategy. For this strategy Fourier transform 
ion cyclotron resonance mass spectrometry (FT-ICR-MS) is required. This is a very 
accurate type of mass spectrometry (accurate to <1ppm), which is required due to the 
accurate mass and LC elution times being used as peptide identifiers. They combined this 
label free method with 18O labelling in an attempt to obtain a broad quantitative method 
which can be used for a wide range of proteins. The results of this were that multiple 
proteins were identified that were differentially expressed among the cancer and non-
cancer cell lines. However, it was also stated that further validation was required to ensure 
the significance of the identified differences. 
Vissers et al (168) investigated label free quantitation as a method to discover novel 
biomarkers for Gaucher disease. This is a genetic disorder, which results in lipid 
accumulation in certain organs such as the spleen, kidneys, lungs and brain. This is caused 
by a deficiency of the enzyme glucocerebrosidase. Patients with Gaucher disease show a 
large elevation in serum of the protein chitotriosidase. Unfortunately there is a frequent 
deficiency in this protein, with one in every 20 Caucasians expressing no chitotriosidase. 
This means that there is the need for new biomarkers for Gaucher disease. In this work 
serum samples from diseased and control patients were analysed using an LC-MS method. 
Depletion of abundant proteins was also investigated in conjunction with label-free 
quantitation. The results of this work were that condition-unique LC-MS protein signatures 
were established; confirming that label free quantitation is a useful technique for biomarker 
discovery. 
Kemperman et al (169) described a label free quantitation method for the analysis of urine 
samples with reference to proteinuria. The urine samples were separated using LC and 
analysed using electrospray Ion-Trap MS. Additionally, they assessed the lower limit of 
detection and the reproducibility of the method. Principal component analysis was used to 
classify the peaks seen from the analysis. 92 peaks were selected as discriminating the 
sample sets, of which 6 were more intense in the majority of the proteinuric samples. Two 
of these peaks were identified as albumin derived peptides. Other albumin-derived peptides 
were found to be non-discriminatory. The group proposed that this indicated preferential 
proteolysis at certain cleavage sites. 
Huang et al (170) investgated label free quantitation as a biomarker discovery method for 
schizophrenia patients using cerebrospinal fluid samples. Only 20 samples were used in 
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this work, 10 from healthy controls and 10 from diseased patients. They found a clear 
difference between the sample sets. 77 proteins were identified, with seven of these being 
newly identified. However, further development is needed for utilisation of this technique 
as a biomarker discovery method. 
As a final example, Metz et al (171) used untargeted label free quantitation in a pilot 
proteomic analysis of human plasma and serum from control and diabetic patients, with the 
goal of identifying biomarkers for type 1 diabetes. FT-ICR-MS was used and five 
candidate biomarkers were identified. However, it was stated that further validation was 
needed prior to moving forward with these markers. 
In the work described in following chapters a label-free relative quantitation method is 
developed and applied to different datasets, for biomarker discovery for hypertension and 
also for the evaluation of a heat treatment system for prevention of proteomic sample 
degradation. Statistical tools are also applied to the datasets in a novel manner, to identify 
and target differences between sample sets. 
1.9 Protein Fractionation Technologies 
As previously mentioned, complexity of biological solutions can pose problems for 
proteomic analysis and biomarker discovery. It is possible to address the problem of large 
dynamic range of biological samples using protein fractionation prior to analysis. This 
involves isolation of the sample into distinguishable fractions. This sample treatment can 
take many forms, including precipitation, centrifugation, filtration abundant protein 
depletion and protein of interest enrichment. The quantity and quality of protein 
identification and quantitation are directly related to the complexity and reproducibility of 
the samples used, therefore the merits and types of protein fractionation must be 
considered carefully. The selection of the fractionation technique depends on the type of 
sample being analysed, the physicochemical properties of the proteins, their subcellular 
location and the objective of the study in question. There is no general fractionation 
protocol that is universally accepted and widely used (172).  
A relatively simple technique for protein fractionation is sample precipitation. This can be 
performed using acetone, TCA, ethanol, diethyl ether, isopropanol, chloroform, methanol, 
ammonium sulphate or PEG (173;174). Ammonium sulphate is used to induce protein de-
stabilisation, otherwise known as ‘salting out’. Organic solvents are used to increase 
attraction between particles of opposite charge in the sample, which leads to protein 
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precipitation. The sample is then redissolved in a smaller volume. Precipitation is not a 
selective fractionation method, and may not be reproducible between samples. It is, 
however, a quick and simple fractionation technique. 
Samples can also be fractionated into their subcellular fractions (nucleus, mitochondria, 
Golgi apparatus, lysosomes, exosomes, peroxisomes and phagosomes), and is another 
straightforward method by which to simplify proteomic samples. There are two main steps, 
first the disruption of the cellular organisation and secondly the fractionation of the 
homogenate to allow separation of the different organelles. This is often performed using 
centrifugation (175). The cells are collected using a low speed centrifugation step and then 
mechanically homogenised. Following this, the nuclei are removed using low-speed 
centrifugation and can be purified from the cell debris and unbroken cells. The remaining 
supernatant contains the cytosol and other organelles in suspension. These can then be 
separated using differential gradient centrifugation (176). Different media can be used for 
the separation, which will affect the degree of separation attained and sucrose is the most 
commonly used medium. Free flow electrophoresis and immunoisolation have also been 
used for subcellular fractionation of organelles (177). For analysis of the total organelle 
proteome, purity of the isolated organelles is of importance, although cross contamination 
between fractions can make complete purification impossible. This can be monitored by 
the use of markers. Enrichment of certain subcellular fractions can then be used to detect 
proteins of low abundance, and also to track their change in abundance (178). This 
technique has been used to identify proteins from the Golgi location in rat liver (179).  
A more specific method of protein fractionation is the use of beads with differently 
functionalised surfaces (180). This sample process is effective and versatile, and is a useful 
technique for discovery and identification of biomarkers or other proteins of interest. A 
commercial system using magnetic beads with functionalised surfaces known as ClinProt 
has been introduced by Bruker Daltonics (see figure 1.9 below). The body fluid sample is 
incubated with the magnetic beads (available with different functionalised surfaces), and 
washed by manipulating the beads with a magnetic strip. The proteins or peptides of 
interest can then be eluted and analysed using MALDI-TOF-MS. It has been shown that 
using the ClinProt system with Anchor Chip Targets from Bruker and human plasma 
samples can be used to generate reproducible protein/peptide profiles (181), which can be 
used for scanning for potential biomarkers for disease. Differences between diseased and 
normal samples can be seen, when statistical analysis software package (ClinProTools, 
provided by Bruker) is used to analyse the profiles.  
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Figure 1.9 ClinProt Workflow(180). Protein samples are incubated with magnetic beads with 
functionalised surfaces. They are then washed to remove unbound material. (Magnetic 
strips are used to move the beads around). Bound proteins or peptides are then eluted and 
can be spotted onto a MALDI target plate for MS analysis 
 
SELDI-TOF-MS is similar technique to the bead based capture technologies that has been 
used as a biomarker discovery platform. In SELDI-TOF-MS a planar array of different 
surface chemistries are used for simultaneous processing and sample fractionation (180) 
prior to analysis by TOF-MS. Proteins are isolated on the surfaces and can be used to 
reduce sample complexity in the same way as the ClinProt bead system.  Unfortunately 
there is limited binding to the SELDI surfaces and extra noise can be obtained from the 
surfaces. A commercial SELDI system is available from Ciphergen, the ProteinChip Array 
System. This system allows for simple sample preparation, and lessens the need for 
expertise in mass spectrometry (182).  
Different surface chemistries can be used including traditional chromatographic separation 
media, such as reverse phase or ion exchange, or biochemical surfaces, such as antibodies 
or enzymes (see figure 1.10).  
 
Figure 1.10 Possible SELDI surface chemistries (182) 
  54 
 
The chemical surfaces have broad binding properties and are usually used in protein 
profiling experiments and for biomarker discovery, in a similar way to the ClinProt beads. 
The biochemical binding surfaces are much more specific, so provide high enrichment of 
particular captured analytes. 
There are various methods and technologies used to deplete high abundance proteins and 
enrich for low abundance proteins. Centrifugation forces can be used to force a liquid 
against a semi-permeable membrane, meaning that low molecular weight solutes and the 
liquid will mass through the membrane and high molecular weight solutes and solids will 
be retained, dependent on the pore size of the membrane. These are available with different 
molecular weight cut-offs, and can be used with different centrifugation speeds (183;184). 
This is a simple method that can be used to remove high abundance proteins such as 
albumin from plasma samples, as their molecular weight is known. It must be considered, 
however, that low abundance features with a high molecular weight will also be removed 
from the sample using this method. Additionally, protein-protein interactions may need to 
be disrupted to disassociate low molecular weight proteins from albumin, and allow them 
to pass through the membrane (185). 
Abundant proteins can also be removed from plasma using antibody affinity systems. The 
multiple affinity removal system (MARS) is used to remove the most abundant proteins 
from plasma samples. It has been shown (186) that using the MARS system, prior to mass 
spectrometry analysis gives a good, reproducible proteome coverage. The MARS column 
removes the six most abundant proteins from the plasma samples (albumin, transferrin, 
IgG, IgA, anti-trypsin and haptoglobin) helping to reduce interference from these, and 
allowing proteins of lower abundance to be detected and analysed. The advantages of this 
technique are that it is quick and easy, however it is an expensive technique and the 
columns have a limited capacity. There are also concerns regarding techniques such as this 
when performed under non-denaturing techniques, as low abundance proteins bound to the 
target proteins may be simultaneously removed from the sample, via the ‘albumin sponge 
effect’. It has been shown that about 210 proteins are associated with the six most abundant 
plasma proteins, and also the removal of albumin causes a significant loss of cytokines 
from the sample (187). This and similar techniques for removal of abundant proteins are 
reviewed in more detail in the introduction to the chapter ‘Discovery and Identification of 
Biomarkers for Hypertension’. 
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Another protein enrichment technique is known as N-linked glycopeptide capture (188), 
and can be used for body fluid samples such as plasma and serum. Protein glycosylation is 
a relatively common post-translational modification. Carbohydrates can be linked to serine 
or threonine residues (O-linked glycosylation) or to asparagine residues (N-linked 
glycosylation) (189). Many biomarkers and drug targets are glycoproteins, as N-linked 
glycosylation is often found in extracellular proteins (190), located in body fluids. 
Peptides that are N-linked glycosylated in the native protein can be isolated (after an 
enzymatic digestion), reducing the complexity of the sample, as every serum protein 
contains (on average) only a few N-linked glycosylation sites. The capture of the 
glycosylated proteins is based on oxidation of hydroxyl groups on adjacent carbons of the 
carbohydrate to aldehydes, by sodium periodate. The aldehydes then covalently couple to 
amine or hydrazine containing molecules, immobilised on beads. The formerly N-linked 
glycosylated peptides can be released via a catalysed reaction with PNGase F, for mass 
spectrometry analysis. It was shown by Zhang et al (189) that this method is reproducible 
and gives more information about low abundance proteins in serum samples, compared to 
mass spectrometry analysis of untreated serum samples. It was also shown (188) that the 
peptide pattern of a mouse with cancer could be differentiated from a genetically identical 
mouse without cancer.  
In conclusion, proteomics is an ever-growing field with many exciting and interesting 
applications. In the chapters that follow several of these are examined and developed, 
mainly concentrating on the theme of biomarker discovery for disease. The literature 
reviewed here concentrates on research relating to that in following chapters, and gives an 
interesting context and background in which to place this work. 
The biological changes in stroke induced mouse brain tissue are studied as an introductory 
experimental chapter. This work was a useful preliminary to the following research and 
helped develop experimental knowledge, planning skills and highlighted the importance of 
careful sample preparation. 
 The prevention of degradation to tissue samples by a novel heat treatment method is 
studied. The issue of possible sample degradation was a logical point to address following 
the analysis of stroke induced mouse brain tissue. 
Finally, the changes to plasma samples from hypertensive, wild type and a congenic strain 
of rat are studied. The focus of this chapter is the development of a label free relative 
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quantitation method for analysis of a rich data set. The application of novel statistical 
methods to the data was the main interest, and this is considered to be an under discussed 
and studied area in this field of research. 
Within the chapters that follow the following aims are addressed: 
•  Optimisation of mouse brain tissue sample preparation for proteomic analysis and 
determination of protein concentration in samples 
• Identification of features by LC-ESI-MS-MS analysis, previously discovered by 
MALDI-MSI analysis, followed by confirmation of identifications using traditional 
1D gel and western blotting analysis 
• Evaluation of the overall effect of heat treatment on the mouse brain tissue sub10 
kDa proteome 
• Development of a label free relative quantitation method in order to quantify the 
differences seen between heat treated samples and snap frozen samples in both 
digested and intact sub 10 kDa proteome 
• Optimisation of sample preparation of plasma samples for LC-MS analysis and 
determination of protein concentration in the rat plasma samples used  
• Evaluation of plasma partitioning spin columns using 2D mini gels and LC-MS 
analysis 
• Evaluation of two types of label free quantitation software, followed by label free 
relative quantitation of features within plasma sample as a possible biomarker 
discovery method 
• Development of a novel statistical analysis for the label free relative quantitation 
dataset 
• Targeted MS-MS analysis for identification of any features of interest, followed by 
western blots as validation of any biomarkers discovered 
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In my research presented here, special attention is paid to sample preparation, the 
importance of experimental design and the application of relevant and useful statistical 
methods to enable the mining of useful information from rich datasets.  
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2 Biomarker Identification in Stroke Brain Guided 
by MALDI-imaging 
2.1 Introduction 
Ischaemic stroke is the second most common cause of death and also the most common 
cause of acquired disability in adults (191;192). Additionally in western countries stroke 
causes 10-12 % of all deaths, with 12% of those deaths in the under 65 age range (193). In 
2002, stroke related disability was judged to be the sixth most common cause of increased 
disability adjusted life-years (DALYs). DALYs are the sum of life-years lost as a result of 
premature death and years lived with disability, adjusted for severity (191). Due to the 
increasing elderly population in western societies, it is estimated that by 2030 stroke 
related disability, in western societies, will be rated as the fourth most important cause of 
DALYs (194). Stroke is also very expensive to society, consuming 2-4 % of total 
healthcare costs, worldwide, and in industrialised countries accounting for over 4 % of 
direct healthcare costs. Costs to UK society were estimated at £7.6 billion, based on 1995 
prices, and the costs to US society were estimated at $40.9 billion, based on 1997 prices. 
This relates to a large cost of $100 per head of US population per year (195). Regardless of 
these high costs to society, the proportion of research funds targeted towards stroke 
remains disproportionately low (196).  
Risk factors for stroke can be classified as modifiable (such as hypertension, diabetes and 
smoking) or fixed (atrial fibrillation and transient ischaemic attack). Risk factors that have 
been identified account for only around 60 % of the attributable risk. In contrast about 90 
% of ischaemic heart disease is explained by identifiable risk factors (197;198).  
Strokes can be classified as being either ischaemic or haemorrhagic, and the management 
of these subtypes is quite different. Therefore, the clinical distinction between these types 
is one of the most important steps in stroke management. This distinction has been made 
much easier by the introduction of CT and MRI scanning (199). Haemorrhagic stroke is 
also known as intracerebral haemorrhage, and the most common cause is hypertensive 
small-vessel disease causing rupturing of small lipohyalinotic aneurysms (200). 
Haemorrhage into a previous infarction can be another contributing factor (201). Around 
two thirds of patients with primary cerebral haemorrhage have either pre-existing or 
recently diagnosed hypertension (202). Ischaemic strokes are more common, accounting 
for around 80 % of all strokes (203). The mechanism that causes vessel occlusion, and 
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therefore ischaemic stroke can be cardioembolic, artery to artery ambolism or in-situ small 
vessel disease. The identification of which mechanism is present is important as it can 
influence acute treatments and secondary prevention strategies (192), meaning that a 
biomarker based assay could have life changing implications. Following vessel occlusion, 
a volume of structurally intact but functionally impaired tissue surrounds the ischemic core 
(204). This is commonly known as the ischaemic penumbra. It is often the target for 
therapeutic treatments, as its recovery is associated with neurological improvement. In the 
ischaemic penumbra a cascade of neurochemical events starts with energy depletion. This 
is followed by disruption of ion homoeostasis, release of glutamate, calcium channel 
dysfunction, release of free radicals, membrane disruption, inflammatory changes and 
necrotic and apoptotic cell death triggering. The infarct core contains unsalvageable tissue, 
however in animal models the cascade can be arrested at various points, which can form 
the basis for neuroprotective therapies (205).  
Stroke prognosis is not good, with around a quarter of stroke patients being dead within a 
month, a third within six months and a half within a year (206;207). Prognosis is worse for 
those with intracerebral and subarachnoid haemorrhage, with the one month mortality 
approaching 50 %. The main cause of early mortality is neurological deterioration; in 
addition contributions are made from infections. Later deaths are more usually caused by 
cardiac disease or further complications (207). The main predictors of stroke recovery at 
three months are initial neurological deficit and age, with other factors being high blood 
glucose concentrations, body temperature and history of previous stroke (208). Following 
the occurrence of minor strokes, the risk of further strokes is high, even as high as 30% in 
some subgroups (209-211). Patients at particular high risk of reoccurrence can be 
identified by their age, blood pressure and characteristics of their symptoms, including 
unilateral weakness and speech impairment (212). Imaging strategies, such as magnetic 
resonance imaging are also used to predict possible high risk of recurrence. The presence 
of diffusion weighted image lesions, or of occluded vessels can help to identify these 
patients (213). 
Mortality rates for stroke are fortunately in decline, and the main reason for this is due to 
improved control of risk factors, including hypertension (214) and blood pressure reducing 
agents have been ever increasing in effectiveness since the 1950s (215). Other risk factors 
may also have had an effect, including reduction in smoking rates, cholesterol, diabetes 
and atrial fibrillation (216). It has been suggested that patients with hypertension, without 
previous stroke should be treated with warfarin if they have atrial fibrillation, lipids 
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reduction can be targeted with statins in patients with pre-existing ischaemic heart disease, 
and women over 45 can be treated with aspirin (217-221). 
In the past 30 years there have been advances in the prevention of recurrent stroke. Aspirin 
was introduced as a prevention strategy in 1978 (222). Evidence has also been presented 
showing that oral administration of aspirin within 48 hours of onset of ischaemic stroke 
reduces 14 day morbidity and mortality (223;224). However, this benefit is relatively 
small, as only around 9 patients per 1000 treated are saved from death or disability, and 
after exclusion factors are taken into account, only 4 patients per 1000 treated are saved 
from death or disability (225). Aspirin is a straightforward treatment, as it low cost, easily 
administered and has low toxic effects (225). Aspirin is not only useful for secondary 
prevention, but penumbral salvage may also be possible (226). Further secondary 
prevention strategies include aspirin with dipyridamole (introduced in 1987) (227), 
warfarin for patients with atrial fibrillation (introduced in 1993) (228), carotid 
andarterectomy for symptomatic carotid-artery stenosis of greater than 70 % (introduced in 
1991) (229;230), clopidogrel (introduced in 1996) (231), blood pressure reduction using 
perindopril and indapamide or ramipril (introduced in 2001) (232;233) and cholesterol 
reduction with atorvastatin (introduced in 2006) (234). Most patients will qualify for at 
least one of these secondary prevention strategies. 
A treatment under recent investigation is carotid angioplasty with stenting. This is now 
generally combined with distal protection devices. This is a minimally invasive procedure, 
which may replace carotid endarterectomy as the treatment of choice in many patients. 
Initial trials have suggested that the surgical risks associated with this procedure are similar 
to those seen in carotid endarterectomy (235;236), but it has been suggested that these risks 
may be increased when the procedure is undertaken by less skilled hands (237). 
Surprisingly, prevention of secondary stroke by modification of risk factors such as blood 
sugar reduction in diabetics (238), reduced alcohol consumption, increased exercise and 
smoking cessation is not substantiated with evidence from clinical trials. However, 
observational studies have shown many potential benefits, small costs and small risk of 
adverse effects, meaning that patients should be advised to stop smoking, drink in 
moderation, eat a balanced diet and to exercise (239-242). 
With regards to treatment of stroke there have also been advances in recent years. One of 
the most effective advances has been the routine management of patients in Stroke Care 
Units (SCUs). This is appropriate for all stroke subtypes, reduces mortality by around 20 
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%, and also improves functional output by around 20 % (243). In addition, a space 
identified as an SCU sees improved outcomes when compared with a dedicated stroke 
team visiting patients on general wards (244).  This is thought to be due to strict blood 
pressure control, early mobilisation and good adherence to best practice (245;246). 
Thrombolytic treatment with recombinant tissue plasminogen activator (tPA) is a 
biologically effective treatment for acute ischaemic stroke, if used within a three hour 
window of stroke onset. However, it does not improve mortality rates, only disability rates 
(225;247), and is therefore not widely used as a treatment method. Decompressive surgery 
is another possible intervention method, but is suitable for only a very small proportion of 
patients. These are young patients with malignant middle-cerebral-artery-territory 
infarction and space-occupying brain oedema. This occurs in 1-10 % of patients with 
supratentorial hemispheric infarcts, and usually arises between 2-5 days after stroke (248).  
There are also various intervention treatments currently under evaluation. Haematoma 
growth in the first few hours of onset of stroke has been shown to be a key factor for poor 
clinical outcome (249). Recombinant factor VII is normally given to patients with 
haemophilia, or to reduce haemorrhagic complications of surgical procedures. It has now 
been shown to attenuate haematoma growth, with additional secondary clinical benefits in 
a phase II trial (250). Another treatment that is under evaluation is thrombectomy devices. 
These are mechanical devices which have been developed to enable removal of a blood 
clot from major vessels, including middle-cerebral and basilar arteries. One of these is the 
mechanical embolus removal in cerebral ischemia (MERCI) retrieval catheter (Concentric 
Medical, Mountain View, CA, USA). This device has a corkscrew shape. It has been 
shown, in a phase II trial, that this device could be used to remove the blood clot, with a 
complication rate similar to that seen when the treatment used is intravenous tPA (251). 
This device has now been FDA approved for clot removal, but not as a stroke therapy, 
which has proved to be a fairly controversial decision (252;253). 
In summary, stroke management and treatment has improved over the past 10 years, but 
still poses interesting challenges for clinicians and researchers. In my research stroke brain 
tissue is investigated, using a mouse model, with the aim to identify markers that are 
associated with stroke. It is proposed that the discovery of biomarkers for stroke could aid 
diagnosis and influence early treatment methods, as well as providing further information 
with regards to tissue recovery.  
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 An imaging technique has previously been used to identify features that differ between 
stroke brain and wild type brain (unpublished work by Dr Richard Goodwin, IBLS, 
Glasgow University). Features are categorised by mass only, and it can be a challenge to 
identify these features. In this work, an effort has been made to use downstream proteomic 
techniques to help improve identification of these features. The imaging technique used is 
known as MALDI-MSI (matrix assisted laser desorption ionisation mass spectrometry 
imaging). This is a technique that is used to investigate the distribution of molecular 
features across thin (µm) slices of tissue, using a MALDI mass spectrometer. It was 
pioneered by Caprioli, Chaurand and Stoeckli (254-257), and has been used to detect 
different types of biomolecules including peptides, proteins, lipids and small molecules 
(258-260). Recently, MALDI-MSI has shown potential for detection of disease progression 
and biomarkers (261-268).  
MALDI-MSI uses conventional MALDI-MS technology to collect a mass spectrum over a 
series of points across a thin section of tissue. These spectra can then be used to plot the 
relative intensity of each m/z peak in the mass spectrum across the tissue area. Therefore, 
the distribution of each feature can be visualised across the tissue, using a pixilated 
intensity map for each feature identified. Assuming the sample preparation and mass 
spectra acquisition is reproducible between tissue samples, these intensity maps can then 
be compared between related samples, in this case between a stroke induced mouse brain 
and a normal, wild type mouse brain. In this way markers for disease can be identified. 
One of the major challenges in MALDI-MSI is the MS based identification of the features 
of interest. Currently, performing MALDI MS-MS analysis directly from the tissue has 
been a difficult process (260). In this work, it is proposed that the mass of interest 
discovered using MALDI-imaging can be used to identify the feature using a different 
method of identification, in this case LC-MS-MS analysis. The mass of interest is targeted 
using the conventional proteomic technology. It is suggested that these techniques will 
prove to be complimentary. There are certain disadvantages to this method, which must be 
taken into account. Certain assumptions must be made regarding the mass shown in the 
MALDI-MSI data, for example it must be assumed that the mass imaged directly from the 
tissue relates exactly to the mass targeted using the LC-MS-MS analysis. One of the most 
important steps to take to assure this assumption is true, is to ensure both mass 
spectrometers are calibrated accurately and often. Additionally experiment validation must 
be undertaken. It is proposed here that validation can be performed using quantitative 
western blotting and the traditional biochemical technique of immunohistochemistry.  
  63 
In this work, a stroke-induced mouse model is used, but in the future these techniques 
could have the potential to be applicable to different tissue types, the diagnosis and 
monitoring of many different disease states, and also different types of complex biological 
samples. Excision of regions of interest can also be used in conjunction with these 
techniques to give useful information from specific areas and also to help avoid low 
abundance changes being missed. 
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2.2 Aims 
There are several important aims in this chapter, which will be discussed in more detail in 
the following sections. 
• Optimisation of mouse brain tissue sample preparation for proteomic analysis  
• Determination of the protein concentration in tissue samples 
• Identification of features by LC-ESI-MS-MS analysis, previously discovered by 
MALDI-MSI analysis 
• Confirmation of identifications using traditional 1D gel and western blotting 
analysis 
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2.3 Methods 
2.3.1 Sample Preparation Protocol 
Male ICR mice (6-8 weeks) brain tissue samples were used in this work, and these were 
obtained from Dr Hilary Carswell from the Institute of Pharmacy and Biomedical 
Sciences, University of Strathclyde. Global ischaemia was induced in the mouse brain. 
Both common carotid arteries were isolated and then occluded using microaneurysm clips 
applied bilaterally for 15 minutes. The clips were removed, and blood flow through the 
arteries was confirmed prior to suture of the wound. The body temperature was controlled 
at 37 ºC during the surgical procedure, and then maintained by an incubator until the 
animals had fully recovered from aneathesia. Wild type, healthy mouse brains were also 
used as a control. 6 stroke induced brains and 10 wild types brains were used in this work. 
Mice were euthanatized by cervical dislocation in accordance with the U.K. Animals 
(Scientific Procedures) Act, 1986 and local ethical guidelines. Brains were removed and 
sliced using a cryostat microtome (Leica Microsystems CM 1900UV, UK) maintained at 
minus 15 ºC.  
Two of the stroke induced brains were sliced to a thickness of 10 µm, two were sliced to a 
thickness of 15 µm and two were sliced to a thickness of 20 µm.  The wild type brains 
were sliced in the same way, with the remaining four wild type brains all sliced to a 
thickness of 15 µm. A protein extraction from brain tissue protocol was optimised for LC-
MS-MS analysis. The samples were cooled with ice during handling. The protocol 
consisted of covering the brain slice with 50µl of a solution of 1% formic acid in distilled 
H2O, in a sample tube (Eppendorf) and then centrifuging for 10 seconds at 20,000 g. The 
sample was then vortexed vigorously prior to probe sonication for 5 seconds, on ice. The 
sample was then vortexed vigorously and then centrifuged for 30 minutes at 20,000 g. The 
supernatant was removed, and size filtered using Microcon Nominal Molecular Weight 
Filters, 10,000 Da, (Millipore, YM10) according to manufacturers protocol. The sub 10 
kDa fraction filtrate was then removed and stored at minus 80 ºC prior to analysis.  
2.3.2 Protein Concentration Determination 
Concentration of tissue sample extractions was determined using a standard protein 
concentration assay. This was performed on extracted tissue samples prior to size 
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fractionation, and also following size fractionation, for 10 µm slices of wild type brain 
tissue and also for 20 µm slices of wild type brain tissue. 
10 µl of tissue extraction solution was used for protein concentration determination. BSA 
standards were used with protein concentrations of 0.0625, 0.125, 0.25, 0.375, 0.5 and 0.75 
mg/ml. The absorbtivity measurement of each standard and sample was repeated three 
times, and the mean signal was calculated. A standard curve was created from the 
absorbtivity and concentration of the known standards. The concentration of tissue 
extraction solution was then determined using this curve.  
2.3.3 LC-MS-MS for Protein Identification 
Extracted protein samples were analysed using a Dionex (4 Albany Court, Camberley, 
Surrey) Ultimate nano-flow LC system and an Applied Biosystems (120 Birchwood 
Boulevard, Warrington) Q-Star Pulsar i. A 90 minute gradient (5% solvent A to 80% 
solvent B) was used. The LC separation was performed on a 15cm C18 PepMap reverse 
phase column with a 75 µm internal diameter, (Dionex). Solvent A was a 2 % acetonitrile, 
0.1 % formic acid solution and solvent B was an 80 % acetonitrile, 0.1 % formic acid. The 
loading solution used was a 2 % acetonitrile, 0.5 % tri-fluoroacetic acid solution. The 
loading flow, onto the trap was maintained at 30 µl/min. The column flow was maintained 
at 0.3 µl/min. This LC system does not have a column oven; therefore the column was 
maintained at room temperature throughout the separation.  
MS and MS-MS data was collected in positive ion mode, using the following Q-Star 
settings: 
Accumulation time: 3 seconds, TOF masses: m/z 200 – 1500, Product ion masses: m/z 50 
– 2000, dynamic exclusion was used, and rolling collision energy. Electrospray was 
performed using ‘picotip’ needles (New Objective) and the standard Q-Star electrospray 
source. 
Q-star ‘wif’ files were extracted using Analyst QS MASCOT plug in (v1.1) and searched 
using MASCOT version 2.1 (Matric Science, London, UK) against database NCBInr 
20070413 (4848751 sequences; 1676925347 residues), using MASCOT search settings as 
follows: 
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Species: Rodentia, Enzyme: No enzyme, Report top hits: Auto, Variable modifications: 
Oxidation of Methionine, Charge: 1+, 2+ and 3+, Peptide tolerance: 1.8 Da, MS/MS 
tolerance: 0.8 Da, Instrument: ESI-TOF. 
From the MASCOT results, a list of detected, and identified, features was constructed. The 
equivalent 1+ m/z was calculated and this was cross referenced with the MALDI-MSI data. 
The MALDI-MSI data used, in this instance, was a list of features that demonstrated 
differing intensity distributions between stroke induced and wild type brain. All MALDI-
MSI work was performed by Dr Richard Goodwin (IBLS, Glasgow University) using a 
Bruker Ultraflex MALDI-TOF mass spectrometer. Any features that occurred in the LC-
MS-MS data set were noted. 
A two dimensional MudPIT analysis was also performed on the brain tissue, size filtered 
samples. This process is described in more detail in the introduction section 1.3. For the 
MudPIT analysis the size filtered protein extraction from tissue samples, prepared as 
described in section 2.3.1, were dried down for 30 minutes to remove solvent and 
subsequently resuspended in 50 µl of 25 mM ammonium bicarbonate and digested using 
sequencing grade modified porcine trypsin.  
The mass spectrometer settings used were as previous. A 90 minute gradient was used for 
each salt step in the MudPIT analysis. Sodium chloride solutions were used at the 
following, increasing concentrations: 
0mM, 25mM, 50mM, 100mM, 150mM, 200mM, 250mM, 300mM, 350mM, 400mM, 1M   
2.3.4 1D gels and Western Blotting for Confirmation of 
Identification 
Following identification of features that possibly related back to MALDI-MSI data, 1D 
gels and western blots were performed as a validation method. Samples used were a 10 µm 
brain slice, extracted as previously described in section 2.3.1, and size filtered <10 kDa, a 
20 µm brain slice, extracted as previously and size filtered <10 kDa, a 10 µm brain slice, 
extracted as previously without size filtration, and two 20 µm brain slices, extracted as 
previously described without size filtration. From each sample 4 µl was used, and diluted 
with 16 µl of protein loading buffer before being denatured at 100 ºC for 5 minutes. 
Protein loading buffer consisted of 1.6ml Glycerol, 1.6ml 10% SDS, 0.5ml 1M Tris (pH 
6.8), 3.9ml water, 0.4ml β-mercaptoethanol, and 0.1g of bromophenol blue. This was 
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diluted 1:5 prior to use. Each sample was then split into two 10 µl aliquots. Each sample 
was then loaded onto a 12 % pre-cast polyacrylamide gel (Invitrogen) and separated for 1 
hour at 200 V, using a pre-made MOPS running buffer (Invitrogen). A protein molecular 
weight marker was loaded in the first lane. This was repeated, in an identical manner for 
the 2 aliqouts of each sample, on two separate gels. One gel was used for silver staining for 
protein visualisation and the second gel was used for western blotting.  
Western blots were performed for several proteins: 
Primary antibody: Anti-myelin basic protein (mouse – developed in rat), Secondary 
antibody: Anti-rat IgG horse radish peroxidase conjugate 
Primary antibody: Anti-MHC Class II antigen (mouse – developed in rat), Secondary 
antibody: Anti-rat IgG horse radish peroxidase conjugate  
Primary antibody: Anti-ATP synthase (mouse – developed in chicken), Secondary 
antibody: Anti-chicken IgY horse radish peroxidase conjugate 
Western blots were performed as follows. The gels were immersed in transfer buffer for 15 
minutes at room temperature. The gel size was measured, and filter papers and western blot 
membrane cut to the same size (1 piece of membrane per gel, and 6 pieces of filter paper 
per gel). The filter paper was soaked in transfer buffer for 5 minutes. The membrane was 
wet in methanol for 15 seconds, soaked in water for 2 minutes, and then in transfer buffer 
for 5 minutes. The transfer stack was assembled in the SemiPhor western blot apparatus. 
This consisted of 3 pieces of filter paper, the western blot membrane, gel and 3 further 
pieces of filter paper. 27 mA of current was applied, per gel, for 1 hour. The membranes 
were then removed and left to air dry overnight. The gels were discarded at this stage. The 
membranes were wet in methanol and then immersed in blocking solution for 1 hour. 
Blocking solution consisted of 100 ml PBS with 5 g of dried milk powder. The membranes 
were then removed and washed in PBS with 0.05 % Tween. The membranes were then 
each immersed in the primary antibody wash for 1 hour, consisting of 20 ml PBS with  
0.05 % Tween, 5 % milk and 10 µl primary antibody. The membranes were then washed 6 
times, for 5 minutes each time, in PBS with 0.05 % Tween, and immersed in secondary 
antibody solution for 1 hour. Secondary antibody solution consisted of of 20 ml PBS with 
0.05 % Tween, 5 % milk and 10 µl secondary antibody.  The six 5 minute washes were 
repeated. Each membrane was then covered in Pierce ECL reagent for 60 seconds. 
Membranes were dabbed dry and exposed onto UV film (Kodak) and developed using an 
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Xomat developer. Five 30 second exposures were used initially, followed by five 2 minute 
exposures.  
The 1D gel and western blot for antibody anti-ATP synthase was repeated using laser 
microdissected tissue samples. These samples consisted of 2 wild type samples and three 
stroke samples. All LMD work was performed by Alastair Michael Lang (IBLS, Glasgow 
University). Laser microdissection is a method used to isolate small regions of tissure 
sample and is discussed in more detail in the introduction section 1.1. 
The tissue slices were placed under a microscope and the stroke region of the brain 
identified visually. A laser was then used to outline and exise the region of interest. This 
was then captured in a sample tube. Hence, LMD selects the tiny tissue sample by area 
alone and protein concentration is not considered. 
In this work the stroke regions were microdissected using LMD apparatus, areas of 900 x 
560 µm. Identical sized regions were dissected from the wild type brains, from the 
corresponding brain region. Protein extraction was performed as described previously 
without size filtration. The 1D gel was also performed as described previously. The 1D gel 
was silver stained for visualisation of the protein bands. The western blot was repeated in 
an identical way to the previously described blot. 
An additional western blot was performed, with a protein loading standard, to normalise 
between protein content of samples. The loading standard used was an antibody for anti-
beta tubulin III (developed in rabbit), with a secondary antibody of anti-rabbit IgG horse 
radish peroxidase conjugate. These antibodies were simply mixed with the original 
antibodies (as described previously) and the blot performed in the same way. 
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2.4 Results 
2.4.1 Protein Extraction 
Several differing protein extraction methods were considered in this research, prior to 
finalising the method as described in section 2.3.1.  
Probe sonication time was considered. Sonication times of 2, 5, 10, 20 and 30 seconds 
were trialled. It was found that for sonication times of over 5 seconds that there was a large 
amount of heating of the sample. Even when performed on ice, the sample tube became hot 
to the touch. It was concluded that this would be detrimental to the samples and could 
cause protein degradation. When a sonication time of 2 seconds was used, it could be seen 
that the tissue sample remained in a pellet at the bottom of the sample tube. Therefore, it 
was concluded that an optimal probe sonication time of 5 seconds would be used in the 
final method. This was performed on ice, in order to preserve the sample integrity and to 
keep sample degradation to an absolute minimum. 
Additionally, the time of centrifugation following sonication was considered. This was 
undertaken by initially centrifuging samples for 10, 20 and 30 minutes (all at 20,000 g). 
The supernatant was examined by eye following each centrifugation time. It was observed 
after the 10 and 20 minute centrifugation that the pellet was not fully formed and that there 
were tissue particles present in the supernatant. After 30 minutes of centrifugation the 
pellet was fully formed and the supernatant was clear. Therefore, it was concluded that a 
30 minute centrifugation was necessary for this sample protocol.  
2.4.2 Protein Concentration Determination 
The protein concentration was determined (as described in section 2.3.2) in the samples 
extracted from the mouse brain tissue using a standard Bradford assay. It was found that a 
10 µm brain slice extraction contained 37 (±2) µg of protein and a 20 µm brain slice 
extraction contained 69 (±4) µg of protein. All brain slices were from mid-brain regions. 
See appendix 1 for the standard curve produced for determination of protein concentration. 
Additionally, it was found that the protein content in the size filtered <10kDa extraction 
samples was too low to measure using this method. This is as expected, due to the majority 
of protein in tissue being larger than 10 kDa in size. 
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2.4.3 LC-MS-MS for Protein Identification 
Two brain slices from each stroke induced mouse brain were extracted for LC-MS analysis 
as described in section 2.3.1.  In addition two brain slices from six of the wild type mouse 
brains were extracted for LC-MS analysis. This resulted in four 10 µm slices, four 15 µm 
slices and four 20 µm slices from stroke induced and wild type mouse brains. 
All LC-MS-MS data was searched using MASCOT version 2.1 against database NCBInr 
20070413 (4848751 sequences; 1676925347 residues), as described in section 2.3.3. 
Masses of proteins identified were compared with masses of interest identified using 
MALDI-MSI, from the stroke brain regions.  
A total of 67 proteins were identified. These identifications are shown in appendix 1. Three 
features were identified which matched masses from the MALDI-MSI analysis. These 
features were considered to be possible markers for stroke; that is features that show up or 
down regulation in stroke brain when compared with wild type brain. 
These features were identified by the LC-MS-MS analysis as being the following proteins: 
ATP synthase, MHC Class II Antigen and Myelin Basic Protein. The MASCOT results 
and are shown in figures 2.1 – 2.3. It can be seen that the MASCOT scores for these 
identifications range from 68 to 185. The mass of each identified protein can be seen in the 
top line of each figure. It should be noted that the scores for the peptides seen in ATP 
synthase and Myelin Basic Protein are higher than those seen in MHC Class II Antigen, 
meaning the identifications are more statistically likely for the peptides with higher scores. 
In addition, the differences between the expected and identified peptides for MHC Class II 
Antigen are rather high. 
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Figure 2.1 MASCOT results from mouse stroke brain, extracted and analysed using Dionex 
Ultimate nano-flow LC system and Applied Biosystems Q-Star in MS-MS mode. ATP 
synthase subunit E is identified. 
 
 
Figure 2.2 MASCOT results from mouse stroke brain, extracted and analysed using Dionex 
Ultimate nano-flow LC system and Applied Biosystems Q-Star in MS-MS mode. MHC Class II 
antigen is identified. 
 
 
Figure 2.3 MASCOT results from mouse stroke brain, extracted and analysed using Dionex 
Ultimate nano-flow LC system and Applied Biosystems Q-Star in MS-MS mode. Myelin Basic 
Protein is identified. 
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The MALDI-MSI image of mouse stroke brain is shown in figure 2.4. As mentioned 
previously, this analysis was undertaken by Dr Richard Goodwin. This image shows a 
‘heat map’ of feature with mass 4964 Da.  
The images are successive sections taken from a stroke induced mouse brain. The stroke 
region occurs in the bottom part of the brain image. The heat map indicates decreased 
concentration of the 4964 Da feature in this region. The 4964 Da feature is identified in the 
LC-MS-MS analysis as ATP-Synthase subunit E. However, it must be considered that all 
spatial information is lost in the LC-MS-MS analysis procedure. This means that further 
validation steps are needed to confirm this identification, simply matching the two masses 
together is not sufficient to conclude this investigation.  
In addition, in the LC-MS-MS data there was no signal seen for a 4964 Da protein.  The 
peptides identified by LC-MS-MS are fragments of the ATP-Synthase subunit E, making it 
difficult to come to the conclusion that ATP-Synthase subunit E is also identified in the 
MALDI-MSI data. 
 
    
Figure 2.4 MALDI-MSI image of feature 4964 Da, in mouse stroke brain, possibly relating to 
ATP-Synthase subunit E.  Three successive sections of the brain are shown, with the stroke 
region occurring in the bottom part of the image.  This figure is a heat map based 
demonstration of the concentration of this mass, with the colour scale shown to the left. It 
can be seen that there is a decreased concentration of the feature in the stroke regions of 
all three images of the brain. 
 
The LC-MS-MS identifications reported above were all made using the simpler one 
dimensional LC separation, as described at the start of section 2.3.3.  
It should be noted here that hese samples have not been digested in the traditional 
proteomic way using trypsin, therefore the proteins and protein fragments within the 
sample are not ‘tryptic’.  
Stroke 
region of 
brain 
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In the digestion process the enzyme trypsin cleaves the proteins at the carboxyl side of the 
amino acids arginine and lysine, resulting in tryptic peptides which have terminal groups of 
either arginine or lysine, the structures of these are shown in figures 2.5 and 2.6. 
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Figure 2.5 Structure of amino acid arginine         Figure 2.6 Structure of amino acid lysine 
 
The fragments produced in MS-MS fragmentation are dependent on many factors. This 
includes the primary sequence of the peptide, the amount of internal energy, the charge 
state of the ion and the way the energy is introduced into the ion. Additionally, the 
fragments will only be detected if they have at least one charge. The fragmentation method 
used here is collision induced dissociation (CID), which is discussed in the introduction 
section 1.3. This involves collision of the peptide with an inert gas to induce 
fragmentation. This usually occurs preferentially at the peptide bond to produce y and b 
ion fragments as shown in figure 2.7. This nomenclature was introduced by Roepstorff and 
Fohlman in 1984 (269). The sequence of these ions then allows identification of the 
peptide. 
 
Figure 2.7 Cleavage of peptide bond to produce b and y ions,  from Barton and Whittaker 
2008 (270) 
 
Tryptic peptides are particularly well suited to CID MS-MS fragmentation, as used here, 
and are usually identified fairly easily. It is proposed here that the non-tryptic peptides 
produced from the intact samples do not fragment well in this way, and are hence difficult 
to identify in this manner. 
Additionally, a two-dimensional separation was performed, described in the latter part of 
section 2.3.3. This two-dimensional separation had a tryptic digestion step included in the 
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protocol. The problem with using a digestion step, in this type of work, is that the features 
identified by the following analysis will be likely to relate to fragments of those seen in the 
MALDI-MSI, rather than intact features. This means that it is very challenging to relate 
these two types of datasets with one another. Additionally, the two-dimensional analysis is 
very time consuming, taking 24 hours for one separation, in comparison with 90 minutes 
for a standard one dimensional separation. However, the advantages of using the two-
dimensional analysis is that low abundance peptides may be identified, which cannot be 
seen in a conventional 1-dimensional LC-MS-MS analysis. 
The two-dimensional analysis did result in further protein identifications, however, it was 
decided that the results were not suitable for this research due to the digestion step in the 
protocol and the challenges this brings with relating the LC-MS-MS data with the MALDI-
MSI data. For this reason these results will not be considered any further in this research.  
2.4.4 Gels and Western Blots as Confirmation of Identification 
A silver stained 1D gel of laser microdissected tissue (900 x 560 µm in area) from mouse 
stroke brain and wild type brain is shown in figure 2.8 below. All samples were taken from 
10 µm thick tissue slices. As previously mentioned all LMD was performed by Alastair 
Michael Lang. 
Lane 1 shows a protein size molecular marker. Lanes 2 and 3 are from wild type mouse 
brain, and lanes 4, 5 and 6 are taken from the stroke region from stroke induced mouse 
brain. The tissue from the wild type brain was taken from the corresponding brain regions 
to the stroke regions from the stroke brains. 
It can be seen that there are many different bands, as would be expected of a complex 
tissue sample. It is also observed that there are certain bands which are stronger in the wild 
type brain lanes. 
Unfortunately, this gel shows some streaking and overloading. In particular the protein 
marker lane is particularly overloaded. The image of the gel is also not ideal. Towards the 
validation stages of this work the tissue sample amounts available for experimentation 
became extremely limited. Ideally, this gel would have been repeated to obtain a higher 
quality image; however, this was not possible due to sample limitations.   
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Figure 2.8 1D gel of mouse brain samples, laser microdissected. Lanes 2 and 3 are from wild 
type healthy brain. Lanes 4, 5 and 6 are stroke region from stroke induced mouse brain. 
Lane 1 is a protein size molecular marker. Laser microdissected area is 900 x 560 µm. 
Tissue slices are 10 µm thick. The gel was visualised using silver staining as discussed in 
section 2.3.4. 
 
Western blots were performed using three antibodies; ATP synthase, MHC Class II antigen 
and Myelin basic protein, as these were the proteins identified in the LC-MS-MS analysis 
that corresponded to features from MALDI-MSI data. All antibodies used were polyclonal 
and hence will recognise multiple epitopes on any one antigen. The advantages of using 
polyclonal antibodies are that they are more likely to be able to recognise denatured 
proteins and generally provide more robust detection. In contrast monoclonal antibodies 
recognise only one epitope and will therefore give more specific detection than polyclonal 
antibodies. Polyclonal antibodies were used here to attempt to obtain a robust, first 
detection of the proteins in question. 
No clear bands were seen for blots of MHC Class II antigen and Myelin basic protein, 
therefore this data is not presented here. This was thought to be due to poor performance of 
antibodies, which is a well known problem with this type of validation technique. It was 
1    2     3      4     5    6
Protein 
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Wild Type 
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83 kDa 
 
 
62 kDa 
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32.5 kDa 
 
25 kDa 
 
16.5 kDa 
 
 
6.5 kDa 
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proposed that these western blots be repeated with alternative antibodies; however this was 
not possible due to lack of sample availability. The initial western blot for ATP synthase, 
using entire brain slices, was very over-exposed, even with a short 30 second exposure 
time and this is not presented here. The repeated western blot for ATP synthase, with laser 
microdissected brain regions is shown in figure 2.9 below. Brain tissue was laser 
microdissected from stroke region of three brain slices, of an area 900 x 560 x 10 µm. This 
was repeated for two wild type brain slices, of an identical size from the same brain region. 
It can be seen that the bands for the wild type brain are larger and more intense than the 
bands for the stroke brain region. This is as predicted by the data obtained from the 
MALDI-MSI.  
 
Figure 2.9 Western blot of laser microdissected stroke induced and wild type mouse brains, 
for ATP synthase. Lanes 1 and 2 are from wild type healthy brain. Lanes 3, 4 and 5 are 
stroke region from stroke induced mouse brain. Laser microdissected area was 900 x 560 
µm. Tissue slices were 10 µm thick. The bands from the wild type mouse brain are more 
intense than those from the stroke induced brains, as predicted by MALDI-MSI.  
 
However, if the corresponding 1D gel image is examined, it can be seen that the wild type 
brain lanes are more intense than those observed in the stroke brain lanes. It is proposed 
that this may be due to oedema in the stroke brain, causing swelling of the tissue. This 
would result in a smaller amount of tissue being sampled in the laser microdissection of an 
equivalent area of stroke brain, as the tissue is sampled by area only and not protein 
concentration. To investigate this, the western blot was repeated using a tubulin loading 
standard. The loading standard will allow confirmation of whether equal protein 
concentrations are being sampled. The results of this are shown in figure 2.10. 
 
1          2           3         4          5 
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Figure 2.10 Western blot of laser microdissected stroke induced and wild type mouse 
brains, for ATP synthase, with a loading standard of Tubulin. Lane 1 is from wild type 
healthy brain. Lane 2 is stroke region from stroke induced mouse brain. Laser 
microdissected area is 900 x 560 µm. Tissue slices are 10 µm thick. The bands from the wild 
type mouse brain are more intense than those from the stroke induced brains, for both ATP 
synthase and for the loading standard, confirming the theory that oedema induced swelling 
has caused a larger amount of tissue to be sampled from the wild type brain with 
comparison to the stroke brain.  
 
The western blot with loading standard concurs with the aforementioned theory of oedema 
induced swelling causing the same area of tissue, but differing overall protein 
concentration to be sampled by laser microdissection.  
It was proposed that western blots be repeated and normalisation performed against 
loading standards. It was also proposed that immunohistochemistry could be used as an 
additional validation technique. Immunohistochemistry would give a direct comparison 
with MALDI-MSI results and would be an ideal validation technique. However, 
unfortunately due to a lack of sample availability this work could not be completed. 
1 2 
Tubulin 
ATP Synthase 
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2.5 Discussion 
The work in this chapter aimed to develop a biomarker identification method, in 
conjunction with, and guided by MALDI-MSI, a previously developed technique. MALDI-
MSI can be used to investigate spatial differences of bio-molecules between diseased and 
healthy tissue samples and identify regions that change and markers that define these 
regions; however it often proves to be a challenge to identify the peptide and protein 
defining differences using MALDI-MSI alone. In this work, a conventional proteomic 
technique LC-MS (described in section 2.3.3) is used in an attempt to identify these 
previously defined features, in this example from mouse stroke induced brain. Previous 
work conducted by Dr Richard Goodwin, found features of interest, but these could not be 
identified.  
LC-MS techniques, including 1D and 2D liquid chromatography were used in an attempt 
to identify the features in question from brain tissue. It was concluded that the 2D analysis 
was not suitable for this type of research, due to the digestion step introducing global 
changes to the sample. This means that the data from the 2D LC-MS cannot be easily 
correlated with the MALDI-MSI data.  
The 1D LC-MS data was searched using MASCOT against NCBInr database, and the 
masses of identified proteins were compared with features of interest previously identified 
in the MALDI-MSI work. 1D gels and western blotting were used to validate the 
identifications made. However, due to lack of sample availability it was not possible to 
complete the validation. It was, however, discovered that samples of different protein 
concentration were unwittingly sampled from the stroke and wild type brain tissue, as 
discussed in section 2.4.4. It was theorized that the stroke induced brain tissue may have 
been swollen due to oedema, causing the difference in sampling by laser microdissection, 
leading to potentially mis-leading results in the western blots. Any future western blots 
from stroke brain tissue will be normalised using a loading standard in order to help to 
avoid this. It was also proposed that immunohistochemistry could be used as a useful 
validation technique, giving a direct comparison to the MALDI-MSI data. 
As this work progressed it became apparent that certain assumptions must be made when 
attempting to relate two datasets of different types. One of the main advantages of 
MALDI-MSI is that spatial information is not lost, allowing features to be investigated in 
their original location. This can allow investigation into different areas of tissue, and is 
very applicable to stroke induced tissue, as the stroke region can be easily visualised. The 
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ideal way to identify these features would be direct MS-MS fragmentation of the feature in 
question from the tissue. In this way it can be certain that the correct feature is being 
targeted for identification. Unfortunately this is a difficult technique to perfect, and often 
direct fragmentation from tissue simply is not possible. When proteins are extracted into 
solution, all spatial information is lost, meaning that the only way to target specific features 
is by mass alone. This has clear disadvantages. Tissue is a complex sample and there are 
likely to be more than one feature with the same mass present in a tissue sample. 
Enzymatic degradation can also cause changes in the features present in samples, and it is 
therefore entirely possible that a feature identified with the same mass by MALDI-MSI 
and LC-MS-MS analysis may in fact be an entirely different feature. For this reason 
validation techniques are vital when using a method such as the one developed here, and in 
this case it is unfortunate that the validation could not be completed.  
During the course of this work direct MS-MS fragmentation from tissue has been 
improved and optimised, and it is thought to be likely that this will be the main target for 
improvement in the future for identification of features found via MALDI-MSI, due to the 
advantages of spatial information, and the reduced need for time-consuming validation 
with traditional biochemical techniques. However, this technique is still only applicable to 
masses above 2.5 – 3 kDa. Additionally, the work here has been a useful exercise in 
developing a method for analysis of brain tissue using LC-MS, and has been applied to the 
following chapter ‘Assessment of Denator Heat Treatment for Prevention of Proteomic 
Sample Degradation using Label Free Relative Quantitation’. In this chapter the issue of 
enzymatic degradation changing the composition of tissue samples is also addressed. This 
is an important issue as uncontrolled sample degradation has been known to give mis-
leading and difficult to interpret results.  
This work in this chapter has clearly demonstrated the importance of sampling issues, as 
changes to tissue due to disease have been seen to cause global changes in protein and 
peptide concentration. Rigorous controls and standards can help to prevent this; however 
physical treatment of biological samples, such as tissue, must also be tightly controlled. 
One of the main conclusions made from this research has been the importance of 
experimental planning and thought prior to experimentation. Sample integrity is one of, if 
not the most important problems in biological proteomic research, and is of vital 
importance when sample availability is limited, as it was here. Prevention of sample 
degradation and maintenance of sample integrity is investigated further in the following 
chapters.            
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3 Assessment of Heat Treatment for Prevention of 
Proteomic Sample Degradation using Label Free 
Relative Quantitation  
3.1 Introduction 
The use of proteomic technologies for analysis of tissue continues to be a growing field 
with many important applications, including biomarker discovery and identification. These 
techniques can be applied to a variety of different disease states and tissue types, such as 
pancreatic cancer, lung cancer, and ovarian cancer (271-274). However, sample 
degradation of protein in tissue samples continues to be an ongoing challenge for 
proteomic analysis, as demonstrated in the previous chapter. Endogenous proteolytic 
enzymatic action can cause large changes in samples following collection and storage to 
point of analysis. Degradation can be rapid and sometimes semi-random, especially if cells 
are ruptured by freeze-thawing or tissue sectioning (275;276). Such degradation can distort 
any qualitative and especially quantitative proteomic analysis, particularly if degradation is 
variable. For instance, if there is the same degree of degradation in each sample this can be 
dealt with, however if degradation is variable between samples, this is when disortion of 
results can be particulary crucial. Traditionally the solution for this problem is to store 
samples at a low temperature (typically below minus 80 ºC) and to use protease inhibitors 
as early in the sample preparation as possible. However this can cause further problems. 
Protease inhibitors can interfere with mass spectrometric analysis, and snap freezing of 
tissue can cause damage and sample loss. Understanding and, if possible, controlling these 
degradation processes will be of significant importance within many areas of proteomic 
research. A sample preservation step that is applied as early as possible after sampling 
would seem like the ideal solution to this problem. 
It has previously been reported that microwave irradiation can prevent changes of labile 
molecules, including cyclic AMP and phosphoproteins (277;278). The principle behind 
this is thermal inactivation of enzymes in the tissue. Further work has demonstrated that 
animals sacrificed with focused microwave irradiation have higher levels of detectable 
neuropeptides, than traditionally sacrificed animals (279-281). Specifically, Svensson et al 
(282) showed that neuropeptides were detected in mice and rats sacrificed using a focused 
microwave irradiation method. A major disadvantage of this method is that the animals 
must be restrained in a stressful manner prior to sacrifice, and additionally the cost of the 
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focused irradiation device (over $40,000). It was hypothesized by Che et al (283) that 
protein degradation occurred in the time between decapitation and dissection of the brain. 
They demonstrated that a conventional microwave oven can be used post-mortem to 
prevent protein breakdown in mouse brain tissue, simply by placing the entire animal head 
in the microwave. The temperature of the brain was monitored using a probe thermometer, 
and varied from 60 – 90 ºC.  This work was a good proof of the principle behind this 
theory, however there were certain issues with the research. Of particular worry is the large 
variation in temperature which cannot be controlled within a microwave oven. 
In my work presented here a denaturing device (Denator AB, Gothenburg, Sweden) has 
been evaluated for sample preservation using brain tissue as a sample tissue. This 
instrument works using a combination of pressure and heat to rapidly and homogenously 
heat the tissue sample preventing proteolytic activity by denaturing enzymes and proteins. 
It is proposed that this fast, homogenous heat distribution will give more effective, 
reproducible sample preservation than alternative denaturing methods, or by sample 
processing at low temperature alone. The use of heat-treatment on tissues immediately 
postmortem, to halt enzymatic degradation by denaturing both enzymes and proteins 
within tissue, is described in this work. The precise and rapid heating of tissue can be 
demonstrated to have a range of beneficial affects such as reducing the number of peptide 
fragments derived from abundant proteins present in samples, and also allowing a 
significant increase in the period that can be spent processing samples at room temperature 
without degradation of protein and peptide molecules. 
High performance liquid chromatography coupled to electrospray mass spectrometry 
(HPLC-ESI-MS) is a well established technique for protein identification, as discussed in 
the previous chapter. It is especially applicable to identification of proteins in complex 
biological mixtures, such as body fluids or tissue extracts, meaning it is an ideal technique 
to quantify differences caused by sample degradation. In this work HPLC-ESI-MS is used 
for identification of proteins, in conjunction with database interrogation. A label free 
relative quantitation method is applied to quantify the differences seen between 
conventionally treated snap frozen samples and heat treated samples, both initially and 
following sample manipulation. Label free relative quantitation is based on the principle of 
comparing identical proteolytically digested peptides, which elute with the same retention 
time using LC-MS analysis, from different samples. The relative ratios of the protein can 
then be calculated. The benefits of label free quantitation are discussed in more detail in 
the introduction in section 1.9. 
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Mouse brain tissue is used from WKY (wild type) mice. In addition, the time the mouse 
brain can be left at room temperature, following heat treatment or snap freezing, without 
detrimental effect on the proteomic data is also evaluated.   
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3.2 Aims 
There are several important aims in this chapter, which will be discussed in more detail in 
the following sections. 
• Evaluate the overall effect of heat treatment on the mouse brain tissue sub10 kDa 
proteome 
• Evaluate the overall effect of heat treatment on the mouse brain tissue digested 
sub10kDa proteome 
• Development of a label free relative quantitation method in order to quantify the 
differences seen between heat treated samples and snap frozen samples in both 
digested and intact sub 10 kDa proteome 
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3.3 Methods 
3.3.1 Sample Preparation 
As described in section 2.3.1, Male ICR mice (6-8 weeks) were euthanatized by cervical 
dislocation in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and 
local ethical guidelines. The brain was rapidly removed and processed. Brains were 
dissected into the two hemispheres. One hemisphere was heat-treated (using the Denator 
system) and then snap-frozen in liquid nitrogen, while the other hemisphere was only snap-
frozen in liquid nitrogen.  The removal and treatment of the brain was accomplished in 
approximately 60 seconds. Samples were then stored at minus 80 oC until required. All 
subsequent movement of tissue was done on dry ice, with all containers pre-chilled to 
minimize the possibility of localized tissue warming. Tissue sections were cut on a cryostat 
microtome to 10 µm thick sections (Leica Microsystems CM 1900UV, UK), with the 
microtome chamber pre-chilled to minus 20 oC. Samples were then placed directly into 
chilled sample tubes (Eppendorf). 
As a time point study of degradation was to be performed, samples were allowed to thaw at 
room temperature for differing lengths of time: 
• Heat treated   0 minutes at room temperature 
• Heat treated  5 minutes at room temperature 
• Heat treated  10 minutes at room temperature. 
 
• Snap frozen   0 minutes at room temperature 
• Snap frozen   5 minutes at room temperature 
• Snap frozen  10 minutes at room temperature. 
Each group contains 3 biological replicates. Each sample was split into two aliquots to 
create two separate sample sets.  
This allows a comparison of protein degradation over time, between frozen and heat 
treated samples. Samples were then split into two further sets. One set was analysed as 
intact protein samples, and the second set of samples were prepared for tryptic digestion. 
Therefore there will be 3 replicates for each sub sample set. 
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For generation of intact protein samples 50 µl of a 1 % formic acid solution was added to 
the tissue sample, in the sample tube. This was then centrifuged for 10 seconds at 14,000 
rpm, before being vortexed vigorously and centrifuged again. A 10 second probe 
sonication was then used for cell lysis. The sample was then vortexed vigorously and 
centrifuged at 14,000 rpm for 30 minutes at 4 ºC. The supernatant was removed and 
applied to a Microcon 10,000 Da molecular weight filter (as described in section 2.3.1). 
This was centrifuged for 30 minutes at 14,000 rpm at 4 ºC, prior to the addition of 50 µl of 
a 1 % formic acid solution. It was then centrifuged again for 30 minutes at 14,000 rpm at 4 
ºC. The below 10,000 Da molecular weight fraction (the filtrate) was collected and then 
stored at minus 20 ºC prior to analysis. The samples for tryptic digestion were processed in 
the same way except that the 1 % formic acid solution was replaced with a 25 mM 
ammonium bicarbonate solution. Following the size filtration step, 2 µl of a 0.5 µg/µl 
sequencing grade porcin trypsin (Promega, catalogue number V5111) was added to each 
sample, and left to incubate overnight at 37 ºC.  
3.3.2 LC-MS 
Following size filtration and digestion (as described in section 3.3.1) the samples were then 
analysed by HPLC-ESI-MS using a Dionex 3000 LC system and a Bruker (Banner Lane, 
Coventry) HCT Ultra. A 60 minute gradient separation was used (5 % Solvent B to 80 % 
solvent B). The LC separation was performed on a 15 cm C18 PepMap reverse phase 
column with a 75 µm internal diameter (Dionex). This was stored in a 37 ºC oven for the 
duration of the separation. Solvent A was a 2 % acetonitrile, 0.1 % formic acid solution 
and solvent B was an 80 % acetonitrile, 0.1 % formic acid. The loading solution used was a 
2 % acetonitrile, 0.5 % tri-fluoroacetic acid solution. The loading flow, onto the trap was 
maintained at 30 µl/min. The column flow was maintained at 0.3 µl/min. MS data was 
collected from m/z 150-2000, in positive ion mode, with an accumulation time of 3 
seconds. Decyder MS (GE Healthcare, Amersham Place, Little Chalfont, 
Buckinghamshire) was used for label free relative quantitation, using the following 
settings: 
Typical peak width of 0.5 minutes, Trap resolution of 0.4 u, charge states of 1-4, uniform 
background model, signal-to-background detection threshold of 4.0, background subtracted 
quantitation, charge assignment enabled where possible, charge assignment from two 
peaks limited, LC peak shape tolerance of 20 %, m/z shift tolerance of 0.1 u, m/z shape 
tolerance of 5 %, remove peptides below S/N of 4.0, remove peptides of unspecified 
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charge below S/N of 4.0, remove peptides with low quality LC peaks, remove overlapping 
peptides, spectrum vs model tolerance of 15 %. 
Settings for spectrum alignment in Decyder MS were as follows: 
Max/stretch compress: 2, Max leader and trailer: 10 %, Stretch compress penalty: 0.1 
Settings for peptide matching in Decyder MS were as follows: 
Time tolerance: 1 minute, Mass tolerance: 0.5 Da, Use aligned retention times, Cross 
detection: Add peptides to intensity maps if present in 1 map 
Normalisation was performed using a measured intensity distribution. This means that the 
entire peptide population is used for normalisation. It is assumed that most samples contain 
peptides that do not vary in intensity and the normalisation is performed without any 
further specifications. This is the recommended method of normalisation, by the 
maufacturers of the software, unless very few peptides are present in the samples. 
The settings used for the Decyder MS analysis were optimised using instructions and 
advice from the manufacturer. The optimisation process included ensuring the correct peak 
width and resolution are used for the instrument in question. Additionally, it ensures noise 
is filtered efficiently and charge assignment is performed correctly. 
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As previously mentioned there are 6 sample groups, and two separate sample sub-sets. 
This is summarised as follows: 
Heat Treated Snap Frozen 
0 minutes at room temperature        
3 samples – Intact                               
3 samples – Digested 
0 minutes at room temperature         
3 samples – Intact                                 
3 samples – Digested 
5 minutes at room temperature        
3 samples – Intact                               
3 samples – Digested 
5 minutes at room temperature         
3 samples – Intact                                 
3 samples – Digested 
10 minutes at room temperature      
3 samples – Intact                               
3 samples – Digested 
10 minutes at room temperature       
3 samples – Intact                                 
3 samples – Digested 
Table 3.1 Table summarising samples sets 
 
3.3.3 Statistical Analysis of LC-MS data for Label Free 
Quantitation 
The LC-MS data was analysed using one-way ANOVA (Analysis of Variance). This is 
discussed in more detail in the results section 3.4.2. 
3.3.4 LC-MS-MS for Targeted and Untargeted Protein 
Identification, using Ion Trap MS 
Subsequent to masses of interest being identified (as described in section 3.3.2), the 
samples were re-analysed, using the Dionex 3000 nano-flow LC system and a Bruker HCT 
Ultra. As in section 3.3.2, a 60 minute gradient was used. The LC separation was 
performed on a 15cm C18 PepMap reverse phase column with a 75 µm internal diameter, 
from Dionex. This was stored in a 37 ºC oven for the duration of the separation. Solvent A 
was a 2 % acetonitrile, 0.1 % formic acid solution and solvent B was an 80 % acetonitrile, 
0.1 % formic acid. The loading solution used was a 2 % acetonitrile, 0.5 % tri-fluoroacetic 
acid solution. The loading flow, onto the trap was maintained at 30 µl/min. The column 
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flow was maintained at 0.3 µl/min. MS data was collected from m/z 150-2000, in positive 
ion mode, with an accumulation time of 3 seconds. Targeted MS-MS (as described in the 
introduction, in section 1.3) was used in conjunction with MASCOT database searching for 
peptide and protein identification. The targeted MS-MS was performed using a simple 
‘Include List’ strategy, in which the mass spectrometer preferentially performs MS-MS 
fragmentation of the specified masses. Again, this was repeated for the lower than 10,000 
Da tryptically digested fraction, and the lower than 10,000 Da intact fraction.  
Electrospray was performed using a Proxeon 30um x 50mm stainless steel nano-
electrospray emitter. Settings used were as follows: 
Ion Mode: Positive, Enhanced, Mass Range: m/z 500-3000, Max Fill Time: 250 ms, 
MS/MS Scans: 5 per MS (Ultrascan). 
Samples were re-analysed in MS-MS mode, without an include list to identify any peptides 
that were missed in the targeted MS-MS experiment. In this case MS-MS was performed 
on the most intense masses detected, as is the usual setting for MS-MS.  
All files were converted into MASCOT compatible ‘mgf’ files using Data Analysis 
(Bruker). They were then searched with MASCOT version 2.1 against database NCBInr 
20080422 (6468149 sequences; 2207779427 residues), using MASCOT search settings as 
follows: 
Species: Rodentia, Enzyme: Trypsin/No enzyme (depending on sample), Report top hits: 
Auto, Variable modifications: Oxidation of Methionine, Charge: 1+, 2+ and 3+, Peptide 
tolerance: 1.2 Da, MS/MS tolerance: 0.8 Da, Instrument: ESI-Trap. 
3.3.5 LC-MS-MS for Targeted and Untargeted Protein 
Identification using Q-TOF-MS 
The samples were also analysed using a Dionex Ultimate nano-flow LC system and an 
Applied Biosystems Q-Star, again both with and without an MS-MS include list. In this 
case an identical 60 minute gradient was used. The LC separation was performed on a 
15cm C18 PepMap reverse phase column with a 75 µm internal diameter, from Dionex. 
Solvent A was a 2 % acetonitrile, 0.1 % formic acid solution and solvent B was an 80 % 
acetonitrile, 0.1 % formic acid. The loading solution used was a 2 % acetonitrile, 0.5 % tri-
fluoroacetic acid solution. The loading flow, onto the trap was maintained at 0.2 ml/min. 
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The column flow was maintained at 0.3 µl/min. This LC system does not have a column 
oven, therefore the column was maintained at room temperature throughout the separation.  
Q-Star settings used were as follows: 
Accumulation time: 3 seconds, TOF masses: m/z 200 – 1500, Polarity: Positive, Cycle 
time: 15 seconds, Product ion masses: m/z 50 – 2000, dynamic exclusion was used, and 
rolling collision energy. Electrospray was performed using ‘picotip’ needles (New 
Objective) and the standard Q-Star electrospray source. 
Q-star ‘wif’ files were searched against database NCBInr 20080422 (6468149 sequences; 
2207779427 residues), using MASCOT search settings as follows: 
Species: Rodentia, Enzyme: No enzyme or trypsin (as appropriate), Report top hits: Auto, 
Variable modifications: Oxidation of Methionine, Charge: 1+, 2+ and 3+, Peptide 
tolerance: 1.2 Da, MS/MS tolerance: 0.8 Da, Instrument: ESI-TOF 
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3.4 Results 
3.4.1 Visual Evaluation of the Heat Treatment effect on Tissue 
The effect of the heat treatment on the structure of the brain tissue was observed. The 
rigidity of the tissue was seen to increase. Little change was observed in the overall brain 
anatomy. The tissue appeared darker in colour following the heat treatment. Following heat 
treatment the tissue was snap frozen and thawed without cracking or loss of structure that 
is often seen when snap freezing without heat treatment. There was also an observed 
reduction in odor from the thawed tissue when compared with untreated tissue. 
3.4.2 LC-MS and Label Free Relative Quantitation 
The LC-MS data obtained from the tissue samples, as detailed in section 3.3.2, was 
analysed using one-way ANOVA (Analysis of Variance). The one-way ANOVA method 
performs comparisons on an arbitrary number of populations. In Decyder MS, each non-
empty experimental group is considered as an ANOVA population. The ANOVA is used 
for each feature to test the null hypothesis that there is no difference in the abundance of 
the feature between the groups. The test does not indicate which groups are different from 
which other groups; it only indicates that there is an overall difference. The ANOVA null 
hypothesis is that the means of all populations are equal. The test is used to compare the 
variance between populations to the variance within populations. The ratio of these 
variances is known as the F-ratio, and this is used to calculate the p-value. A large F-ratio 
corresponds to a small p-value, which therefore indicates that the variation between 
populations is large in comparison to the variation within populations. This would mean 
that the populations may show a difference in abundance of the particular feature being 
tested. If the ANOVA p-value between two populations is 0.01, then under the null 
hypothesis the probability of obtaining the observed difference in abundance by chance is 
1 in 100. The ANOVA test assumes that the data points are normally (or approximately 
normally) distributed, and also that the variance of the populations are equal. Small 
deviations from a normal distribution are unlikely to affect the calculation greatly. 
However, if the variance among the groups differs greatly the ANOVA p-value may not be 
valid. This must be taken into account when using ANOVA p-values to determine 
differences in feature abundance between groups. In this analysis one of the most 
important decisions to be made is at what level to set a significant p-value. A common 
method is to simply choose an arbitrary value of 0.01, 0.005 or 0.001, and this is the 
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method of choice used in this chapter. This would mean that the probability of obtaining 
the observed difference by chance would be 1 in 100, 0.5 in 100, or 0.1 in 100, 
respectively. 
There are many other ways of statistically analysing data-sets such as these. This is 
explored and discussed more fully in the following chapter, “Discovery and Identification 
of Biomarkers for Hypertension”. However, in this chapter the fairly universally accepted 
method, of using arbitrarily defined ANOVA p-values is the method of choice. 
The samples analysed are summarised as follows 
• Sub 10kDa intact samples (heat treated and snap frozen) see section 3.4.2.1 
• Sub 10kDa digested samples (heat treated and snap frozen) see section 3.4.2.2 
3.4.2.1 Sub 10kDa Intact Sample Results 
The LC-MS datasets, as generated using the sub 10kDa samples (described in section 
3.3.2), were analysed using Decyder MS label free relative quantitation software. Each 
mass detected throughout the dataset will be referred to as a ‘Feature’, as the only 
information available at this stage in the analysis is mass, retention time, and relative 
intensity between groups. 
The total number of features detected across all 18 samples was 6034. An ANOVA score 
was calculated for each feature, across all 6 groups. This indicates whether that particular 
feature has a significant change between the groups. ANOVA calculates the within group 
variance, and compares it to the between groups variance. Therefore, the value does not 
tell us anything about the change in intensity, other than whether it is significant, or not. 
This means that this ANOVA score gives a starting point for the analysis. The expression 
profiles of these significant features must be analysed further for quantitation purposes. 
Various significant p-values were defined, and peptides with a p-value equal to or less than 
this were deemed to have a significant change between sample sets. This is summarised in 
the table 3.2: 
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Significant p value  Number of features with 
significant changes 
Percentage of features 
showing significant changes 
≤ 0.001 50 0.83 % 
≤ 0.005 80 1.33 % 
≤ 0.05 200 3.31 % 
 
Table 3.2 Summary of label free relative quantitation of heat treated and snap frozen 
samples (<10kDa intact samples). Shows three differing arbitrarily defined ANOVA p-values, 
and the affect this has on the percentage of features demonstrating significant changes 
between the six sample groups. (Total number of features identified was 6034) 
 
It is shown that even with a fairly high significant p-value, only 3.31 % of the total features 
identified have significant changes. This indicates that the heat treatment does not 
substantially alter the detected proteome, when compared with the snap frozen samples, 
and that the majority of proteins and peptides in the brain tissue do not degrade, or degrade 
to the same extent, regardless of the treatment applied to the samples. The small percentage 
of features that do have significantly different abundances in the differentially treated 
samples are of interest in this work  These features may be proteins and peptides that are 
either preserved, or stabilised, by the heat treatment, or equally could be destroyed by the 
treatment. The expression profiles across the sample sets are investigated for these 
particular features, and they will also be targeted for identification using MS-MS analysis. 
This will allow the heat treatment system to be assessed, in comparison with the 
conventional snap freezing treatment.   
All expression profiles for the 50 features with p-values ≤ 0.001 are shown in appendix 3.  
From visual examination of the profiles it is demonstrated that 7 show expression profile as 
predicted by figure 3.2 C and 25 show expression profile as predicted by figure 3.2 D. 
Predicted profiles are shown below.  
The average number of detected features across the sample groups is summarised in figure 
3.1. The average number of features detected across all six groups was 1186 with a 
standard deviation of 188.4.  
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Figure 3.1  Bar chart of average number of features detected by label free relative 
quantitation, for samples, sub 10kDa 
 
As the label free relative quantitation gives information for each feature regarding, mass, 
retention time and relative intensity, each feature can be visualised using what is known as 
an ‘Expression Profile’. This allows a simple visualisation of the relative intensity of the 
feature in question between the different groups.   
‘Relative intensity’ is a measure of how abundant the feature is, within the sample.  In 
mass spectrometry the abundance of a feature is measured by the current produced by the 
number of ions arriving at the detector, therefore the relative, not the absolute, intensity is 
measured.  In addition, the LC-MS data expressed here has been normalised against the 
total intensity of all peptides in the sample, as discussed in section 3.3.2, therefore the 
‘relative intensity’ of each feature presented in this work refers to the abundance of each 
feature relative to the other features present in the sample set. 
As mentioned previously the features which change significantly across the sample groups 
are of particular interest here. The predicted profiles that would demonstrate different 
effects caused by the heat treatment process on features within the samples are shown in 
figure 3.2 (A-D): 
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 A      B 
 
      
 C      D 
 
Figure 3.2 D0, D5 and D10 refer to the three timepoints, denator heat treated. F0, F5 and F10 
refer to the three time points, snap frozen.  These potential expression profiles have several 
possible explanations, which are expanded below. 
 
Figure 3.2 (A) shows the predicted expression profile indicating that the heat treatment has 
stabilised this feature prior to, during and following slicing of the tissue. Figure 3.2 (B) 
shows the predicted expression profile indicating that the heat treatment has had no effect 
on the tissue. Figure 3.2 (C) shows the predicted expression profile indicating that the heat 
treatment has stabilised this feature prior to and during slicing of the tissue. Figure 3.2 (D) 
shows the predicted expression profile indicating that the heat treatment has stabilised this 
feature prior to and during slicing of the tissue, suggesting a larger mass has degraded to 
produce a higher intensity of a smaller mass. Conversely, this could show that the heat 
treatment has degraded this feature prior to and during slicing 
In an attempt to focus purely on the features with the largest and most significant changes, 
only those with an ANOVA p-value of < 0.001 were focused upon. Example expression 
profiles for a selected number of these features are shown in figures 3.3 to 3.6.  
These figures relate to the mean relative intensity within each group, with error bars 
representing +/- one standard deviation. The y-axis shows the Average Log2 Intensity, and 
the x-axis represents the six different sample groups. The expression profiles seen here are 
visually compared with the predicted expression profiles shown in figure 3.2. 
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Intensity 
D0            D5        D10         F0          F5          F10 
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D0           D5         D10       F0          F5        F10 
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Figure 3.3 Expression profile showing relative mean intensity across all six groups of 
the feature with mass 1832.980 Da and p value of 1.66E-11. Insert shows predicted 
expression profile for comparison. 
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Figure 3.4 Expression profile showing relative mean intensity across all six groups of 
the feature with mass 1228.512 Da and p value of 1.11E-07. Insert shows predicted 
expression profile for comparison. 
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Figure 3.5 Expression profile showing relative mean intensity across all six groups of 
the feature with mass 2021.021 Da and p value of 1.52E-07. Insert shows predicted 
expression profile for comparison. 
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Figure 3.6 Expression profile showing relative mean intensity across all six groups of 
the feature with mass 543.124 Da and p value of 8.87E-07. Insert shows predicted 
expression profile for comparison. 
 
These selected expression profiles, as seen in figures 3.3 to 3.6, demonstrate that the heat 
treatment has a range of effects on different features. It may degrade some proteins and 
peptides, and conversely it may denature enzymes, stabilising and preserving other 
proteins and peptides. Therefore, the heat treatment may enable detection of features that 
are otherwise degraded prior to mass spectrometry treatment. This may mean detection of 
interesting biomarkers and disease targets. The features that have differing abundances 
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between the groups are targeted for identification, to enable further insight into the effects 
of the heat treatment, as opposed to conventional snap freezing. 
3.4.2.2 Sub 10kDa Digested Sample Results 
The sample data from the digested samples, prepared as described in section 3.3.1, was 
analysed as described in section 3.3.2, using Decyder MS label free quantitation software.  
The total number of features detected across all 18 samples was 4282. Again (as in section 
3.4.2.1), various significant p-values were defined, and peptides with a p-value equal to or 
less than this were deemed to have a significant change. This is summarised in the table 
3.3: 
Significant p value  
(from ANOVA) 
Number of Features with 
significant changes 
Percentage of Features 
showing significant changes 
≤ 0.001 39 0.91 % 
≤ 0.005 104 2.43 % 
≤ 0.05 376 8.78 % 
Table 3.3 Summary of heat treatment analysis of <10kDa digested samples. Shows three 
differing arbitrarily defined ANOVA p-values, and the effect this has on the percentage of 
features demonstrating significant changes between the six sample groups. (Total number 
of features identified was 4282). 
 
The distribution of total features detected is summarised in figure 3.7 below. There are less 
total features detected in the digested samples in comparison to the intact samples; 
however there are more features detected in each individual sample. This indicates that 
there are a larger number of the same features detected in each digested sample in 
comparison to the intact samples. This is possibly due to the tryptic digestion creating 
reproducible samples, which are easier to analyse using LC-MS. Peptide samples may have 
more reproducible LC retention times, and are less likely to block columns and be lost due 
to sample processing, in comparison with the undigested samples.  
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Figure 3.7 Bar chart of average number of features detected by label free relative 
quantitation, for samples, sub 10kDa tryptically digested 
 
Again as in section 3.4.2.1, in an attempt to focus purely on the features with the largest 
changes, only those with an ANOVA p-value of < 0.001 were focused upon. Example 
expression profiles for a selected number of these features are shown in figures 3.8 to 3.11 
below. These are also visually compared with the predicted expression profiles, shown in 
figure 3.2. 
All expression profiles for the 39 features with p-values ≤ 0.001 are shown in appendix 4.  
From visual examination of the profiles it is demonstrated that 6 show expression profiles 
which match figure 3.2 C and 5 show expression profile which match figure 3.2 D. 
Predicted profiles are shown below.  
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Figure 3.8 Expression profile showing relative mean intensity across all six groups of 
the feature with mass 654.489 Da and p value of 4.53E-06. Insert shows predicted 
expression profile for comparison. 
 
12
13
14
15
16
17
18
19
D0 D5 D10 F0 F5 F10
A
ve
ra
ge
 L
og
2 I
nt
en
si
ty
 
Figure 3.9 Expression profile showing relative mean intensity across all six groups of 
the feature with mass 289.713 Da and p value8.95E-05. Insert shows predicted expression 
profile for comparison. 
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Figure 3.10 Expression profile showing relative mean intensity across all six groups of 
the feature with mass 1114.749 Da and p value of 0.000127. Insert shows predicted 
expression profile for comparison. 
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Figure 3.11 Expression profile showing relative mean intensity across all six groups of 
the feature with mass 537.157 Da and p value of 0.000646. Insert shows predicted 
expression profile for comparison. 
 
As with the sub10kDa undigested samples, discussed in section 3.4.2.1, these selected 
expression profiles demonstrate that heat treatment will have a differing effect on different 
types of features. It may degrade some proteins and peptides, and conversely it may 
denature enzymes, stabilising and preserving other proteins and peptides. This means that 
the heat treatment may enable detection of features that are otherwise degraded prior to 
mass spectrometry treatment. This may mean detection of interesting biomarkers and 
disease targets. Again, the features that have differing abundances between the groups are 
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targeted for identification, to enable further insight into the effects of the heat treatment, as 
opposed to the traditional snap freezing. 
3.4.3 LC-MS-MS for Targeted Protein ID using Ion Trap MS 
3.4.3.1 <10kDa Intact Sample Results 
It should be noted that the features of interest are identified by mass, retention time and 
relative quantity across the six groups only. There is still no information available 
regarding the actual identity of the feature. To remedy this situation, two separate mass 
spectrometers were used to target the masses of interest for fragmentation and subsequent 
identification. The features within the <10kDa intact samples proved extremely 
challenging to identify. Targeted MS-MS was performed for the features of interest, on 
these samples. Very poor quality MS-MS spectra were obtained, of low intensity. 
Unfortunately no identifications were able to be made from these, and this data is not 
presented here.  
As in chapter 2, the samples here have not been digested in the traditional way using 
trypsin, meaning it can be challenging to identify the peptides using collision induced 
dissociation fragmentation. The reasons for this are discussed in more detail in section 
2.4.3. 
Potentially a different manner of fragmentation could be used to gain identifications, such 
as electron transfer dissociation (284) or electron capture dissociation (285). These 
methods were not available in this research, but could be potential avenues for 
investigation in the future. 
3.4.3.2 Sub 10kDa Digested Sample Results 
Targeted MS-MS was also performed for the features of interest, on the sub10kDa digested 
samples. These features in the digested samples are likely to be tryptic peptides, as 
discussed in section 3.4.2.1, and hence proved rather more straightforward to identify using 
the CID fragmentation method. Therefore, this analysis resulted in the identification of a 
number of the significantly changing features, and these are summarised in table, 3.3. 
Table 3.3 shows that the percentage changes in masses between the original LC-MS data, 
and the following, targeted LC-MS data is very small (less than 0.04 %). This is as 
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expected, as the mass spectrometer was calibrated weekly, to minimise mass inaccuracy. 
The LC retention times show a larger percentage difference between the original LC-MS 
data, and the following, targeted LC-MS data. This is possibly due to slightly differing 
conditions between the two experiments, although in theory this should be minimised with 
strict temperature and flow control on in the LC system. Other possible explanations could 
be slight differences in solvents used, slight voids in the system or slightly differing 
column properties. It can be seen, from examination of table 3.3, that there are several 
identifications which have two peptide identifications. This can be used as a useful 
validation of results, as peptides from the same protein should, show similar expression 
profiles. Identifications were matched back to original expression profiles, and these are 
shown in figures 3.15 to 3.25. 
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Mass 
(Da) 
RT 
(min) Identification gi number 
RT in 
MS-
MS 
run 
(min) 
Change 
in RT 
(min) 
% 
Change 
in RT 
m/z in 
MS-MS 
run 
Mass in 
MS-MS 
run 
Change 
in Mass 
(Da) 
% 
Change 
in Mass 
Higher 
abundance 
seen in: 
Abundance 
difference 
(average 
fold 
change) 
1114.749 13.9 Prosomatostatin gi|207019  15.6 1.7 12.23 558.384 1114.6814 0.0676 0.0061
Heat 
treated 
8.5 
1089.384 27.6 Purkinje cell protein 4  gi|6679227 24.3 -3.3 -11.96 545.87 1089.7254 -0.3414 -0.0313
Heat 
treated
7.1 
1459.848 33.5 Myelin basic protein  gi|199051  31 -2.5 -7.46 487.616 1459.8262 0.0218 0.0015
Snap 
frozen
20.1 
1130.705 15.2 Myelin basic protein  gi|199051  16.6 1.4 9.21 566.34 1130.6654 0.0396 0.0035
Snap 
frozen
7.0 
1153.619 37.7 
Peptidylprolyl isomerase 
A gi|6679439  32.1 -5.6 -14.85 557.886 1153.5655 0.0535 0.0046
Heat 
treated
19.9 
2004.98 52.6 
Peptidylprolyl isomerase 
A gi|6679439  44.5 -8.1 -15.40 669.333 2004.9772 0.0028 0.0001
Heat 
treated
16.0 
1478.882 43.8 Alpha-fetoprotein gi|191765  36.8 -7 -15.98 740.449 1478.8834 -0.0014 -0.0001
Heat 
treated
15.0 
1698.979 38.6 Proprotein convertase gi|7305455  31.8 -6.8 -17.62 850.488 1698.9614 0.0176 0.0010
Heat 
treated
2.1 
1108.863 21.2 Keratin 10 gi|57012436 29.2 8 37.74 555.334 1108.6534 0.2096 0.0189
Snap 
frozen
3.6 
1675.534 30.7 Secretogranin II  gi|6677865 25.7 -5 -16.29 838.953 1675.8914 -0.3574 -0.0213
Heat 
treated
3.1 
2468.978 43.8 Secretogranin II  gi|6677865 36.2 -7.6 -17.35 824.094 2469.2602 -0.2822 -0.0114
Heat 
treated
3.4 
 
Table 3.4 Summary of identifications from targeted MS-MS experiment, for <10kDa digested samples. A proportion of the target masses were identified. It can 
be seen that there is only a very small percentage change in mass from the target mass. However, some of the retention time changes are rather significant. It 
is proposed that this is due to poorly reproducible chromatography. 
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Figure 3.12 Expression profile showing relative mean intensity across all six groups of 
the feature identified as a peptide from Prosomatostatin with mass 1114.749 Da. Insert 
shows predicted expression profile for comparison. 
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Figure 3.13 Expression profile showing relative mean intensity across all six groups of 
the feature identified as a peptide from Purkinje cell protein 4 with mass 1089.384 Da. Insert 
shows predicted expression profile for comparison. 
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Figure 3.14 Expression profile showing relative mean intensity across all six groups of 
the feature identified as a peptide from Myelin Basic Protein with mass 1459.848 Da. Insert 
shows predicted expression profile for comparison. 
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Figure 3.15  Expression profile showing relative mean intensity across all six groups of 
the feature identified as a peptide from Myelin Basic Protein with mass 1130.705 Da. Insert 
shows predicted expression profile for comparison. 
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Figure 3.16 Expression profile showing relative mean intensity across all six groups of 
the feature identified as a peptide from Peptidylprolyl isomerase A with mass 1153.619 Da. 
Insert shows predicted expression profile for comparison.  
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Figure 3.17 Expression profile showing relative mean intensity across all six groups of 
the feature identified as a peptide from Peptidylprolyl isomerase A with mass 2004.980 Da. 
Insert shows predicted expression profile for comparison.  
 
It should be noted that this particular expression profile is very similar to that seen in figure 
3.19. This is as predicted, as both these peptides are identified as being from the same 
protein. 
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Figure 3.18 Expression profile showing relative mean intensity across all six groups of 
the feature identified as a peptide from Alpha-fetoprotein with mass 1478.882 Da. Insert 
shows predicted expression profile for comparison.  
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Figure 3.19 Expression profile showing relative mean intensity across all six groups of 
the feature identified as a peptide from Proprotein convertase with mass 1698.979 Da. Insert 
shows predicted expression profile for comparison.  
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Figure 3.20 Expression profile showing relative mean intensity across all six groups of 
the feature identified as a peptide from Keratin 10 with mass 1108.863 Da. Insert shows 
predicted expression profile for comparison.  
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Figure 3.21 Expression profile showing relative mean intensity across all six groups of 
the feature identified as a peptide from Secretogranin II with mass 1675.534 Da. Insert 
shows predicted expression profile for comparison.  
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Figure 3.22 Expression profile showing relative mean intensity across all six groups of 
the feature identified as a peptide from Secretogranin II with mass 2468.978 Da. Insert 
shows predicted expression profile for comparison.  
 
It should be noted here that the only expression profiles, from the predicted profiles, 
identified are as shown in figures 3.2 C, D and B.  
From the top 39 features, with p-values less than 0.001, 6 show expression profile as 
predicted by figure 3.2 C and 5 show expression profile as predicted by figure 3.2 D. The 
remaining profiles show expression profile as predicted by B or are not able to be 
categorised.  
It is therefore concluded that the heat treatment either stabilises the features identified prior 
to and during tissue slicing, degrades the features identified prior to and during tissue 
slicing or has no effect on features identified.  
However, examination of the expression profiles does demonstrate that there are some 
overlapping error bars between sample sets. This is a result of sample variation within the 
sample sets analysed. This analysis would benefit from larger sample numbers to attempt 
to minimise the sample variation within sets. 
It should, again, be noted at this point that the majority of features, not targeted for 
identification, show no significant effect from the heat treatment. Predicted expression 
profiles in figures 3.2 A was not identified in the features targeted for identification.  
111 
From this, the conclusion can be drawn that if the heat treatment is going to have a 
significant effect on any feature, it will occur prior to, and during tissue slicing. This is as 
predicted, as any enzymes which are inactivated due to the treatment, will be activated 
immediately following dissection and prior to slicing. A further advantage of this effect is 
a more efficient tryptic digestion will take place in the heat treated samples, as opposed to 
the snap frozen samples, as unwanted enzyme action should be minimised.  
Peptides identified from the same protein show similar expression profiles as demonstrated 
in figures 3.16 and 3.17 giving an extra validation to the profiles. 
3.4.4 LC-MS-MS for Targeted and Untargeted Protein 
Identification using Q-TOF-MS 
3.4.4.1 Sub 10kDa Intact Sample Results 
Targeted MS-MS and untargeted MS-MS was performed on an alternative mass 
spectrometer (Applied Biosystems Q-Star) in an attempt to identify features from the <10 
kDa intact fraction. As previously discussed (in section 3.4.2.1), identification of the 
features from these samples proved to be very challenging. The Q-Star mass spectrometer 
also uses CID fragmentation, in the same way as the Bruker HCT. 
Unfortunately, again, no peptides or proteins could be identified using this method. Again 
the spectra obtained were of very low intensity and the data is not presented here. This 
reinforces the conclusion that the poor quality MS-MS data is due to the fact that the non-
tryptic peptides in these samples do not fragment efficiently, using CID fragmentation. 
The conclusion drawn from this is that a different method of MS-MS fragmentation may 
be the only way to obtain identification of the features in the intact <10kDa samples used 
in this work. As mentioned previously in section 3.4.2.1 possible choices for this could be 
electron transfer dissociation or electron capture dissociation fragmentation. It was 
unfortunate that these methods were not available in this research; however they could 
provide a future investigation. 
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3.5 Discussion 
In my research presented here a heat treatment system (Denator AB) has been evaluated in 
comparison with conventional snap freezing for preservation of proteomic data in tissue 
samples, specifically mouse brain tissue. This evaluation was undertaken using LC-MS 
and Label Free Relative Quantitation, using Decyder MS software from GE Healthcare. 
From this analysis it is concluded that the treatment has little affect on the sub 10 kDa 
proteomic data. This conclusion was reached, due to the fact that for over 6000 detected 
features in the intact sample and over 4000 detected features in the digested samples, less 
than 1% of features show significant changes between the groups, when an ANOVA p-
value of 0.001 is set.  This is discussed in sections 3.4.2.1 and 3.4.2.2. 
It should be noted at this stage that the changes in intensity discussed here, relates to the 
relative signal intensity between groups and not the absolute intensity of the features in 
question. The features that do show significant changes between the sample groups showed 
a number of different types of expression profiles, varying from showing feature 
preservation when the heat treatment is used, to sample degradation when the treatment is 
used. An additional conclusion, as discussed in section 3.4.3.2 was that if any significant 
effect was observed on a a feature, it occurred prior to and during tissue slicing. This was 
as hypothesized, as any enzymes that are denatured by the heat treatment will be active in 
the untreated tissue immediately following dissection and prior to tissue slicing. An 
advantage of this effect is thought to be that a more efficient tryptic digestion will take 
place in the heat treated samples, as any unspecific enzyme action should be minimised.  
It is concluded from this work that the heat treatment system may be a useful technique 
when particular targets cannot be detected using conventional snap freezing treatment. 
However, for analysis of the sub 10 kDa LC-MS proteomic data from brain tissue sample 
studied here, it is not expected that the Denator heat treatment will become a widely used 
sample preparation technique, due to the small change it demonstrates on the majority of 
the data.  
This result can be compared with work undertaken by Goodwin et al (286), who studied 
the effects of heat treatment on proteomic samples using MALDI-MS imaging and 2D-
DIGE. It was concluded in this work that rapid and controlled heat treatment of brain tissue 
reduces the non-specific proteomic degradation caused by endogenous enzyme action, 
making the Denator heat treatment system a useful process for quantitative proteomic 
analysis and may also increase the opportunity for tissue handling at room temperature, 
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such as sample dissection. However, it was also found that the heat treatment system did 
reduce the quality of tissue sections that could be obtained for MALDI-MS imaging. This 
result confirms the conclusion reached in the work presented here, that the Denator heat 
treatment system may prove useful in certain types of analysis for particular targets, 
however it may not be necessary or may even prove detrimental to other studies. 
It has also been found here that MS-MS identification of non-tryptically digested protein 
and peptide fragments in sub 10 kDa brain tissue samples is extremely challenging. The 
use of trypsin for protein analysis generates peptides with a basic C-terminal amino acid 
(287). When these peptides are protonated and fragmentated a predominant y-ion series is 
formed, simplifying the interpretation of the product ion spectra. It has been reported 
previously (288) that fragmentation of non-tryptic peptides can result in a mixture of b and 
y fragment ions, which can prevent unambiguous assignment of fragment ion types.  This 
phenomenon may impede the interpretation of the product ion spectra. 
Two different types of mass spectrometer were used in this work, in an attempt to identify 
features of interest from these samples. However, it proved to not be possible with either of 
these methods. As discussed in section 3.4.2.1, this is thought to be due to poor 
fragmentation from non-tryptic peptides and protein fragments by collision induced 
dissociation. Different techniques have been developed that may help to alleviate this 
problem such as electron transfer dissociation fragmentation (289), electron capture 
dissociation fragmentation (290), charge-directed fragmentation (291) and sodiation 
induced tryptic peptide-like fragmentation (288). Unfortunately, these techniques were not 
available in this work however they could be possible future avenues of investigation. 
It is also possible that the features of interest in these samples may not be peptides or 
protein fragments, and they may in fact be other types of molecules, such as lipids. This 
would explain why these features could not be identified using the proteomic MS-MS 
techniques employed in this research. This could potentially indicate that the heat 
treatment may have a more significant effect on molecules which are not peptides and 
proteins. This concept has not been investigated in this work, but could prove to be an 
interesting future project. 
As this work progressed it became apparent that the widely used ANOVA statistical 
analysis may not be the most appropriate method to discover significant differences in 
datasets of this type, even though this is a widely accepted and utilised method. Further 
ways of discovering significant changes in datasets such as this one, especially in datasets 
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with multiple groups, has been further and fully investigated. This is discussed and 
implemented in chapter 4, entitled ‘Discovery and Identification of Biomarkers for 
Hypertension’. 
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4 Discovery and Identification of Biomarkers for 
Hypertension 
4.1 Introduction 
Systemic hypertension is one of the most common diseases in the developed world, and is 
responsible for many symptoms including heart failure and stroke. Hypertension is defined 
as persistent raised blood pressure of ≥ 140/90 mm Hg (292). Worldwide, the number of 
adults with hypertension by 2025 is expected to increase by up to 60 %, to a total number 
of 1.56 billion (293). By this time cardiovascular disease is predicted to be the most 
common cause of death worldwide, with hypertension being the most reversible factor 
(293).  The risks of raised blood pressure are well documented and studied (294;295). 
Meta-analysis of pooled data sets has confirmed the relationship between continuous raised 
blood pressure and cerebrovascular disease and coronary heart disease (296). Hypertension 
has also been shown to be directly related to left ventricular hypertrophy, heart failure, 
peripheral vascular disease, renal disease and atherosclerosis (294). Hypertensive patients 
are also more likely to have type 2 diabetes and lowered levels of high density lipoprotein 
cholesterol (297), the common factor may be insulin resistance, due to high levels of co-
existing hypertension and obesity (298). 
In recent years there has been a greater emphasis on prevention of hypertension (299). In 
order to accomplish this goal it is important to be able to understand the mechanisms of the 
disease, as well as to establish new screening techniques which can predict the occurrence 
of hypertension. Essential hypertension has many causes (300), that can differ greatly from 
patient to patient, and not all are well understood or documented. The relationship between 
high levels of dietary salt and increased blood pressure has been well documented for 
many years (301-305). The current opinion being that a high level of dietary salt is 
associated with increased blood pressure in later life, and other cardiovascular diseases 
(301). In order to understand the reasons for this relationship, it is first important to discuss 
the mechanisms that actually lead to abnormal arterial constriction and elevated blood 
pressure. The pressure required to circulate the blood is provided by the pumping of the 
heart (known as cardiac output) and the tone of the arteries (known as peripheral 
resistance). The cardiac contraction propels the blood through the arteries, but it is the 
dynamic regulation of artery diameter, especially in the smaller arteries that regulates flow 
in the periphery and hence blood pressure. Due to the episodic ejection of blood from the 
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heart, pressure in the vessels has a periodic variation. These peaks and troughs of pressure 
refer to the systolic and diastolic pressures that can be measured intra-arterially or by a 
blood pressure cuff. Blood pressure is closely regulated in the body to ensure continuous 
perfusion of the vital organs (306).   
In the short term, flow and blood pressure can be adjusted via the control of neural and 
humoral factors that can rapidly constrict or dilate arteries in order to meet short term 
circulatory demands (307).  Baroreceptor reflexes then play an important role in resetting 
blood pressure, following acute changes, and could also have a role in long term blood 
pressure regulation via sympathetic nerve activity and renal Na+ excretion in hypertension 
(308). Over the long term blood pressure is primarily controlled by water and salt balance, 
due to the infinite gain property of the kidneys to rapidly eliminate excess water and salt. If 
renal function is reduced this results in an increase in the extra-cellular fluid volume 
(ECV), inevitably causing a rise in blood pressure (309). It has long been known that total 
body sodium content determines extra-cellular fluid volume (ECV), via osmotic activity 
(302). Hypertension that results from salt retention is preceded by a rise in total plasma 
volume (310). In this state the elevated blood pressure promotes a pressure natriuresis, 
meaning that normal ECV is restored, at the expense of elevated pressure. The basis of the 
ECV is an isotonic salt solution, mainly consisting of NaCl. As the kidneys are the primary 
regulator of salt and water balance, it follows that renal function and salt are widely 
recognised as critical factors in the pathogenesis of hypertension. It has also been known 
for sometime that diuretic/natriuretic agents, such as hydrochlorothiazide, which 
counteract the tendency for salt and water retention, can be effective treatments for 
hypertension (299;311). In addition renal transplantation studies in rats and humans show 
that the hypertension travels with the hypertensive donor kidney (312-314). 
There is substantial evidence implicating genetic causes of hypertension. Monogenic 
defects in renal salt transport have a clear effect on blood pressure, those that promote salt 
retention being associated with hypertension and conversely those that promote salt 
wasting are associated with hypotension (306;315;316). Additionally, mutation or knock 
out of genes which affect blood pressure induce either salt dependent hyper or 
hypotension, or unusual forms of salt independent alterations in blood pressure. These 
unusual forms are, in general, associated with genes that affect the synthesis and secretion 
of humoral vasoconstrictors or vasodilators (317). Further evidence of genetic influence on 
hypertension comes in the form of twin studies, showing a greater concordance of blood 
pressures of monozygotic than dizygotic twins (318), and population studies, showing a 
greater similarities of blood pressures within families, than between families (319). 
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In western societies the frequency of hypertension increases with age. It has been 
suggested that the reason for this may be that the primary cause of  the disease, in many 
patients, is from a subtle renal injury rather than a genetic cause (320). To summarise, 
hypertension is a complex disease with genetic and environmental influences in which the 
role of the kidneys and the salt/water balance is central. 
Genetic studies in hypertension, especially in humans, can be very complex, due to 
multifactorial determination. A variety of factors, in addition to genetic, may contribute to 
hypertension, including environmental and demographic.  Therefore genetic study design 
in the general population is, at best, challenging. One possible approach is to investigate 
rare forms of blood pressure variation, in which a single gene mutation causes large 
changes. Success in this work has been able to define pathways fundamental to 
hypertension (306), in particular 8 genes have been identified in this way that cause 
hypertension in humans. Interestingly, all of these 8 genes act in the same pathway in the 
kidneys, which alters net renal salt reabsorption. As mentioned previously the kidneys play 
a vital role in maintaining the salt/water balance in the kidneys. In a normal day they filter 
around 170 litres of water, containing 23 moles of salt. To maintain salt homeostasis (on an 
average diet) the kidneys must re-absorb 99.5 % of the filtered salt. The kidneys 
accomplish this via a system of ion channels, exchangers and transporters, with 60 % of 
the filtered sodium reabsorbed in the proximal tubule of the nephron, mainly by Na+/H+ 
exchange and 30 % in the thick ascending limb of Henle by Na-K-2Cl co-transport. A 
further 7 % is reabsorbed by Na-Cl co-transport in the distal convoluted tubule. The final 2 
% is reabsorbed through the epithelial Na+ channel in the cortical collecting tubule. 
Although this final step accounts for the smallest fraction of salt reabsorption, it is also the 
main site where net salt balance is determined. Mutations that affect the pathway involved 
in the reabsorption at this site have been identified by investigation of families with 
extreme variations in blood pressure (either high or low), firmly establishing this pathway 
as central in hypertension. Increased net renal salt reabsorption causes increased water 
reabsorption to maintain plasma sodium concentration. This results in increased 
intravascular volume, increasing blood return to the heart and raising cardiac output. This 
then leads directly to elevated blood pressure. 
Further genetic mutations involved with hypertension have been identified, including 
mutations affecting circulating mineralocorticoid hormones (which is the main regulator of 
the epithelial Na+ channel) (321-324) and mutations affecting the mineralocorticoid 
receptor (325). This mutation affecting the mineralocorticoid receptor is involved with 
hypertension which is exacerbated in pregnancy (pre-eclampsia), which occurs in 6 % of 
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all pregnancies and is a major cause of maternal and foetal morbidity. Although these 
genetic mutations have been very insightful to certain pathways surrounding hypertension, 
and also tend to cause large blood pressure changes in the individuals involved, they are 
actually very rare. Hence, they likely account for a very small percentage of patients with 
hypertension in the general population.        
As discussed more extensively in the main introduction, in recent years, focus has started 
to turn to proteomics as a tool to understand disease (1), and also to identify possible 
biomarkers to diagnosis and monitor disease (6).  Problematically the increased importance 
of proteomics has not been accompanied with an improvement in analytical tools and 
methods, in particular if compared to tools available for the study of genomics, meaning 
method development in this field is as, if not more, important than the biological research 
itself. The theory behind biomarker discovery is in essence very simple. Body fluids pass 
through diseased tissue and collect biomolecules, such as peptides, that can indicate status 
of health. If these biomolecules can indicate the presence of a disease they are called 
biomarkers. A biomarker is used as a way to diagnose, classify disease and also to measure 
progress and therapeutic response of disease. The ideal biomarker is a substance or 
symptom that is present only in diseased patients and absent in healthy controls, or vice 
versa. In this work biomarkers are considered as biomolecules and in this respect a 
biomarker will often be a change in biomolecule abundance, meaning that it is important to 
characterise as many biomolecules as possible, with high accuracy and resolution (7). 
There have been past studies which have identified possible biomarkers for hypertension, 
such as C-reactive protein, which is a marker for inflammation, serum aldosterone, which 
has a neurohormonal activity, and brain natriuretic peptide, which is an indicator of 
ventricular wall stress. These have been seen at elevated levels, prior to the onset of 
hypertension in humans (326-329). These types of studies are often limited by their focus 
on only one pathway, or marker. It is thought that a multi-marker process would be able to 
give a more accurate prediction of the occurrence of hypertension. A study conducted by 
Wang et al (330) did just that. The levels of nine previously detected biomarkers were 
measured in a large group of non-hypertensive individuals. From this, a set of three 
markers were detected to be strongly associated with the risk of development of 
hypertension. The nine initial possible markers investigated were C-reactive protein 
(inflammation), fibrinogen (inflammation and thrombosis), plasminogen activator 
inhibitor-1 (fibrinolytic potential), aldosterone, rennin, B-type natriuretic peptide, and N-
terminal proatrial natriuretic peptide (neurohormonal activity), homocysteine (renal 
function and oxidant stress) and urinary albumin/creatinine ratio (glomerular endotheliar 
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function). These possible markers were all taken from pathways previously implicated in 
the pathogenesis of hypertension. The levels of these markers were measured in 1456 
patients, of which 232 developed incident hypertension over three years. Of the nine 
potential markers, three were found to be significantly related to incident hypertension; C-
reactive protein, plasminogen activator inhibitor-1 and urinary albumin/creatinine ratio. 
Higher levels of these three biomarkers were found to be strongly associated with the 
development of incident hypertension.  
One of the major limitations of this work is that the biomarker discovery step is guided by 
previous knowledge and availability of arrays alone. As the occurrence of, and possible 
predisposition to, hypertension is not fully understood this may limit possible biomarker 
discovery significantly.  
An unguided biomarker discovery process has been utilized and reported by Kiga et al (40) 
to identify haptoglobin as a biomarker for stroke. In this work changes in the expression of 
plasma proteins in spontaneously hypertensive stroke-prone rats were investigated using 
surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. The study 
found that decreased levels of haptoglobin were seen in the diseased rats compared with 
the wild type controls. This finding was validated using the traditional biochemistry 
technique of western blot analysis.  This result shows that unguided biomarker discovery 
can be used in a meaningful way to identify biomarkers and learn more about disease.  
Unguided methods have also been used and reported for other applications, such as 
detection of preeclampsia (331).  In this work by Carty et al urine samples taken from 
women throughout pregnancy. The samples were analysed using capillary electrophoresis 
coupled to time-of-flight mass spectrometry and disease specific peptide patterns were then 
generated using support vector machine-based software. Potential biomarkers were then 
identified using liquid chromatography and tandem mass spectrometry. A model of 50 
biomarkers was developed which could be shown to predict preeclampsia from gestational 
week 28, however it was noted that further validations were required. 
Silbeger et al (41) have reported the use of surface enhanced laser desorption/deionisation 
time of flight mass spectrometry in an unguided manner to identify differentially expressed 
proteins in human myocardial infarction plasma samples. In this case statistical analysis 
was used to identify potential biomarkers for early stage acute myocardial infarction, 
however it was noted that the sample size used was rather small and further validation 
would be required. 
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Dayarathna et al (332) have reported the use of an unguided biomarker discovery 
technique to quantify differences in plasma samples between several disease groups; 
obesity, diabetes and hypertension. In this work human plasma samples from the three 
disease states and healthy controls were analysed using liquid chromatography and tandem 
mass spectrometry. In addition, the use of depletion of abundant proteins was used (this 
method is dicussed in more detail in the following pages). Dayarathna et al were able to 
identify changes in the level of several proteins. Angiotensinogen was found to be present 
at high levels in patients with obesity, diabetes and hypertension. Apolipoprotein CI was 
shown to be elevated in all disease groups. These findings were supported by a review of 
the literature. 
It is proposed here that biomarkers for hypertension are currently still not particularly well 
characterised. In the work presented here biomarkers for hypertension are investigated in a 
completely unguided manner. A label free relative quantitation method is used to examine 
differences between diseased and healthy samples, mainly concentrating on plasma 
samples. In this instance, no previous knowledge of the disease is used, meaning that it is 
possible to discover entirely new markers, which may come from unknown functions of 
hypertension. This not only enables biomarker discovery for early detection of disease, but 
also a new method for understanding hypertension and identifying new disease 
pathologies. This unguided biomarker discovery method could be applied to any disease 
state in the future, without the requirement of prior knowledge of the disease in question.  
To perform these studies a rat model is used. The model systems are a Stroke Prone 
Spontaneously Hypertensive Rat (SHRSP), Wistar-Kyoto wild type (WKY) and a 
congenic strain showing intermediate symptoms. The effect of salt treatment on the 
peptides in this study is also investigated, as salt/water balance and renal function is so 
pivotal to the mechanisms surrounding hypertension. In this model, a major technique used 
for identifying genetic determinants which underlie disease is the identification of 
quantitative trait loci (QTL). This is then followed by the development of the congenic and 
sub-strains in order to evaluate candidate genes (333). 
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Genetic models used were as follows, and as pictured in figure 4.1: 
• SHRSP – Spontaneously Hypertensive Rat Stroke Prone 
• Wistar Kyoto Rat (wild type) 
• Congenic Strain – SP.WKYGla2k 
 
Figure 4.1 Schematic demonstrating genetic models used in this study. The genetic models 
used are SHRSP, WKY and a congenic strain where WKY segments are introgressed into 
the SHRSP strain genetic background. The congenic strain is discussed in more detail in 
section 4.3.1. 
 
The SHRSP strain is a well characterised model for essential hypertension. It is known to 
show left ventricular hypertrophy, endothelial dysfunction and salt sensitivity (334-336). 
The WKY rat model has a contrasting phenotype, and demonstrates less of a blood 
pressure response to salt treatment (334). In a study by Clark et al (334) quantitative trait 
loci were identified for baseline and salt-sensitive blood pressure on rat chromosome 2. 
Following this, these quantitative trait loci were confirmed, using reciprocal chromosome 2 
congenic strains (336;337). Studies combining congenic mapping and microarray analysis 
identified the functional candidate gene Gstm1 (337;338). This gene is involved in the 
endogenous defence against oxidative stress. A combined strategy of congenic substrain 
production and microarray expression profiling has identified two positional candidate 
genes (Edg1 and Vcam1) for salt sensitive hypertension in the SHRSP model (333).  
Congenic strains are models where the chromosomal region containing the quantitative 
trait loci of interest in one strain (recipient) has been replaced by the homologous region 
from a second strain (donor). If the blood pressure of the congenic strain is significantly 
different from the recipient strain, it can be inferred that this chromosomal fragment does 
possess a quantitative trait loci which contributes to a difference in blood pressure between 
the donor and recipient strains. The traditional way to produce congenic strains is to 
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serially backcross the donor and recipient strain, at every generation selecting for progeny 
heterozygous for the desired chromosomal region. Mendelian principles dictate that 8 to 12 
backcrosses are necessary, in order to ensure that > 99 % of the donor strain’s genetic 
background is replaced by that of the recipient strain. After these backcrosses brother/sister 
mating is used to make the desired chromosomal region homozygous for the donor strain’s 
alleles (336). The samples used in this work are created using a ‘speed’ congenic breeding 
strategy. The theory of this strategy is based on calculations by Lander and Schork (339) 
which showed that the congenic strain production can be speeded up, using repeated 
screening of polymorphic marker loci distributed throughout the genetic background, 
allowing specific selection of a male from each backcross with the fewest amount of donor 
alleles remaining in the genetic background. Breeding these males would then allow the 
rate of background donor elimination to be accelerated. This, in turn, reduces the number 
of generations necessary for creation of a congenic strain. 
In my research presented here, an animal model is used for biomarker discovery which can 
be problematic. The differences between a study performed on a set of human samples and 
animal samples are multiple. One of the reasons for choosing to use an animal model is to 
minimise the sample heterogeneity. Human samples may differ in many ways that cannot 
be controlled and that can significantly affect the outcome of a study. For instance lifestyle 
choices such as diet and exercise and underlying genetic differences can cause large 
differences between individuals. In contrast, conditions surrounding animals can be tightly 
controlled and maintained. This should help to minimise the sample variance, meaning that 
the disease being studied should cause any significant differences between sample groups 
(340). Clearly, experimental design will be simpler when using an animal model, as the 
sample sets are clearly defined from the start of the experiment, as opposed to in an 
‘observational’ human study, in which a large group is monitored over a significant time 
period. Additionally, an animal model study can be conducted over a much shorter period 
of time. It must, however, be considered that using an animal model for biomarker 
discovery does not give a true view of the normal sample variation between individuals. It 
is therefore often used as a precursor to a wider, human study. 
However, experimental design must still be carefully considered even when using an 
animal model for a biomarker discovery study, to avoid bias in the results. Certain threats 
to a valid study have been reported (340) as being ‘chance’, ‘generalizability’ and ‘bias’. 
Chance refers to a type I error, otherwise known as a false positive result, or a type II error, 
which is known as a false negative result. These ‘chance’ errors cannot be completely 
avoided, but can be minimised by increasing sample size. A further chance based error, 
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more specific to the discovery based ‘-omics’ type research, is known as over-fitting (341). 
Over-fitting can occur when multivariate models are made to fit a data set, in order to 
discriminate one set from another. Sometimes a pattern will discriminate between the two 
sample sets purely by chance, and will not be reproducible in any other sample sets. To 
avoid this error, a validation sample set should be used in order to assess reproducibility of 
the results. The second type of possible error is ‘generalizability’, and is also known as 
‘external validity’ (340). This refers to who the results of the study would apply to. For 
instance, if an animal model is used initially, the results of the study may not be applicable 
to humans with the same disease. This is perfectly acceptable as a proof of principle study, 
and it would be expected that positive results could then be moved forward to a more 
expensive, larger study in humans, giving the results a wider generalizability. It has been 
proposed that this step-wise method for biomarker discovery is the most efficient and cost-
effective way of conducting such a study (342). Bias is a more difficult error to monitor, as 
it is usually unintentional and unconscious. It can be defined as ‘the systematic erroneous 
association of some characteristic with a group in a way that distorts a comparison with 
another group’ (340). The most important step to avoid bias in a study is to keep every 
possible factor throughout the study as equal as possible, during the design, conduct and 
also the interpretation of results. In addition, randomisation of the order of sample analysis 
is important to help avoid the introduction of bias into the study.   
In my research presented here, plasma is the sample of choice. This further complicates 
experimental design as plasma can be a difficult sample to analyse. Plasma is an interesting 
biofluid, in many senses. It is complex, containing a wide dynamic range of proteins, 
spanning over ten orders of magnitude. The complexity of plasma samples is even more 
problematic when subjected to LC-MS analysis, as the samples will often be protease 
digested, adding an additional level of complexity to the samples. This makes the high 
dynamic range of proteins even more challenging to cope with experimentally. Plasma also 
contains ‘leakage proteins’ from tissue, meaning as well as the classical plasma proteome, 
it also contains a sub-set of tissue proteomes. It is also notoriously difficult to analyse due 
to the high percentage presence of a single protein, albumin (343).  One of the greatest 
challenges in biomarker discovery from plasma is identifying these low abundance 
proteins, that make up less than 1 % of the entire plasma proteome, whereas the 20 most 
abundant plasma proteins make up the remaining 99 % of the proteome (344;345). 
Biomarker discovery can be assisted by removal of these highly abundant, well 
characterised proteins from biological solutions (346). Potential markers and interesting 
proteins may be masked by the presence of this small number of highly abundant proteins. 
Protein depletion has been used in the past to remove albumin from plasma for biomarker 
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discovery (347;348), but the removal of more than simply albumin may be desirable. There 
are a number of different strategies available to the researcher for plasma depletion, also 
known as protein pre-fractionation. Removal of the abundant proteins is probably the most 
common technique used. There are different depletion systems available, and they are 
mostly centred around antibody affinity. Depletion systems that remove one (349), two 
(350-352), three (353), six (350;351;354-356), seven (357), 12 (356;358;359), 14 (360), 20 
(361) and 58 (362) abundant proteins have been described. Alternatively, ProteoMiner 
beads is a new technology available for plasma depletion (363). They use a library of hexa-
peptides coupled to beads, with each bead being present in equal numbers. As proteins 
bind to the peptide ligands, proteins are retained on the beads. As there is a limited number 
of each bead, only a limited number of each protein will be retained, reducing the high 
dynamic range of proteins present without removing any specific protein. The 
disadvantage of this system is that protein concentration differences between samples may 
be altered, making downstream quantitation difficult. A further strategy is as an alternative 
to removing abundant proteins, is to attempt to enrich for interesting proteins. This is done, 
for example, by enriching for carbonylated proteins. Reactive oxygen species (ROS) are 
well known for their role in diseases such as cancer, heart disease and Alzheimer’s (364-
366). Exposure to ROS can cause irreversible oxidation of amino acid side chains, which 
introduces aldehyde or ketone groups (367). Biotinylation of oxidised proteins with biotin 
hydrazide and affinity selection with monomeric avidin affinity chromatography can be 
used to enrich carbonylated proteins from plasma. They may then be analysed using LC-
MS-MS. It was shown (368) that when this enrichment was performed 92 % of the 146 
proteins identified were tissue derived, and not classical plasma proteins, showing the 
potential of this method for biomarker discovery. However, as the enrichment is for a 
specific modification, the method is somewhat limited. Other types of pre-fractionation 
used are peptide based. In general this is used to reduce complexity caused by digestion, or 
can also be used to target and enrich sub-proteomes within the plasma. This can take the 
form of cysteine containing peptide enrichment (369). This has been shown to have no 
positive effect on the number of proteins identified (351), suggested to be due to the fact 
that 95 % of cysteinyl peptides in human plasma are from two abundant proteins, albumin 
and transferrin.    
Combined protein/peptide pre-fractionation can also be used. Around 50 % of all proteins 
are thought to be glycosylated (370), and glycoproteins secreted into plasma are a main 
part of the plasma proteome. As protein glycosylation is known to play an important role in 
disease, such as cancer (371) these can be an interesting set of proteins to analyse. 
Enrichment for glycoproteins is mainly based around lectin affinity (372), hydrazide 
125 
affinity (373) or other carbohydrate affinity (374;375). These techniques both reduce the 
complexity of plasma by looking at a sub-proteome and also reduce the additional 
complexity caused by digestion, meaning the end enriched product is only the glycosylated 
peptides from the glycoproteins.  
Metal affinity based fractionation is used quite frequently in proteomics (376), however to 
date immobilized metal affinity chromatography has only been used in a limited number of 
studies with plasma or serum samples, and these are primarily with MALDI-TOF-MS 
(377-379).  
It must, however, be considered that plasma depletion or pre-fractionation for biomarker 
discovery may not always be advantageous. Additional sample processing steps can cause 
sample loss and poor sample reproducibility. In addition, removal of abundant proteins 
may cause further loss of less known and low abundance associated proteins and peptides 
(380) . Another disadvantage of plasma depletion is the high cost. This can be around £12 
for each 15 µl sample, as for the spin columns evaluated in my research, making it an 
expensive step in sample preparation, especially for the high number of samples that must 
be analysed for biomarker discovery. In this work Beckman Coulter plasma partitioning 
spin columns are evaluated, this is discussed further in section 4.3.2. These are based on 
antibody affinity capture, and remove the seven most abundant proteins from rat plasma.  
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4.2 Aims 
The main aims in this chapter are as follows: 
• Optimisation of sample preparation of plasma samples for LC-MS analysis 
• Determination of protein concentration in the rat plasma samples used  
• Evaluation of plasma partitioning spin columns using 2D mini gels and LC-MS 
analysis 
• LC-MS analysis of plasma samples 
• Evaluation of two types of label free quantitation software 
• Label free relative quantitation of features within plasma sample as a possible 
biomarker discovery method 
• Development of a novel statistical analysis for the label free relative quantitation 
dataset 
• Targeted MS-MS analysis for identification of any features of interest 
• Western blots as validation of any biomarkers discovered 
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4.3 Methods 
4.3.1 Sample Preparation 
Samples for this study were provided by Dr Martin McBride of the Institute of 
Cardiovascular and Medical Sciences, Glasgow University. Inbred colonies of SHRSP and 
WKY rats have been kept at the Cardiovascular Research Group, in the University of 
Glasgow since 1991. Strain SP.WKYGla2a and SPWKYGLA2c* are generated using the 
marker-assisted ‘speed’ congenic strategy, where WKY segments are introgressed into the 
SHRSP strain genetic background (339). The strains are named with the first abbreviation 
belonging to the recipient strain, and the second abbreviation belonging to the donor strain. 
Gla indicates that the strain originates from Glasgow colonies, and the number 2 refers to 
rat chromosome 2. Congenic substrains are generated by backcrossing male 
SP.WKYGla2a congenic rats with SHRSP females. Progeny generated from this are 
heterozygous throughout the congenic interval. Brother/sister mating is carried out to 
generate and fix substrains, which contain smaller congenic intervals. These include 
SP.WKYGla2b, SP.WKYGla2e, SP.WKYGla2f, SP.WKYGla2g, SP.WKYGla2i and 
SP.WKYGla2k. In this research the substrain used is the SP.WKYGla2k. A genetic map of 
the congenic strains is shown in figure 4.2 (taken from Graham et al (333)). 
 
Figure 4.2 Comparison of chromosome 2 genetic map among SP.WKYGla2a, SP.WKYGla2k, 
and SP.WKYGla2c* strains. Dark gray bars indicate regions of WKY homozygosity. Lighter 
gray bars represent regions of SHRSP homozygosity. Hatched bars represent regions of 
recombination and heterozygosity. To the right, a physical map of an _6-Mb region, which 
delineates the different lower boundary markers between the SP.WKYGla2c* strain and the 
SP.WKYGla2a or SP.WKYGla2k strains, is expanded to illustrate a selection of genes 
contained within this congenic interval. The location of Gstm1 is indicated outside of the 
implicated region. From Graham et al (333). 
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From weaning the rats were fed on normal rat chow. All rats were euthanized at 21 weeks 
old. A salt treatment was carried out on a proportion of the animals. This involved a 1 % 
NaCl solution as drinking water from 18 weeks onwards. A total of 38 rat plasma samples 
were used in this work, shown in table 4.1.  
Prior to euthanasia blood was obtained by resection at the end of the rat tail under 
anesthesia and collected into EDTA-tubes. Plasma was separated by centrifugation (3000g, 
10min) and then stored at minus 80ºC until further analysis. The rearing of rats and 
collection of plasma was undertaken by Dr Martin McBride (Institute of Cardiovascular 
and Medical Sciences, University of Glasgow). 
From this point forwards the congenic SP.WKYGla2k strain is referred to simply as 
Congenic Strain. Blood pressure was measured using the Dataquest IV telemetry system, 
implanted at 12 weeks of age. This directly measures systolic blood pressure. An example 
of blood pressure differences recorded by the Cardiovascular Research Group at Glasgow 
University is shown in figure 4.3 (taken from Graham et al (333)).  
WKY no 
salt 
WKY salt SHRSP no 
salt 
SHRSP 
salt 
Congenic 
(SP.WKYGla2k) 
no salt 
Congenic 
(SP.WKYGla2k) 
salt 
A4659 A4631 C5952 C5847 N6690 N6686 
A4660 A4637 C5953 C5848 N6692 N6687 
A4695 A4803 C5989 C5849 N7036 N6688 
A4696  C6157 C5850 N7037 N6718 
A4792  C6169 C5851  N6839 
A4798   C5990  N6840 
A4800   C5991  N6841 
A4802   C5992  N6842 
   C6155   
   C6156   
Table 4.1 Hypertension study sample numbers 
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Figure 4.3 This figure shows an example of blood pressure levels in the strains of rat used 
in this work and was produced by the Cardiovascular Research Group at Glasgow 
University. Systolic blood pressure measured by radiotelemetry in male SHRSP (n_13), 
SP.WKYGla2a (n_8), SP.WKYGla2c* (n_12), and SP.WKYGla2k (n_7) strains. Baseline 
systolic blood pressure was significantly reduced in SP.WKYGla2a (F_12.98; P_0.002), 
SP.WKYGla2c* (F_6.35; P_0.021), SP.WKYGla2k (F_4.47; P_0.049), and WKY (F_130.8; 
P_0.00001) strains vs SHRSP (repeated-measures ANOVA). Systolic blood pressure was 
significantly lower in WKY rats vs SHRSPs during the salt-loading period (F_110.3; 
P_0.00001). Salt-loaded systolic blood pressure was significantly and equivalently reduced 
in SP.WKYGla2a (F_18.82; P_0.0001) and SP.WKYGla2k (F_11.06; P_0.004) strains but was 
not significantly reduced in SP.WKYGla2c* (F_1.94; P_0.179; repeated-measures ANOVA) vs 
SHRSP strains. From Graham et al (333). 
 
All plasma samples were aliqouted into 50 µl portions and stored at minus 80ºC until 
required for analysis. For initial work plasma samples were treated with protein de-salting 
spin columns (Pierce, product number 89849) as described by the manufacturer’s protocol. 
All plasma samples were tryptically digested for LC-MS analysis, using a trypsin to 
protein ratio of 1:100 by weight. Sequencing grade porcine trypsin (Promega, as used in 
chapter 3) was dissolved in 25 mM ammonium bicarbonate, added to plasma samples and 
left to digest overnight at 37 ºC. 
4.3.2 Determination of Plasma Protein Concentration  
Concentration of plasma samples was determined using a standard protein concentration 
assay, as used in chapter 2 (Bradford Assay). 1 µl of each plasma sample was diluted to 
100 µl with distilled water. 10 µl of this was then used for protein concentration 
determination. BSA standards were used with protein concentrations of 0.0625, 0.125, 
0.25, 0.375, 0.5 and 0.75 mg/ml. The absorbtivity measurement of each standard and 
sample was repeated three times, and the mean signal was calculated. A standard curve 
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was created from the absorbtivity and concentration of the known standards. The 
concentration of plasma samples was then determined using this curve.  
4.3.3 Plasma Partitioning Spin Columns – 2D mini gels and LC-
MS analysis 
Plasma partitioning spin columns were purchased from Beckman Coulter (ProteomeLab 
IgY Spin Columns). The effectiveness of this process was evaluated using 2D mini-gel 
electrophoresis along with LC-MS analysis. The columns are designed to deplete the seven 
most abundant proteins from rat plasma samples via an affinity capture method. These 
proteins are albumin, IgG, Transferrin, Fibrinogen, IgM, a1-antitrypsin and haptoglobin. 
Plasma samples were depleted in 15 µl portions, following the protocol given by the 
manufacturer. This effectively partitions the plasma sample into the abundant protein 
fraction and the remaining plasma fraction, with additional wash fractions. As the 
‘depleted’ proteins are recovered and available for analysis, the protocol is referred to as 
partitioning rather than depletion.  
This affinity capture plasma partitioning was compared with a simpler, size fractionation 
of plasma samples. The size separation was performed using Microcon Nominal Molecular 
Weight Filters, 30,000 Da Microcon (Millipore, YM30). These filters separate the plasma 
sample into 2 fractions, based on the molecular weight of the component molecules, in this 
case less than, and above 30kDa. Again, these were used as directed by the manufacturer.  
Each of the fractions from the plasma partitioning spin column and the Microcon Nominal 
Molecular Weight Filter fractionation, as well as an untreated plasma sample was 
separated using a 2D mini gel, 4-12 % gradient (Invitrogen) with a pH 4-7 isoelectric 
focussing strip. One plasma sample was used only, from a WKY rat (A4696). For the 
untreated plasma sample 3 µl of plasma was diluted to 20 µl with water. For the partitioned 
sample fractions 15 µl of each fraction (from an original plasma sample of 15 µl) was 
diluted to 20 µl with water. For the size filtered samples, 15 µl of untreated plasma was 
size fractionated and the resulting fractions diluted to 20 µl with water.  
Each of these 20 µl samples was then diluted to 125 µl by addition of rehydration buffer. 
This consisted of Urea (7 M), Thiourea (2 M), CHAPS (4 %), bromophenol blue (0.002 
%), DTT (100 mM) and IPG buffer (0.5 %). The samples were vortexed and each was 
layered onto a separate ceramic focussing strip holder. The plastic backing was removed 
from the IPG strips (pH 4-7) (GE Healthcare), and these were then placed, gel side down, 
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on top of the samples. Each sample and strip was then overlaid with 1 ml of oil. The 
samples were then left to focus overnight on an IPG machine, until 20,000 Vhrs were 
accumulated with program 30 V step and hold for 12 hours, 300 V step and hold for 2 
hours, 1000 V gradient for 2 hours, 8000 V gradient for 5 hours, 8000 V step and hold for 
8 hours and 1000 V step and hold for 24 hours.. The strips were then removed and placed 
in plastic tubes, with the plastic backing against a wall. The strips were washed briefly in 
running buffer, consisting of 6.06 g Tris, 28.8 g Glycine, 4 g SDS in 2 litres of water. The 
strips were then covered with 10 ml of equilibration buffer, with the addition of 100 mg 
DTT, and left to rock for 15 minutes. Equilibration buffer consisted of Tris HCl (50 mM), 
Urea (6 M), Glycerol (30 % v/v), SDS (2 % w/v) and bromophenol blue (0.002 % w/v). 
The strips were removed and washed in running buffer. They were again covered with 10 
ml of equilibration buffer, with the addition of 250 mg of iodoacetamide, and left to rock 
for 15 minutes. The strips were then applied to the pre-cast 4-12 % gradient 
polyacrylamide gels (Invitrogen), with the plastic backing in contact with the backplate, 
and sealed with agarose gel. The gel tanks were filled with running buffer (as previous). A 
voltage was applied to the gels of 200 V for 2 hours to separate the samples. Finally, the 
gels were stained using a coomassie blue stain, scanned on the G-Box scanner from 
Syngene and evaluated visually.  
The same samples were also all tryptically digested and analysed using a Dionex 3000 
Nano-flow Liquid Chromatography (LC) system and a Bruker High Capacity Trap (HCT). 
The LC separation was performed on a 15 cm C18 PepMap reverse phase column with a 
75 µm internal diameter, from Dionex. This was stored in a 37 ºC oven for the duration of 
the separation. Solvent A was a 2 % acetonitrile, 0.1 % formic acid solution and solvent B 
was an 80 % acetonitrile, 0.1 % formic acid. The loading solution used was a 2 % 
acetonitrile, 0.5 % tri-fluoroacetic acid solution. The loading flow, onto the trap was 
maintained at 30 µl/min. The column flow was maintained at 0.3 µl/min. The sample was 
loaded onto the pre-column trap and washed for 15 minutes, before the valves were 
switched to allow the sample to flow onto the column. Initially the ratio of solvents was 95 
% solvent A and 5 % solvent B. Between 15 and 70 minutes, this ratio was increased to 50 
% of each solvent. At 70.1 minutes, the ratio was increased to 90 % solvent B, and 
maintained there till 75 minutes. This was then decreased to 5 % at 80 minutes, and 
maintained there till 90 minutes. This gives a total LC method of 90 minutes. The mass 
spectrometer was set in standard (enhanced) mode, with positive polarity, scanning from 
m/z 100 – 2000, a maximum accumulation time of 100 ms and 8 average spectra. 
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The MS-MS data was converted to an mgf file in Data analysis (Bruker). It was then 
searched using MASCOT version 2.1, against database NCBInr 20090424 (8300899 
sequences; 2858238196 residues).  
MASCOT search settings were as follows: 
Species: Rodentia, Enzyme: Trypsin, Report top hits: Auto, Variable modifications: 
Oxidation of Methionine, Charge: 1+, 2+ and 3+, Peptide tolerance: 1.2 Da, MS/MS 
tolerance: 0.8 Da, Instrument: ESI-Trap 
4.3.4 LC-MS of Plasma samples for Label Free Quantitation using 
MicroTOFq, HCT and Q-Star 
Initially, plasma samples were analysed using a Dionex Ultimate Nano-flow Liquid 
Chromatography system and an Applied Biosystems Q-Star. Repeatability and 
reproducibility of this system was evaluated using standard BSA digest samples and 
plasma samples. Base peak chromatograms were created for each sample, and overlaid for 
comparisons. This was repeated for: 
• the same sample analysed on the same day 
•  the same sample analysed on different days 
•  different samples, from the same sample set, analysed on the same days 
 The LC method used was identical to that in the previous section, 4.3.3, although the 15 
minute de-salting wash on the trap was not included in the method. MS data was collected 
from m/z 150-2000, in positive ion mode, with an accumulation time of 3 seconds.  
Plasma samples were also analysed using a Dionex 3000 Nano-flow Liquid 
Chromatography system and a Bruker High Capacity Trap (HCT). Again repeatability and 
reproducibility of this system were evaluated using standard BSA digest samples and 
plasma samples. Base peak chromatograms were created for each sample, and overlaid for 
comparisons. This was repeated, as described previously, for: 
• the same sample analysed on the same day 
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• the same sample analysed on different days  
• different samples, from the same sample set, analysed on the same days 
Plasma sample de-salting was also evaluated. A comparison was made of the use of 
previously mentioned (section 4.3.3) Pierce de-salting spin columns, and an automated de-
salting step, incorporated into the liquid chromatography. The LC method used was 
identical to that in the previous section, 4.3.3, although initially the 15 minute de-salting 
wash on the trap was not included in the method. The mass spectrometer was set in 
standard (enhanced) mode, with positive polarity, scanning from m/z 100 – 2000, a 
maximum accumulation time of 100 ms and 8 average spectra. 
For the label free quantitation analysis plasma samples were analysed using the same 
aforementioned Dionex 3000 Nano-flow Liquid Chromatography system, coupled to a 
Bruker MicroTOFq. Every plasma sample was analysed, using the automated de-salting 
step. The LC method used was identical to that in the previous section, 4.3.3. 
The sample order (of all 38 samples) was randomised, to help prevent bias (as discussed in 
the introduction section 4.1) in the results. MS data, only, was collected on the 
microTOFq. Mass range used was m/z 150-3000. Each MS data file was converted to an 
‘mzxml’ file which is compatible for import into label free quantitation software. 
4.3.5 Label Free Relative Quantitation 
Label free relative quantitation, as discussed in the main introduction, is a technique used 
to identify differences between samples. In this study two different types of software are 
evaluated for this purpose. These are Progenesis LC-MS from Non-Linear Dynamics and 
Decyder MS from GE Healthcare. The outcome of this is discussed in the results section 
4.4.4.   
Each MS data file was input into the label free quantitation software for analysis, therefore 
for each feature there exists a m/z ratio, a retention time and an intensity signal. This 
information is used to create a 3 dimensional map for each sample. 
Peptide detection settings were optimised for the particular dataset used here, in order to 
minimise false positive and false negative detections. Settings for Peptide Detection in 
Decyder MS were as follows: 
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Typical peak width: 0.5 minutes, TOF, resolution: 8000, Charge states: 1-10, Uniform 
Background model type, Signal-to-background detection threshold: 4.0, Background 
subtracted quantitation, Enable charge assignment where possible, Charge assignment 
from two peaks: Limited, LC peak shape tolerance: 20 % , m/z shift tolerance: 0 u, m/z 
shape tolerance: 5 %, Remove peptides below S/N of 4.0, Remove peptides of unspecified 
charge below S/N of 4.0, Remove peptides with low quality LC peaks, Remove 
overlapping peptides, Spectrum vs model tolerance: 15 % 
Settings for spectrum alignment in Decyder MS were as follows: 
Max/stretch compress: 2, Max leader and trailer: 10 %, Stretch compress penalty: 0.1 
Settings for peptide matching in Decyder MS were as follows: 
Time tolerance: 1 minute, Mass tolerance: 0.5 Da, Use aligned retention times, Cross 
detection: Add peptides to intensity maps if present in 1 map 
Normalisation was performed using a measured intensity distribution, as in chapter 3. This 
means that the entire peptide population is used for normalisation. It is assumed that most 
samples contain peptides that do not vary in intensity and the normalisation is performed 
without any further specifications. This is the recommended method of normalisation, by 
the maufacturers of the software, unless very few peptides are present in the samples. 
4.3.6 Targeted MS-MS for Protein Identification 
Following identification of features of interest, these were targeted for identification using 
an MS-MS method. A Dionex 3000 Nano-flow Liquid Chromatography system was used, 
in conjunction with an Applied Biosystems Q-Star. The targeted MS-MS was performed in 
two ways, initially targeting the features of interest via their masses alone, known as the 
‘include list strategy’, and secondly using retention time windows in conjunction with the 
feature mass, known as the ‘retention time strategy’. The resulting MS-MS data was then 
searched against the MASCOT database for possible identifications.  
The LC method used for this experiment was identical to that used in the initial MS 
experiment.  
Settings on the Q-Star for the Include List Strategy were as follows: 
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Acquisition time: 90 minutes, Accumulation time: 3 seconds, TOF masses: 200 – 1500 
m/z, Polarity: Positive, Cycles: 360, Cycle time: 15 seconds, Product ion masses: m/z 50 – 
2000  
The masses for the include lists were taken from the results of the statistical analysis for 
label free relative quantitation. Retention times were not specified. Samples analysed 
included one from each sample group.  
Settings on the Q-Star for the retention time strategy were the same as above, with the 
exception that the product ion scans were divided into 10 minute windows with 4 product 
ion masses in each. The method was set to scan through each mass in turn. 
All MS-MS data was searched using MASCOT version 2.1, against NCBInr database 
20090424 (8300899 sequences; 2858238196 residues). The search settings were as 
follows: 
Species: Rodentia, Enzyme: Trypsin, Report top hits: Auto, Variable modifications: 
Oxidation of Methionine, Charge: 1+, 2+ and 3+, Peptide tolerance: 1.2 Da, MS/MS 
tolerance: 0.8 Da, Instrument: ESI-TOF 
4.3.7 Western Blots as a Validation Technique 
In order to confirm the quantitation and identification achieved by mass spectrometry and 
label free quantitation western blots were used as a validation technique for two of the 
proteins identified.  
For the western blot analysis plasma samples from each group were pooled together. 50 µl 
of each plasma sample was taken and combined with the relevant samples, giving 6 
samples WKY no salt, WKY salt, Congenic no salt, Congenic salt, SHRSP no salt, SHRSP 
salt. From each samples 1 µl of plasma was taken, and diluted to 10 µl with water. 1 µl of 
this diluted sample was then made up to 10 µl with protein loading buffer. The plasma 
samples were heated to 99 ºC for 5 minutes, to denature the protein. The samples, along 
with a protein molecular weight ladder, were loaded onto a 4-12 % pre-cast 
polyacrylamide gel, from Invitrogen. This was replicated 4 times, to allow for 2 western 
blots, and two coomassie stained gels. The gels were immersed in pre-mixed SDS running 
buffer, also from Invitrogen. A voltage of 200 V, and the samples were left to separate on 
the gel for 2 hours. Following the separation, the gels were extracted from the plastic 
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casing, and the top part of the gel cut away. Two of the gels were immersed in Coomassie 
stain for 2 hours, followed by Coomassie de-stain for 30 mins, or until bands were visible. 
The gels were then scanned and visually evaluated. The second two gels were retained for 
western blot transfer. These gels were immersed in transfer buffer for 15 minutes at room 
temperature. The gel size was measured, and filter papers and western blot membrane cut 
to the same size (1 piece of membrane per gel, and 6 pieces of filter paper per gel). The 
filter paper was soaked in transfer buffer for 5 minutes. The membrane was wet in 
methanol for 15 seconds, soaked in water for 2 minutes, and then in transfer buffer for 5 
minutes. The transfer stack was assembled in the Semi-Phor western blot apparatus. This 
consisted of 3 pieces of filter paper, the western blot membrane, gel and 3 further pieces of 
filter paper. 27 mA of current was applied, per gel, for 1 hour. The membranes were then 
removed and left to air dry overnight. The gels were discarded at this stage. The 
membranes were wet in methanol and then immersed in blocking solution for 1 hour. 
Blocking solution consisted of 100 ml PBS with 5 g of dried milk powder. The membranes 
were then removed and washed in PBS with 0.05 % Tween. The membranes were then 
each immersed in the primary antibody wash for 1 hour, consisting of 20 ml PBS with 0.05 
% Tween, 5 % milk and 10 µl primary antibody. The membranes were then washed 6 
times, for 5 minutes each time, in PBS with 0.05 % Tween, and immersed in secondary 
antibody solution for 1 hour. Secondary antibody solution consisted of of 20 ml PBS with 
0.05 % Tween, 5 % milk and 10 µl secondary antibody.  The six 5 minute washes were 
repeated. Each membrane was then covered in Pierce ECL reagent for 60 seconds. 
Membranes were dabbed dry and exposed and scanned using the G-Box scanner, from 
Syngene. Five 30 second exposures were used initially, followed by five 2 minute 
exposures. The primary antibodies used were chicken anti-rat hemopexin and chicken anti-
rat fibrinogen alpha-1-isoform. The secondary antibody used was chicken IgY horse-radish 
peroxidase conjugate. 
Quantitative information was extracted from the western blots by measuring the total raw 
pixel volume from each band. This was background corrected by subtracting an identical 
total pixel volume, taken from a background region of the blot. The data was normalised 
against the total pixel volume intensities from one band, taken from each sample, from the 
appropriate coomassie blue stained gel. These were then plotted in an expression profile 
style, for comparison with the expression profiles obtained from the label free relative 
quantitation experiment. 
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4.4 Results 
4.4.1 Protein Concentration in Plasma Samples 
Protein concentration was determined in all plasma samples. The results from the protein 
concentration assay of all rat plasma samples are shown in figure 4.4 below. The overall 
average protein concentration is 55.2 mg/ml with a standard deviation of 8.3 mg/ml. 
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Figure 4.4 Results of protein concentration assay, across all plasma samples. The mean 
protein concentration within the labelled group is shown. Error bars represent ± one 
standard deviation.  
 
As expected there is a high concentration of protein in the plasma samples. As previously 
mentioned, in section 4.1, plasma contains a wide dynamic range of proteins. Depletion of 
the most abundant proteins should be considered, in order to investigate the low 
concentration proteins which may be masked. Otherwise, the plasma samples must be 
diluted significantly prior to LC-MS analysis. As mentioned in the main introduction 
(section 1.4) nano-LC columns are easily blocked and overloaded, and the concentration of 
the plasma samples must be considered carefully prior to analysis to prevent damage. 
4.4.2 Evaluation of the Effectiveness of Plasma Partitioning using 
2D mini gels and LC-MS analysis 
Plasma partitioning spin columns from Beckman Coulter (ProteomeLab IgY Spin 
Columns) were evaluated using 2D mini-gel electrophoresis in conjunction with LC-MS 
analysis.  
The results of the 2D mini-gel analysis are shown in figures 4.5 – 4.8. The different 
samples separated and visualised on the 2D gels were an untreated plasma sample, plasma 
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with abundant proteins removed, the wash step from the partitioning column and the 
removed abundant proteins.  
                             
Figure 4.5 2D mini gel of untreated plasma sample, stained with Coomassie blue  
 
 
              
Figure 4.6 2D mini gel of plasma sample with seven abundant proteins removed using the 
Beckman Coulter IgY plasma partitioning spin column, stained with Coomassie blue. 
 
 
Figure 4.7 2D mini gel of wash step from plasma sample when treated with the Beckman 
Coulter IgY plasma partitioning spin column, when treated with Coomassie blue. 
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Figure 4.8 2D mini gel of the seven abundant proteins removed from plasma using the 
Beckman Coulter IgY plasma partitioning spin column, stained with Coomassie blue.
 
The 2D mini gels emphasize the complexity of the plasma samples, and also the high 
abundance of certain proteins, seen as larger smears on the gels. The large black smear 
seen in the centre of all the gels is presumed to be albumin, as it is seen in such high 
abundance. It is present even in the gel of the plasma sample treated with partitioning spin 
columns, where in theory it should be removed. This demonstrates that although the 
columns undoubtedly remove a proportion of the abundant proteins from the plasma 
samples, it is clear this is not a completely efficient process. From examination of the gel, 
of the sample consisting of the abundant, removed, proteins it is clear that there are more 
than seven spots present on the gel. Some of these may be due to modified versions of the 
abundant proteins, but it is proposed that some of these spots may be proteins that have 
been associated with the abundant proteins, and were unintentionally removed from the 
plasma samples. This type of pre-treatment causes problems when the samples are to be 
analysed quantitatively. If differing amounts of low abundance proteins, or indeed the 7 
high abundance proteins, are removed from plasma samples, this could indicate artificial 
quantitative differences in the samples. It is suggested here that this type of plasma 
partitioning is not appropriate to be used in a quantitative biomarker discovery study, due 
to the differing amounts of protein that is removed from each sample, and also due to 
unintentional removal of low abundance proteins which may be of relevance.  
Each fraction from the depletion column separation was also analysed using LC-MS-MS 
analysis and the results searched against the MASCOT database. Table 4.2 shows in which 
fraction each of the 7 abundant proteins was identified as being present: 
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Protein Fractions Identified 
Albumin Wash fraction, Abundant proteins 
IgG None 
Transferrin None 
Fibrinogen All fractions 
IgM None 
A1-antitrypsin Wash fraction, Abundant proteins 
Haptoglobin None 
Table 4.2 Seven abundant proteins as partitioned by the Beckman Coulter IgY plasma 
partitioning spin column. Shown here is a summary of which fractions the proteins were 
identified in, to help evaluate the efficiency of the column. 
 
It can be seen from table 4.2 that the only three proteins identified in the ‘abundant 
proteins’ fraction are albumin, fibrinogen and a1-antitrypsin. Fibrinogen is also identified 
in all other fractions, indicating that it has certainly not been efficiently removed from the 
plasma sample. IgG, Transferrin, IgM and Haptoglobin were not identified in any of the 
fractions. It is proposed here that this indicates that these proteins are all in fact present in 
the abundant protein fraction, as indicated by the 2D mini gel, but are unable to be 
identified due to the high abundance of albumin and fibrinogen also present in this 
fraction. That they are not identified in the depleted plasma fraction may indicate that they 
have been efficiently removed from this sample, however this is a rather tenuos conclusion 
as no identifications were made of these proteins. The results presented here only 
emphasise the difficulties and challenges encountered when attempting to analyse plasma 
samples in this method. 
It is concluded from the study and results presented in this section, that this type of plasma 
partitioning is not appropriate for use in a quantitative biomarker discovery study. This is 
predominantly due to the differing amounts of abundant proteins that are removed from 
each sample, which would undoubtedly distort any attempt at a quantitative analysis. 
Additionally, the unintentional removal of interesting low abundance proteins is a 
significant disadvantage to this type of experimental procedure.  
A second, simpler type of plasma partitioning was also evaluated using a 2D mini gel. This 
was a molecular weight separation strategy, using Microcon Nominal Molecular Weight 
Filters. This separates the plasma sample into two separate fractions, one above 30 kDa in 
size and one below. The fraction above 30 kDa can be seen in the figure, 4.9, below: 
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Figure 4.9 2D mini gel of plasma sample. (>30 kDa) after being size fractionated using 
Microcon Nominal Molecular Weight Filters 
 
It can be seen, if compared with the untreated plasma gel in figure 4.5, that the majority of 
the proteins spots seen in the untreated plasma gel are also present in the above 30 kDa 
fraction gel. If low abundance, small proteins are to be targeted for identification, this 
could be an effective way of removing the majority of the protein contingent from the 
plasma sample. Additionally, this method is much cheaper and less labour intensive than 
the partitioning columns evaluated above. 
However, it has been decided, for this study, that this is not an appropriate sample 
preparation method. The research presented here is an unguided, biomarker discovery 
project and therefore the removal of potentially interesting proteins could be detrimental to 
the project. Additionally, it has also been decided that the samples should be manipulated, 
and treated, as little as possible for this work. This will minimise the chance of artificial 
differences and bias being introduced into the samples. However, it is suggested that if 
depletion is a sample pre-treatment strategy of choice, then size fractionation may be a 
cheaper and more efficient method than antibody affinity partitioning.   
4.4.3 LC-MS - Repeatability and Reproducibility Evaluations 
A high level of repeatability and reproducibility in the LC-MS system is of vital 
importance for a label free quantitation experiment, due to the need to compare samples 
analysed at slightly different times. The reproducibility must be evaluated and kept to as 
high a level as possible throughout the biomarker study, to avoid introducing bias, or 
artificial, distorted differences into the results. The repeatability of the protocol was 
evaluated on different LC systems and compared, prior to the main sample analysis.   
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The repeatability of the Dionex Ultimate LC system and the Applied Biosystems Q-Star 
was evaluated, by analysing the same sample on three separate days. A base peak 
chromatogram was created for each sample and these were overlaid, as can be seen in the 
figure, 4.10, below. A base peak chromatogram monitors the most intense peak in each 
spectrum. Therefore when a base peak chromatogram is plotted it represents the intensity 
of the most intense peak at every point in the analysis. Base peak chromatograms are often 
used as they focus on a single analyte at each point in the analysis, meaning the 
background signal is reduced. 
Examination of figure 4.10 shows that the repeatability of this system is not ideal. This is 
presumed to be due to the fact that the LC system does not have a good level of flow 
control. The column is also not temperature controlled, meaning analyte retention times are 
unlikely to be highly reproducible.   
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Figure 4.10 Base peak chromatogram from plasma sample analysed using Dionex Ultimate 
LC system and Applied Biosystems Q-Star. The different colour represent data collected on 
different days, with the dates depicted in the legend to the right. It can be seen that the day-
to-day repeatability of this analysis is poor. This is thought to be due to due to the poor flow 
control and lack of temperature control on this LC system. 
 
The repeatability of a Dionex 3000 LC system coupled to a Bruker High Capacity Trap 
(HCT) was also evaluated. Initially this was performed using a standard BSA digest 
analysed on the same day. The base peak chromatogram created from this experiment is 
shown in figure 4.11. On examination of figure 4.11 it can be seen here that there is a 
much higher level of repeatability when compared with figure 4.10. This is due to the fact 
143 
that this LC system has a high level of flow control and, in addition, the LC column is 
contained in a temperature controlled oven, minimizing temperature differences between 
samples. 
 
Figure 4.11 Base peak chromatogram from BSA digest (used as a standard sample) 
analysed using a Dionex 3000 LC system and a Bruker High Capacity Trap (HCT). Again the 
different colours represent data collected on different days. A higher level of repeatability 
can be seen with this LC system, as is has better flow control, as well as a temperature 
controlled oven for the column. This combination gives a higher level of repeatability. 
 
Also shown, in the figures 4.12 and 4.13, is an enlarged extracted ion chromatogram from 
a particular peptide (421.5 Da) from the BSA digest, from two separate, and also six 
separate samples analysed on the same day. In an extracted ion chromatrogram a single 
analyte is monitored throughout the entire analysis. The total intensity (within a mass 
tolerance window) around the mass of interest is plotted at each point in time. 
Again, this demonstrates that this system has a highly reproducible retention time for a 
particular peptide. 
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Figure 4.12  XIC of Trypsin peak 421.5 Da, from a BSA digest sample analysed using a 
Dionex 3000 LC system and a Bruker High Capacity Trap (HCT), on one day. The different 
colours represent the same analysis repeated twice on the same day. This shows the high 
level of repeatability of retention time from a particular peptide. 
 
 
Figure 4.13  XIC of Trypsin peak 421.5 Da, from a BSA digest sample analysed on the 
same day. The different colours represent the same analysis repeated on the same day. This 
shows the high level of repeatability of retention time from a particular peptide. 
 
In the next repeatability test, the BSA digest was analysed using the Dionex 3000 LC 
system coupled to a Bruker High Capacity Trap, on a day-to-day basis. Again, the base 
peak chromatogram of two samples can be seen in figure 4.14. On examination of this base 
peak chromatogram, it can be seen that the day-to-day repeatability is slightly lower than 
that of the same day repeatability. The retention times seem to be slightly shifted between 
days. This, however, is not a big problem for the label free relative quantitation performed 
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in this work, as the software can be used to align small retention time shifts between 
samples. 
 
Figure 4.14 Base peak chromatogram from BSA digest analysed on a Dionex 3000 LC and 
Bruker HCT, showing day-to-day repeatability. The two different colour represent data 
collected on different days. 
 
Following this, the repeatability of plasma samples was analysed, again using a 3000 LC 
system coupled to a Bruker High Capacity Trap. The results of overlaid base peak 
chromatogram from this can be seen in the figures 4.15 and 4.16. To evaluate the 
reproducibility of the sample preparation protocol, one plasma sample was separated and 
treated with the Pierce de-salting columns, and again the base peak chromatograms were 
overlaid. Examination of figure 4.15 shows that this process has a slightly lower level of 
reproducibility. This is thought to be due to differing protein sample loss from the de-
salting columns. This is not acceptable for this type of study, due to possible artificial 
differences being introduced into the samples. Following this, the same experiment was 
repeated, however, as an alternative to the de-salting columns, an automated de-salting step 
was used, incorporated into the LC method. This involved loading the digested plasma 
sample onto the LC-MS trap, and washing for 15 minutes, prior to separation on the 
column. It is demonstrated by the base peak chromatogram (shown in figure 4.16) from 
this experiment, that this process improves the reproducibility of the sample preparation 
protocol to an acceptable level for this study. 
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Figure 4.15 Base peak chromatogram from one plasma sample prepared and analysed three 
times using the Dionex 3000 LC system and Bruker HCT, showing a lower level of 
reproducibility, thought to be due to sample loss during the de-salting step of the protocol. 
The different colours represent data collected from one sample multiple times on the same 
day. 
 
 
Figure 4.16 Base peak chromatogram from one plasma sample prepared, without de-salting 
columns and with automated de-salting LC method, and analysed three times using the 
Dionex 3000 LC system and Bruker HCT, showing a higher level of reproducibility, thought 
to be due removal of the de-salting step of the protocol. To replace this, a de-salting step is 
included in the LC separation. The different colours represent data collected from one 
sample multiple times on the same day. It can be seen that the chromatograms overlay 
closely on top of one another. 
 
It is concluded from this study, that the Dionex 3000 LC system used here has an 
acceptable level of repeatability for further work of this type. Additionally, it is also 
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concluded that using an automated de-salting step with the LC system is preferable to de-
salting spin columns, which seem to alter the samples somewhat.  
It should be noted at this point that the mass spectrometer used is not important for the 
repeatability and reproducibility of the experiment. This LC system can be coupled to any 
electrospray mass spectrometer, and should still give the same high level of repeatability 
and reproducibility. For the MS and label free quantitation experiment the Dionex 3000 LC 
system is used coupled to a Bruker MicroTOFq mass spectrometer, and for the targeted 
MS-MS experiment the same LC system is used, this time coupled to the Applied 
Biosystems Q-Star.  
4.4.4 Evaluation of Label Free Relative Quantitation Software 
As previously mentioned, in the method section 4.3.5, in this study two different types of 
software were initially evaluated for the label free relative quantitation study. These were 
Progenesis LC-MS from Non-Linear Dynamics and Decyder MS from GE Healthcare. 
However, all data presented in this work is obtained from Decyder MS. The reasons for 
this are discussed in the following paragraphs.  
There are significant differences to the way these two softwares work, although the basic 
principle behind both of them is the same. Label free relative quantitation is based on the 
principle of comparing identical proteolytically digested peptides, which elute with the 
same retention time using LC-MS analysis, from different samples. The relative ratios of 
the protein can then be calculated. 
Progenesis LC-MS was the first software to be evaluated in this project. It is user friendly 
software, designed to be simple to use, even for a user with no previous experience of label 
free quantitation. It has an appealing user interface, and the statistical output is straight-
forward to interpret. However the disadvantage of this software is that it is very inflexible. 
Settings are all standardised and cannot be adjusted. It is also difficult to export data for 
further analysis.  
Decyder MS is a more specialised tool for label free quantitation, designed for use by a 
user with specific needs. The mass spectrometer type used is definable, for instance a trap, 
time-of-flight or FT-ICR mass spectrometer. If MS-MS has been performed on the data 
set, the sampling can be easily evaluated visually, as this is displayed in a 2D LC-MS plot. 
Detection parameters can be set by the user, for instance typical peak width, resolution and 
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desired range of charge states. Decyder MS also has an advanced detection parameters tab 
allowing advanced parameters to be defined, for instance, background correction 
algorithm, signal to background detection threshold, whether charge assignment is 
required, increased sensitivity for small peptides, charge state matching parameters, m/z 
shift tolerance, m/z shape tolerance and filtering parameters. Following peptide detection 
manual editing can be performed, meaning charge assignments can be manually modified 
and comments can be added. MS-MS identification can be performed through Decyder MS 
with either Mascot or Sequest databases. Time alignment parameters are also user defined. 
Time alignment parameters refer to maximum stretch/compression allowed, maximum 
leader and trailer and stretch/compress penalty. Following peptide matching cross-
detection can be performed. This adds matched peptides present in at least a user specified 
number of intensity maps to all other intensity maps. The intensity values for these 
peptides are then measured. Cross detection is essential for statistical evaluation of 
presence/absence experiments. Peptides detected can be ordered according to many more 
parameters in Decyder MS, than in Progenesis LC-MS, including number of profiles 
present in, mass and retention time. Expression profiles can be viewed in two ways, either 
as individual peptides or experimental groups. Decyder MS allows normalization to be 
performed in a user defined manner. This gives the option to use internal standards for 
normalization, or alternatively the entire peptide population. Decyder MS reports ANOVA 
and t-test statistics, along with average difference and average ratio of peptides. Decyder 
MS data is easily exportable into excel format for further statistical analysis. 
For these reasons it was decided that Decyder MS is more suitable for use in this study and 
all biological replicates and final data was analysed with Decyder MS. The main steps in 
label free quantitation using Decyder MS are: 
• Peptide detection in each sample 
• Definition of experimental groups 
• Alignment of intensity maps 
• Matching of detected peptides 
• Cross-detection of matched peptides 
• Evaluation of matched result 
• Statistical analysis 
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4.4.5 MS and Label Free Relative Quantitation for Biomarker 
Discovery in Plasma 
MS data for all 38 samples was collected in a randomised manner, using the Dionex 3000 
LC system, coupled to the Bruker MicroTOFq. The randomisation of the samples was used 
to prevent the introduction of bias into the quantitative results. The MS data from each 
sample was converted into an ‘mzxml’, compatible for import into Decyder MS. From this, 
a 2D map was created for each sample with the axes being m/z and retention time. The 
features in each map were automatically detected across each sample, before being 
retention time aligned. Cross-detection across all samples was then performed, and a 
summary of features detected in each sample group is shown in the figure 4.17. The 
average number of features detected in each sample is between 8880 with a standard 
deviation of 947.  
 
 
 
 
 
Figure 4.17  Graph demonstrating the average number of features detected in each 
sample group, with error bars representing ± one standard deviation. It is shown that 
between 8000 and 10,000 features are detected within each sample group.  
 
The large number of features detected in the plasma samples is as expected, due to the high 
level of complexity of the samples and the wide dynamic range of proteins present. It can 
be seen from examination of figure 4.17 that a higher number of features were detected in 
the congenic plasma samples, when compared with the wild type samples. In addition the 
SHRSP samples show a higher number of detected features when compared with the wild 
type samples. The reason for these differences is unclear at this stage.  
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4.4.6 Statistical Analysis of LC-MS data for Label Free 
Quantitation 
The LC-MS data from the different groups of plasma was analysed in several different 
ways. Initially a simple one-way analysis of variance (ANOVA) calculation was 
performed. The principle behind ANOVA analysis is described in detail in the previous 
chapter ‘Assessment of Denator Heat Treatment for Prevention of Proteomic Sample 
Degradation using Label Free Relative Quantitation’.  
In this analysis a decision must to be made regarding what level to set a significant p-
value. As previously stated, a common method is to simply choose an arbitrary value of 
0.01, 0.005 or 0.001. This would mean that the probability of obtaining the observed 
difference by chance would be 1 in 100, 0.5 in 100, or 0.1 in 100, respectively. This 
decision is somewhat further complicated by the number of features present, and therefore 
ANOVA calculations present in the dataset. In this case there are around 12,000 features 
present in the dataset, meaning that determining the significance of features detected can 
be somewhat complicated, as if enough tests are performed it is inevitable that a 
‘significant’ feature will be found eventually, simply by chance. The researcher must be 
aware of attaching too much weight to a lone, or a few, significant results amongst a large 
amount of ‘non-significant’ results. One method of helping to determine true significance 
is reducing the significance level of the p-value, based on the number of tests performed. 
This is known as the Bonferroni correction. The Bonferroni correction is based on the 
reasoning (381-383) that if a null hypothesis is true, i.e. there is not a change in abundance 
between populations, then a significant difference, p < 0.05, will be observed by chance 
once in every 20 experiments. This is known as the type I error, or α. When 20 
independent tests are performed, or in this case 20 different features are tested for 
significance, and the null hypothesis is true for all 20, then the chance of each test being 
determined as significant is no longer 0.05, but 0.64. The formula for this error rate is       
1-(1-α)n, where n is the number of tests performed. However, the Bonferroni adjustment 
reduces the α applied to each feature, so the error rate across the experiment remains at 
0.05. The reduced significance level is 1-(1-α)1/n, giving 0.00256 in this case. This is often 
approximated as α/n (0.0025). Therefore, for this dataset (with around 12,000 features) the 
reduced significance level could be approximated as 0.05/12000 = 4.16x10-6. This would 
clearly give an extremely reduced number of ‘significant’ features, when compared with a 
standard p-value of 0.05. In this dataset if the p-value used is 0.05 there are over 5000 
features deemed to be ‘significant’. In comparison if the Bonferroni method is used as 
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described above this is reduced to around 500, which is clearly a much more manageable 
number to target for identification. 
There is, however, an alternative school of thought, which suggests that the Bonferroni 
correction is not appropriate in many cases (384;385). The Bonferroni adjustment implies 
that any comparison will be interpreted in a different way, depending on the number of 
tests that are performed. Furthermore, type I errors cannot be decreased without the 
inflation of type II errors.  
Type II errors refer to the probability of accepting the null hypothesis when it is not true. In 
this case, this would mean that the chance of not detecting a change in feature abundance 
when it is in fact present would be increased. Most advocates of the Bonferroni correction 
would include all statistical tests in a given report as a basis for the n-number by which to 
adjust p values. This in itself can cause further complications, as further tests may have 
been performed that were not included in the publication, or were included in other, related 
papers, meaning that a decision must be made regarding the value of the true n-number. 
A further statistical method that has been developed in order to control the high false 
positive rate in microarray data is known as the False Discovery Rate (FDR) (386). The 
false discovery rate of a test is defined as the expected proportion of false positives within 
the declared significant results (387-389). Therefore the FDR can be a more useful 
statistical value than a p-value. The data set collected here, via LC-MS, has certain 
parallels which can be drawn with microarray data. Microarray data sets tend to test a large 
number of genes, which can be related to the high number of LC-MS features tested here. 
It is proposed here that using a statistical method designed for microarray data may be the 
most appropriate way of dealing with this type of LC-MS dataset. 
FDR was originally described in 1995 by Benjamimi and Hochberg (387) and is a 
statistical method used in multiple hypothesis testing to identify the expected proportion of 
false positives among all significant hypotheses. For example if 100 observations were 
predicted to be different and a maximum FDR for these observations was 0.1 then the 
expectation would be that 10 of the observations were false positives. 
Benjamimi and Hochberg then went on to demonstrate that the FDR can be developed into 
a simple and powerful procedure. It has since been used routinely for many microarray 
applications (386;390-393). More recently, this type of statistical analysis developed for 
use with microarrays has been applied to proteomics data (394-397). 
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In my research presented here, the false discovery rate calculation has been used in two 
separate ways. Both methods use multiple pairwise comparisons between the six groups, 
instead of the previous general comparison across all six groups. The pairwise comparisons 
can be visualised using a set of three Venn diagrams as shown in figures 4.18 to 4.20.  
 
Figure 4.18 Venn Diagram number 1, showing pairwise comparisons of salt treated samples. 
Features are deemed to be significant between different sample groups based on a 5% FDR 
cut off value. 
 
 
Figure 4.19 Venn diagram number 2 showing pairwise comparisons of untreated samples. 
Features are deemed to be significant between different sample groups based on a 5% FDR 
cut off value. 
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Figure 4.20 Venn diagram number 3, showing pairwise comparisons between salt treated 
and untreated samples. Features are deemed to be significant between different sample 
groups based on a 5% FDR cut off value. 
 
Each part of the Venn diagram can be thought of as the statistically significant features 
from one pairwise comparison. The features are defined as significant in two separate 
ways, firstly using a pairwise Student’s t-test and false discovery rate, and secondly with a 
method known as RankProducts analysis (RP) and false discovery rate.  
The Student’s t-test (henceforth referred to as t-test), is a commonly used statistical test. It 
is similar to the previously mentioned one-way ANOVA test, but it may only be used on 
two populations. It is used to test whether there is any significant difference between the 
means of the two populations. In this case a t-test is performed for each feature, for each 
pairwise comparison, as defined by the Venn diagrams. A small t-test p-value would 
indicate that there could be a significant difference between the two groups. The t-test used 
here is an equal variance two-tailed test, meaning it considers both increases and decreases 
in intensity. The t-test requires a minimum of two data points in each population, and in 
general the statistical significance will improve with the number of data points. The t-test 
null hypothesis is again similar to that of the one-way ANOVA, being that there is no 
change in feature abundance between the populations.  
The RankProducts analysis was originally developed for use with microarray data 
(398;399). It is known as a ‘primary’ method for identification of differential genes 
between small groups of biologically replicated samples. It has been shown that the 
‘significant’ lists of samples achieved using RP analysis are superior to those obtained 
using standard t-tests, if the number of biological replicates is less than ten.  
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In RP analysis it is assumed that only a minority of features will demonstrate expression 
changes, measurements are independent between replicate samples, most changes are 
independent of one another and measurement variance is roughly equal for all features. 
The method used to identify differentially expressed features within the dataset is based on 
the assumption that it is extremely unlikely to observe a single feature with a higher 
intensity in one set of samples compared with another if none of the the features are in fact 
present in different intensities, i.e. if all null hypothesis are true. A list of features can be 
created with the top feature showing the largest intensity difference between the two 
sample sets, the second feature showing the second largest intensity difference and so on 
down the list. These RP values assigned to each feature can then be used to sort the 
features by the likelihood of observing them so high on the list by chance. 
Both the pairwise t-tests and the RankProducts analyses were conducted using a false 
discovery rate with a 5 % cut off value. All RankProducts analyses was undertaken by Dr 
McClure (Institure of Cardiovascular and Medical Science, University of Glasgow) using a 
Perl script and a corresponding Windows executable system developed by R Breitling 
(Bioinformatics Research Centre, Institute of Biomedical and Life Sciences, University of 
Glasgow). 
From this statistical analysis lists of significant features were composed. The most 
‘interesting’ features were defined as those in which the congenic strain either behaved as 
the WKY strain, or showed an intermediate behaviour between the WKY and the SHRSP 
strains. The congenic strain has a background from the SHRSP strain with chromosome 2 
from the WKY strain. These specific features should occur in the AB and ABC portions of 
Venn diagrams 1 and 2 (see figures 4.18 to 4.20). Therefore, the features occurring here 
were focussed upon. The individual expression profile for each feature was evaluated 
visually and a decision made regarding its interest. These feature lists were then used for 
targeted MS-MS analysis for peptide and protein identification. 
As mentioned earlier, the initial statistical analysis of this dataset was to perform a simple 
ANOVA calculation across all six sample sets. This is shown in the figure, 4.21, below. It 
is seen here that, if even a fairly strict, p-value of 0.001 is set, there are still around 2000 
features deemed to have significant changes across the six sample sets. 2000 features are 
far too many to target for further investigation and identification, in any sort of efficient 
manner. This prompted the move to investigate further statistical methods of analysis.As 
discussed above, this can be visualised in the form of three Venn diagrams. These three 
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Venn diagrams are repeated twice, using pairwise t-tests and 5 % FDR and also 
RankProducts analysis and 5 % FDR. The results of this analysis are shown in the Venn 
diagram format, with the numbers present in each section representative of the number of 
features deemed as having a significant difference between groups. This is shown in 
figures 4.22 – 4.27. 
 
 
 
 
 
Figure 4.21 Graph displaying results from one-way ANOVA analysis of LC-MS analysis. This 
demonstrates that with a significant p value of 0.001 there are around 2000 features deemed 
to be significant. 
 
 
 
Figure 4.22 Venn diagram showing the no salt pairwise t-test statistical analysis with a 5 % 
FDR cut off value. Numbers represent the number of features determined as significant 
using each statistical test. 
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Figure 4.23 Venn diagram showing the salt pairwise t-test statistical analysis with a 5 % FDR 
cut off value. Numbers represent the number of features determined as significant using 
each statistical test. 
 
 
 
Figure 4.24 Venn diagram showing the salt vs no salt pairwise t-test statistical analysis with 
a 5 % FDR cut off value. Numbers represent the number of features determined as 
significant using each statistical test 
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Figure 4.25 Venn diagram showing the no salt pairwise RP statistical analysis with a 5 % 
FDR cut off value. Numbers represent the number of features determined as significant 
using each statistical test. 
 
 
 
Figure 4.26 Venn diagram showing the salt pairwise RP statistical analysis with a 5 % FDR 
cut off value. Numbers represent the number of features determined as significant using 
each statistical test. 
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Figure 4.27 Venn diagram showing the salt vs no salt pairwise RP statistical analysis with a 
5 % FDR cut off value. Numbers represent the number of features determined as significant 
using each statistical test. 
 
From visual examination of any features falling into the AB or ABC parts of Venn 
diagrams 1 and 2, for the RP and t-test analysis, the following features were identified as 
possible interesting targets for LC-MS: 
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AB - Match 
Number  Mass (Da) 2+ 3+ 
Retention Time 
(min) 
1762 360.197 181.098 121.066 59.201
2212 1279.121 640.560 427.374 62.745
2348 931.457 466.729 311.486 56.532
3573 972.719 487.360 325.240 66.335
4263 1393.236 697.618 465.412 50.259
5007 440.231 221.115 147.744 58.908
5780 2232.123 1117.061 745.041 56.840
6441 1016.013 509.006 339.671 60.347
6699 444.273 223.136 149.091 57.399
6892 425.219 213.609 142.740 61.802
7065 1351.687 676.843 451.562 57.928
7195 790.450 396.225 264.483 59.945
7467 640.301 321.151 214.434 47.652
7539 2185.062 1093.531 729.354 47.977
7588 1247.683 624.841 416.894 58.977
7637 848.462 425.231 283.821 59.987
7854 769.444 385.722 257.481 60.702
7880 766.409 384.205 256.470 57.658
7957 1533.844 767.922 512.281 59.499
8259 408.207 205.104 137.069 62.690
8270 894.463 448.232 299.154 58.591
8770 475.207 238.604 159.402 58.913
8788 431.210 216.605 144.737 57.220
9193 1705.823 853.911 569.608 48.768
Table 4.3 Table of features of interest from AB Venn diagram untreated samples and 
pairwise t-test analysis 
 
ABC - Match 
Number  
Mass 
(Da) 2+ 3+ 
Retention Time 
(min) 
2304 1508.827 755.414 503.942 62.720 
6668 447.230 224.615 150.077 56.086 
7679 2150.106 1076.053 717.702 59.419 
7840 1307.587 654.793 436.862 60.932 
Table 4.4 Table of features of interest from ABC Venn diagram untreated samples and 
pairwise t-test analysis 
 
AB - Match 
Number  
Mass 
(Da) 2+ 3+ 
Retention Time 
(min) 
2620 1119.178 560.589 374.059 58.947 
2749 1127.779 564.889 376.926 73.518 
Table 4.5 Table of features of interest from AB Venn diagram salt treated samples and 
pairwise t-test analysis 
 
ABC - Match 
Number  
Mass 
(Da) 2+ 3+ 
Retention Time 
(min) 
2797 946.619 474.309 316.540 56.569 
Table 4.6 Table of features of interest from ABC Venn diagram salt treated samples and 
pairwise t-test analysis 
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AB - Match 
Number  
Mass 
(Da) 2+ 3+ 
Retention Time 
(min) 
1696 700.542 351.271 234.514 55.445 
2258 1044.964 523.482 349.321 51.490 
3992 2154.372 1078.186 719.124 67.930 
Table 4.7 Table of features of interest from AB Venn diagram untreated samples and 
pairwise RP analysis 
 
AB - Match 
Number  
Mass 
(Da) 2+ 3+ 
Retention Time 
(min) 
1951 1086.758 544.379 363.253 55.152 
2698 2109.122 1055.561 704.041 54.492 
2024 1807.877 904.939 603.626 61.047 
2369 1790.967 896.483 597.989 54.570 
1615 1274.231 638.116 425.744 70.261 
2969 2148.369 1075.184 717.123 58.640 
2056 2268.298 1135.149 757.099 61.475 
4167 3700.054 1851.027 1234.351 53.897 
2981 1636.020 819.010 546.340 56.122 
1346 685.709 343.855 229.570 62.257 
1243 811.537 406.769 271.512 68.022 
4280 1451.477 726.738 484.826 58.977 
4012 946.110 474.055 316.370 68.698 
1600 942.445 472.222 315.148 61.127 
2220 843.127 422.564 282.042 60.506 
Table 4.8 Table of features of interest from AB Venn diagram salt treated samples and 
pairwise RP analysis 
 
ABC - Match 
Number  
Mass 
(Da) 2+ 3+ 
Retention Time 
(min) 
4371 677.063 339.531 226.688 57.400 
Table 4.9 Table of features of interest from ABC Venn diagram salt treated samples and 
pairwise RP analysis 
 
Expression profiles of selected features are shown in the figures 4.28 to 4.33. All of these 
features, in tables 4.4 to 4.10), were subsequently targeted for MS-MS identification. 
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Figure 4.28 Expression profile of feature 1696. This shows the differing intensities across 
the three relevant sample groups 
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Figure 4.29 Expression profile of feature 2348. This shows the differing intensities across 
the three relevant sample groups 
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Figure 4.30 Expression profile of feature 3573. This shows the differing intensities across 
the three relevant sample groups 
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Figure 4.31 Expression profile of feature 6699. This shows the differing intensities across 
the three relevant sample groups 
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Figure 4.32 Expression profile of feature 2620. This shows the differing intensities across 
the three relevant sample groups 
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Figure 4.33 Expression profile of feature 4012. This shows the differing intensities across 
the three relevant sample groups 
 
Examination of figures 4.28 to 4.33 demonstrates that the features selected show different 
expression profiles across the sample groups. The features shown in figures 4.28, 4.29, 
4.30 and 4.32 show an intermediate intensity in the congenic samples, when compared to 
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the wild type and SHRSP samples. The features shown in figures 4.31 and 4.33 show a 
similar intensity in the congenic and wild type samples and a different intensity in the 
SHRSP samples. It is concluded that any of these features could be possible markers for 
disease. However, it is now important to gain identifications of these features. This will be 
discussed in the following section 4.4.7. 
4.4.7 Targeted MS-MS for Protein Identification in Plasma 
Targeted MS-MS analysis was performed, on the Dionex 3000 LC-MS coupled to the 
Applied Biosystems Q-Star. The MS-MS data from each sample was searched using 
MASCOT version 2.1 against NCBInr database 20090424. The identified peptides were 
then matched to the features of interest, using mass and retention time.  
From this analysis, four features were identified as being from specific proteins. Their 
expression profiles and MASCOT identifications are shown in figures 4.34 to 4.41. 
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Figure 4.34 Expression profile from feature number 7065, 1351.687 Da (57.9 mins), from 
Pairwise t tests AB 
 
 
Figure 4.35 MASCOt results showing feature number 7065, identified as contrapsin-like 
protease inhibitor. Analsyed using Dionex 3000 LC system and Applied Biosystems Q-Star 
 
Examination of the expression profile in figure 4.34 shows that the selected feature, with 
mass 1351.687 Da, has an increased intensity in the SHRSP no salt samples, when 
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compared with the WKY no salt samples. Additionally, the feature has an intermediate 
intensity in the congenic no salt samples. Therefore, the selected feature is a potential 
marker for hypertension. Figure 4.35 shows the identification of this feature from targeted 
MS-MS analysis. The mass of 1351.7936 Da corresponds to a peptide from the protein 
contrapsin-like protease inhibitor. 
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Figure 4.36 Expression profile from feature number 7679, 2150.106 Da (59.4 mins) from 
pairwise t tests ABC analysis 
 
 
Figure 4.37 MASCOT results showing feature number 7679, identified as fibrinogen alpha 
chain isoform 1. Analsyed using Dionex 3000 LC system and Applied Biosystems Q-Star 
 
Examination of the expression profile in figure 4.36 shows that the selected feature, with 
mass 2150.106 Da, has an increased intensity in the SHRSP no salt samples, when 
compared with the WKY no salt samples. As for figure 4.34, the feature has an 
intermediate intensity in the congenic no salt samples. Therefore, as before, the selected 
feature is a potential marker for hypertension. Figure 4.37 shows the identification of this 
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feature from targeted MS-MS analysis. The mass of 2150.3782 Da corresponds to a 
peptide from the protein fibrinogen alpha chain isoform 1. 
It should, however, be noted that the identification of this peptide is questionable. The 
difference between the predicted and observed mass is rather large, at 0.6273, and in 
addition the score of 15 is lower than the expected score.  
As several other peptides have also been identified from this protein, it would be possible 
to examine their expression profiles and compare them with the expression profile shown 
in figure 4.36. This could be a potential avenue for future research. 
2369 AB Expression Profile from Venn
0
5
10
15
20
25
WKY salt Congenic salt SHRSP salt
A
ve
ra
ge
 N
or
m
al
is
ed
 L
og
2 I
nt
en
si
ty
 
Figure 4.38 Expression profile from feature number 2369, 1790.967 Da (54.5 mins) from 
pairwise RP AB analysis. 
 
 
Figure 4.39 MASCOT results showing feature number 2369, identified as pregnancy zone 
protein/alpha-1-macroglobulin. Analsyed using Dionex 3000 LC system and Applied 
Biosystems Q-Star 
 
Examination of the expression profile in figure 4.38 shows that the selected feature, with 
mass 1790.967 Da, has an increased intensity in the SHRSP salt samples, when compared 
with the WKY salt samples, however the error bars from the SHRSP samples do overlap 
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with the lower intensity signals from the WKY and wild type samples, which could mean 
the higher intensity observed is questionable. In this example the feature has similar 
intensities in the congenic salt samples and the WKY samples. This feature has still been 
included here as a potential marker for hypertension, as as mentioned previously the 
congenic strain has a background from the SHRSP strain with chromosome 2 from the 
WKY strain. Figure 4.39 shows the identification of this feature from targeted MS-MS 
analysis. The mass of 1790.0276 Da corresponds to a peptide from the pregnancy zone 
protein, although the difference between the predicted and observed mass of this peptide is 
rather larger than the ideal. 
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Figure 4.40 Expression profile from feature number 2749, 1127.779 Da (73.5 mins) from 
pairwise t tests AB analsyis. 
 
 
Figure 4.41 MASCOT results showing feature number 2749, identified as Hemopexin. 
Analsyed using Dionex 3000 LC system and Applied Biosystems Q-Star 
 
Examination of the expression profile in figure 4.40 shows that the selected feature, with 
mass 1127.779 Da, has an increased intensity in the SHRSP salt samples, when compared 
with the WKY salt samples. As for the previous example the feature has similar intensities 
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in the congenic salt samples and the WKY samples. This means that the selected feature is 
a potential marker for hypertension, as for the feature in figure 4.38. Figure 4.41 shows the 
identification of this feature from targeted MS-MS analysis. The mass of 1127.5834 Da 
corresponds to a peptide from the hemopexin protein, however it should be noted that the 
score of 14 for this identification is rather lower than the expected score of 67, which is not 
ideal for a peptide identification. 
The possible biological significance of these proteins is discussed in section 4.4.9. 
From these four identifications of possible biomarkers, antibodies were available for two 
of them, hemopexin and fibrinogen alpha-1-isoform. 
4.4.8 Western Blotting for Confirmation of Protein Identifications 
The western blots of hemopexin and fibrinogen alpha-1-isoform are shown in figures 4.42 
and 4.43. Lanes 1 to 6 represent the six different sample groups WKY no salt, WKY salt, 
Congenic no salt, Congenic salt, SHRSP no salt and SHRSP salt. It was expected that the 
results from these western blots would mimic the quantitation data from the label free 
relative quantitation expression profiles.  
 
 
Figure 4.42 Quantitative western blot for fibrinogen alpha-1-isoform. Lane 1 is WKY no salt, 
lane 2 is WKY salt, lane 3 is congenic no salt, lane 4 is congenic salt, lane 5 is SHRSP no 
salt and lane 6 is SHRSP salt. 
 
 
 
Figure 4.43 Quantitative western blot for Hemopexin. Lane 1 is WKY no salt, lane 2 is WKY 
salt, lane 3 is congenic no salt, lane 4 is congenic salt, lane 5 is SHRSP no salt and lane 6 is 
SHRSP salt. 
 
 1        2    3       4        5        6 
 1        2   3   4       5       6 
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Visual examination of the western blots confirms that the two proteins, fibrinogen alpha 1 
isoform and hemopexin, are present in all 6 samples. It is difficult to draw any further 
conclusions from the blots using only a visual analysis. Quantitative information was 
extracted from these western blots, using the total pixel intensity from each band. This was 
then plotted in an expression profile style for comparison with the label free relative 
quantitation results. This is shown in figures 4.44 and 4.45, error bars shown ± one 
standard deviation.  
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Figure 4.44 Expression profile from quantitative western blot for Fibrinogen 
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Figure 4.45 Expression profile from quantitative western blot for Hemopexin 
 
It can be seen that the pattern of the expression profiles from the quantitative western blots 
does not directly mimic the expression profiles seen from the label free quantitation data. 
However, in both western blots, the intensity is higher in the SHRSP samples, relative to 
the WKY and congenic samples. This is as predicted by the relative label free quantitation 
experiment. The profiles may not be exactly the same as those seen in the label free 
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quantitation experiment for several reasons. The quantitation from the western blots may 
not be entirely accurate due to the fact that pooled samples were used as opposed to 
western blots being performed against every sample available, and average results being 
taken. It is also possible that the label free relative quantitation may not be entirely 
accurate, due to the relatively low number of replicate samples available. Unfortunately 
this could not be avoided in this case, but it should be noted for future work that a higher 
number of replicate samples in each sample set would be preferable.  
The western blot serves as a good validation method for the quantitative data previously 
collected. However, it should be taken into consideration that if the results do not exactly 
mimic each other, it can be challenging as to what conclusions to draw. 
4.4.9 Biological Significance of the Identified Proteins 
4.4.9.1 Hemopexin 
The main function of hemopexin is known to be binding heme and transporting it to the 
liver, for breakdown and iron recovery. Following this the free hemopexin is returned to 
circulation. Hemopexin is expressed by the liver and secreted in the plasma. It is a plasma 
glycoprotein, and is has the highest known heme affinity. It is also known to be an acute 
phase protein, with levels being increased in correlation with inflammation (400;401).  
4.4.9.2 Fibrinogen alpha-1-isoform 
Fibrinogen is known to have two functions, yielding monomers that polymerize into fibrin 
and also acting as a co-factor in platelet aggregation (UniProt Protein Knowledgebase, 
http://www.uniprot.org). 
4.4.9.3 Pregnancy zone protein (Alpha-1-macroglobulin) 
Pregnancy zone protein is known to inhibit all four classes of proteinases using a unique 
'trapping' mechanism. It has a peptide stretch, called the 'bait region' which contains 
specific cleavage sites for different proteinases. When a proteinase cleaves the bait region, 
a conformational change is induced in the protein trapping the proteinase. The entrapped 
enzyme remains active against low molecular weight substrates (although activity against 
high molecular weight substrates is greatly reduced). Following cleavage in the bait region 
a thioester bond is hydrolyzed and mediates the covalent binding of the protein to the 
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proteinase. It is found in plasma, and is found in high abundance during the late stages of 
pregnancy (UniProt Protein Knowledgebase, http://www.uniprot.org). 
4.4.9.4 Contrapsin-like-protease inhibitor 
Contrapsin-like-protease inhibitor (alternative name Serine protease inhibitor A3K) is 
known to bind to and inhibit kallikreins. It inhibits trypsin but not chymotrypsin or 
elastase. It is found in the liver and in plasma. Its level is known to be reduced by 
inflammation. Its level is also known to be higher in male rats, than in female (402-405).  
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4.5 Discussion 
This work has had several aims, all of which have been achieved. Firstly, the efficiency of 
two different plasma partitioning strategies have been evaluated, using 2D mini gel and 
LC-MS analysis. It was concluded that although plasma partitioning has its place as a 
sample preparation method, neither antibody affinity partitioning or size separation 
depletion are appropriate for use in a quantitative biomarker discovery project, such as this 
one. This is for several reasons, the prime one being the possibility of the introduction of 
artificial differences into the sample set. This has the possibility of causing misleading 
results, and also may mask true, biological differences between the samples. A second 
reason that plasma partitioning is not appropriate for biomarker discovery projects is due to 
what may be lost with the removed fractions. The removal of abundant proteins is likely to 
also remove interesting, low abundance proteins, which are associated with the more 
abundant proteins. Therefore, it was concluded that plasma partitioning, or depletion, 
would not be used in this project. 
Secondly, the repeatability and reproducibility of two nano-flow liquid chromatography 
systems were evaluated. This is a step which cannot be under-estimated when label free 
quantitation is performed. If the liquid chromatography is not reproducible, none of the 
quantitation results will be accurate. It was concluded from this, that the Dionex 3000 
nano-flow liquid chromatography system, with a 15 cm C18 column was the most 
appropriate system for this work available, and the Dionex Ultimate nano-flow liquid 
chromatography system was not appropriate, due to poor flow control and lack of 
temperature control. It was also concluded that automated de-salting gave better sample 
reproducibility than manual de-salting spin columns. Ensuring reproducibility of results is 
a vital step in this type of analysis, and should perhaps consume the majority of 
experimental time. Following assurance of reproducibility biological replicates can be 
analysed relatively quickly, with minimal changes to the equipment to help ensure valid 
results are obtained. Additionally, degradation of samples should be closely monitored to 
help prevent mis-leading results. 
Thirdly, LC-MS data was collected for all rat plasma samples available. This was analysed 
using Label Free Relative Quantitation software, Decyder MS. This software was also 
thoroughly evaluated and it was decided to be the most appropriate software available for 
this project.  
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One of the main novel aspects of this research is the new application of statistical methods 
to a relatively new type of dataset. LC-MS and label free relative quantitation of biological 
samples, such as plasma, produce a wealth of information. There have been many different 
ways of analysing datasets such as this reported, ranging from simple ANOVA analysis 
(406), statistical tests such as the Mann-Whitney U test (40) or partial least-squares 
discriminant analysis (407) to more complicated statistical analysis involving different 
ways of filtering the dataset and techniques such as FDR (41). 
One of the largest challenges here is extracting data in a useful and meaningful way, in 
order to conduct biomarker research. It is certainly not as straightforward as may initially 
be imagined, and mining this data for useful changes in abundance needs careful 
experimental planning and additionally, the extremely careful application of the correct 
statistical techniques. Simply using a certain technique because it is widely accepted in the 
field is not an acceptable selection technique. Careful thought and research must be applied 
to statistics, and it should be one of the most important parts of the data analysis, and not 
simply an afterthought. Additionally, perhaps statisticians will begin to be incorporated 
further into biological research, to help enable a fresh view point on these challenging 
datasets, and more importantly an expert application of the techniques, and possibly even 
development of new, tailor-made statistical analysis.  
In the work presented here a great deal of thought, discussion, expert advice and trialling 
of different methods has gone into the statistical analysis performed. It is proposed here 
that the most appropriate method available has been chosen to attempt to identify 
interesting changes in abundance from this complicated dataset. Different statistical 
analysis including ANOVA and sets of pairwise t-tests and RankProducts with false 
discovery rate were evaluated. It was decided that a simple ANOVA calculation was not 
useful with this dataset, even though it is the most widely accepted and used type of 
analysis in this field, mainly because it did not specifically target the interesting features of 
the dataset. Both the pairwise t tests and RankProducts analysis with a 5% FDR helped to 
target these features in a more specific manner.  
For future work it would be possible to investigate the use of two or three-way ANOVA to 
identify features of interest. A significant p-value resulting from a one-way ANOVA test 
indicates that a feature is present at a significantly different level in at least one of the 
groups analyzed. However, if there are more than two groups being analyzed, the one-way 
ANOVA does not specifically indicate which pair of groups exhibits statistical differences. 
Two-way ANOVA tests (also called two-factor analysis of variance) can be used to 
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measure the effects of two factors simultaneously, for example the effect of the disease and 
the salt treatment. Two-way ANOVA is able to assess both disease and salt treatment in 
the same test, and also whether there is an interaction between the parameters. Three-way 
ANOVA works in a similar way for three factors. These methods were not applied in this 
work, in order to keep the statisical analysis used simple and, in addition, to investigate the 
effect of using RankProducts and FDR anaylsis on the dataset. The two or three-way 
ANOVA could be a possible future avenue for investigation. 
Following the statistical analysis, a targeted MS-MS strategy was used to attempt to 
identify the features of interest. This resulted in four identifications of possible biomarkers. 
This was then followed up by two separate quantitative western blots to validate these 
results; however the quantitation could not be exactly replicated. Validation of these results 
using traditional biochemical techniques is a vitally important part of the experiment and is 
widely used (40;41). It will take some time, if ever, before label free relative quantitation is 
accepted as a stand-alone technique through which to discover and monitor changes in 
peptide abundance. It is likely, due to expense and the expert operation required that it will 
always remain as a tool for the research laboratory, and will not spread into the clinical 
field. However, these methods can still play an important role in the future of proteomic 
research into diseases such as hypertension and many others. It will not be possible to 
investigate the levels of certain molecules in biological samples through other techniques, 
and the application of proteomics to biomarker discovery is expected to continue to grow 
over the coming years. Following the perfection of techniques, such as the one described 
here, it will be simple to apply these to a wide variety, if not all, human diseases. There is a 
huge amount of knowledge to be obtained in this way, and the continuation of focussed 
research is vitally important to our continued improvements in treatment of disease. 
It is concluded that label free relative quantitation is a valid tool for biomarker discovery, 
for a disease such as hypertension. Different types of statistical analysis can be used to 
target the results in a specific way, by identifying potential markers showing certain types 
of expression. This is a particularly useful type of analysis when there is more than two 
sample sets, as in this case. This method could be applied to any disease state, where 
multiple samples are available. As this is an unguided biomarker discovery method, no 
previous disease knowledge is required, making it a particularly useful and powerful 
technique. 
174 
5 Conclusions and Discussion 
 
The work presented here has been broken down into three main chapters, namely: 
• Biomarker Identification in Stroke Brain guided by MALDI-imaging 
• Assessment of Denator Heat Treatment for Prevention of Proteomic Sample 
Degradation using Label Free Relative Quantitation 
• Discovery and Identification of Biomarkers for Hypertension 
Between these three chapters runs a joint theme, with all the work presented aiming to 
better proteomic research relating to biomarker discovery. This is with reference to sample 
preparation, the importance of experimental design (especially when working with limited 
samples) and the application of relevant and useful statistical methods to help mine into 
rich datasets.  
The importance of investigating and learning about ischemic stroke was emphasised, and 
the current challenges facing researchers when attempting to gain identification of 
interesting up or down-regulated biomolecules seen in diseased tissue, using a fairly new 
technique known as MALDI-MSI. It is certainly not a straight forward process and 
obstacles were encountered. One of the important challenges in this work was the changes 
the disease made to the physicality of the tissue, causing global changes to protein levels in 
the samples used. The only way to overcome this issue is to use strict controls and 
meticulous experimental design. A further challenge in this part of the research was severe 
lack of sample availability, resulting in the work not being fully completed. This signifies 
the importance of precise experimental design, prior to practical experimentation. 
Following on from this was the investigation into a new heat treatment device, aiming to 
prevent sample degradation. This is an important issue in any sort of research conducted 
using biological samples, as the researcher will wish to analyse the samples with as few 
artificial changes as possible. Enzymatic action causes large changes in samples following 
collection and storage to point of analysis. This degradation is important as it can give mis-
leading results in any qualitative or, more importantly, quantitative proteomic analysis. In 
the past, the way to avoid this has been to store samples at a low temperature and to apply 
protease inhibitors, causing problems with mass spectrometric interference and possible 
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sample loss. Controlling the degradation processes will be of significant importance within 
many areas of proteomic and other types of biological research. A sample preservation step 
that is applied as early as possible after sampling was investigated as a possible solution to 
this problem. A denaturing device (Denator AB, Gothenburg, Sweden) was evaluated for 
sample preservation using mouse brain tissue as the subject. This instrument works using a 
combination of pressure and heat to rapidly and homogenously heat the tissue sample 
preventing proteolytic activity. It was proposed that this fast, homogenous heat distribution 
may give more effective, reproducible sample preservation. The use of heat-treatment on 
tissues immediately postmortem, to halt enzymatic degradation by denaturing both 
enzymes and proteins within tissue, was described here. To assess this device and process, 
in comparison with conventional snap freezing, LC-MS and Label Free Relative 
Quantitation were employed.  
It was concluded that the heat treatment had little affect on the sub 10 kDa proteomic data. 
The features that did show significant changes between the frozen and heat treated groups 
showed a number of different types of changes, varying from showing feature preservation 
when the heat treatment is used, to sample degradation by the treatment. It was concluded 
that the heat treatment could potentially be a useful technique when particular targets 
cannot be detected using conventional snap freezing treatment. However, for analysis of 
the sub 10 kDa LC-MS proteomic data from mouse brain tissue sample studied here, it is 
not expected that the heat treatment system will become a popular sample preparation 
technique, due to the small change it demonstrates on the majority of the data and the 
additional expense it incurs to the research laboratory.  
A further conclusion was that MS-MS identification of non-tryptically digested protein and 
peptide fragments can be challenging, as it was not possible to identify these features, 
using the techniques employed in this work. Additionally, it must be considered that the 
features under investigation were biomolecules such as lipids, and not proteins or peptides, 
as assumed. This could potentially be investigated in the future, along with the heat 
treatment affect on these types of molecule. Statistical analysis techniques were also 
investigated here, and the outcome of this was carried forward into further work conducted 
in the proceeding chapter regarding biomarkers for hypertension in rat plasma samples. 
Hypertension was an interesting disease to study, due to its common occurrence and also 
its link with coronary heart disease, ventricular hypertrophy, heart failure, peripheral 
vascular disease, renal disease and atherosclerosis. To enable the prevention of these 
diseases, increased understanding of hypertension is paramount. Additionally, the 
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relationship with dietary salt is of interest, as the current opinion is that a high level of 
dietary salt is associated with increased blood pressure in later life. Previously conducted 
studies into biomarkers for hypertension have been limited in the fact that they have been 
guided by previous knowledge alone. As the occurrence of, and possible predisposition to, 
hypertension is not fully understood this must have limited possible biomarker discovery 
significantly. It was proposed here that biomarkers for hypertension are currently not 
particularly well characterised. In my research, biomarkers for hypertension were 
investigated in a completely unguided manner, which is not a common practice. A label 
free relative quantitation method was again used, this time to examine differences between 
diseased and healthy samples, mainly concentrating on plasma samples. In this work a rat 
model was used, and the effect of salt treatment was also investigated. The advantages and 
disadvantages of the use of an animal model were also discussed, with the main reason, in 
this case, for using an animal model being the reduction of sample heterogeneity. 
Additionally, the importance of experimental design was discussed, with emphasis put on 
the avoidance of introducing bias into an experimental study such as this. In this work 
plasma samples were used, and the challenges and issues of this type of sample were also 
discussed. The main challenge of analysing plasma samples was stated as being the the 
extremely high dynamic range of the samples and the high abundance levels of a small 
number of proteins. Different types of sample depletion and enrichment were considered 
and investigated. The efficiency of two different plasma partitioning strategies was 
evaluated, using two types of analysis, a traditional 2D mini gel and an LC-MS analysis. It 
was found that while plasma partitioning may have a place as a possible sample 
preparation method, neither antibody affinity partitioning or size separation depletion are 
particularly appropriate for use in a quantitative biomarker discovery project. The main 
problem with this type of sample preparation is the possibility of introducing artificial 
differences into the samples, in turn giving potentially mis-leading results. Additionally, 
important parts of the sample may be lost using this type of sample preparation. Hence, 
plasma depletion was not used in this work. 
Repeatability and reproducibility was emphasised as being a vitally important part of the 
biomarker discovery process, and it was proposed that this should not be underestimated 
as, perhaps, one of the most important parts of the research. This was fully investigated 
prior to collection of biological replicate samples, and should ensure consistent results 
throughout the work. Another important part of this work is the selection of the most 
appropriate statistical method, and this was also fully discussed and investigated. The 
methods used were pairwise t-tests and RankProduct analysis, developed for use with 
microarray data. 
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The outcome of this work was that several features were found to be differentially 
regulated between diseased and healthy animals. These were subsequently identified as 
being from the following proteins: 
• Hemopexin 
• Fibrinogen alpha-1-isoform 
• Pregnancy zone protein (alpha-1-macroglobulin) 
• Contrapsin-like-protease inhibitor 
The biological significance of these markers was summarised in chapter four. A future 
possible project will be further investigation into the significance of these, and possibly 
even their occurrence in humans.  
Ultimately, however, this project has not been a biological one. The development and 
perfection of techniques has been the main goal throughout, and the biological samples 
applied are somewhat irrelevant. The perfected proteomic biomarker discovery and 
identification project could therefore be applied to any disease of interest in the future.  
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Appendix 1 – Biomarker Identification in Stroke 
Brain Guided by MALDI imaging 
The graph below shows the standard curve used for determination of protein concentration 
in mouse brain tissue, as discussed in section 2.4.2. 
Standard Curve
y = 0.0119x + 0.4496
R2 = 0.9927
0.0000
0.2000
0.4000
0.6000
0.8000
1.0000
1.2000
1.4000
1.6000
1.8000
0 20 40 60 80 100 120
Protein content (µg)
A
ve
ra
ge
 s
ig
na
l
  
179 
Appendix 2 – Biomarker Identification in Stroke 
Brain Guided by MALDI imaging 
The following table shows 67 proteins identified from LC-MS-MS data searched using 
MASCOT version 2.1 against the NCBInr database 20070413 as detailed in section 2.3. In 
addition, selected mascot results for the identified proteins are shown below the table. 
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Proteins Identified Gi Identification Number 
from NCBInr 20070413 
Mass (Da) Mowse Score 
Beta 1 Globin  gi/4760586 15699 491 
Hemoglobin alpha chain gi/122421 15076 609 
Complexin 1 Mouse gi/31542416 15140 167 
Microtubule associated protein 
2, isoform 2 
gi/68341935 
 
49306 342 
Predicted: Solute carrier 
family 25 (mitochondrial 
carrier, adenine nucleotide 
translocator) 
gi/82917337 
 
27960 119 
ATP Synthase, H+ 
transporting, mitochondrial FO 
Complex, subunit F 
gi/7949005 
 
12489 
 
66 
FABP-I, fatty acid binding 
protein (N-terminal) 
gi/404383 
 
3733 65 
Hemoglobin beta chain 
complex 
gi/ 158969 15969 
 
144 
Ig Heavy Chain V region gi/90771 
 
12993 65 
Peptidylproyl Isomerase A gi/8394009 17863 91 
Hemoglobin alpha 2 chain gi/60678292 15275 240 
Myelin Basic Protein gi/293725 3956 82 
Myelin Basic Protein gi/4454311 14184 230 
Cytochrome C Oxidase Subunit 
Viic 
gi/6680991 
 
7328 86 
Eukaryotic translation 
initiation factor 5A 
gi/4503545 
 
16821 65 
Polyglutamine containing 
protein 
gi/60223071 
 
81444 86 
Atp5b protein gi/17390926 10152 65 
37kd Protein gi/205964 7428 125 
Mitochondrial malate 
dehydrogenase 2, NAD 
gi/89574115 
 
31657 
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DJ – 1 Protein-Rat gi/16924002 19961 81 
H(+) – ATP Synthase subunit e 
(N terminal)-rat 
gi/258788 
 
 4964 79 
Migration Inhibitory Factor gi/191491 11877 68 
MHC Class II Antigen – rat gi/18958188 6937 68 
Atp2b3 protein gi/111600317 121813 52 
Aspartate aminotransferase gi/871422 
 
46203 149 
Predicted Similar to Ubiquitin 
– protein ligase EDDI – mouse 
gi/94399459 333979 64 
Chain A, Macrophage Migration 
Inhibitory Factor Y95f Mutant 
gi/5822092 
 
12349 
 
102 
Phosphoglycerate mutase, p29 gi/235503 
 
1328 84 
Gln Synthetase gi/228136 40411 78 
Actin, gamma, cytoplasmic gi/123298588 16723 65 
Profilin 1 gi/56206029 11813 98 
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Actin, gamma, cytoplasmic gi/123298588 16723 87 
Triosephosphate Isomerase gi/538426 26904 70 
Ubiquitin carboxyl-terminal 
hydrolase isozyme L1 (UCH-L1) 
gi/1717867 
 
1815 
 
67 
Rod Outer segment membrane 
protein 1 (ROSP1) 
gi/417693 
 
37242 65 
Claudin 11 gi/6679186 22099 65 
Predicted Similar to 
Glyceraldehyde-3-phosphate 
dehydrogenase 
gi/109484558 
 
35760 104 
Predicted similar to NADH-
ubiquinone oxidoreductase 
MLRQ subunit 
gi/109471761 
 
8984 82 
Cytochrome c oxidase, subunit 
7a 3 –rat 
gi/11968072 9347 64 
GAPDH protein gi/66364570 14920 155 
Ubiquitin carboxy-terminal 
hydrolase L1 
gi/6755929 
 
24822 
 
155 
Predicted similar to 
glyceraldehyde-3-phosphate 
dehydrogenase 
gi/51769013 
 
35807 149 
Pyruvate kinase gi/16757994 57781 145 
Creatine Kinase-B gi/203476 40598 141 
Pgam1 Protein gi/45767854 22401 138 
Microtubule associated protein 
2 
gi/6981182 198446 131 
Unnamed protein product gi/12842521 9854 114 
Enolase 2, gamma gi/26023949 47111 83 
Choline transporter-like 
protein 2 (solute carrier family 
44 member 2, inner ear 
supporting cell a) 
gi/73918927 
 
79918 
 
77 
Glyoxylase 1 –rat gi/46485429 20806 75 
Beta Actin gi/28950674 11856 140 
Creatine Kinase, Brain gi/31542401 42685 111 
Actin Cytoplasmic, 1 (Beta 
actin) 
gi/1351867 
 
41711 99 
Mlrq like protein gi/1401252 8509 72 
Macrophage migration 
inhibitory factor 
gi/694108 
 
12538 65 
Myelin Basic Protein Isoform 6 gi/69885073 14202 85 
ATP Synthase, H+ 
Transporting, mitochondrial F1 
complex, beta subunit 
gi/54792127 
 
56318 143 
DJ-1 Protein-rat gi/16924002 19961 78 
Pyruvate kinase muscle –rat gi/16757994 57781 76 
Macrophage Migration 
inhibitory factor homolog –rat 
gi/285058 
 
2904 74 
VN Precursor – rat gi/1334229 13072 66 
Beta globin gi/193767 5687 135 
Calm2 protein gi/14715123 11067 70 
Myelin basic protein isoform 5 gi/8393759 
 
14202 91 
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Selected mascot results for the identified proteins are shown below: 
 
 
 
Ulip2 Protein gi/1915913 62132 95 
Alpha Globin gi/30027750 9346 133 
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Appendix 3 – Assessment of Heat Treatment for 
Prevention of Proteomic Sample Degradation 
using Label Free Relative Quantitation 
The figures shown below demonstrate the expression profiles exhibited by the 50 features 
with p-values ≤ 0.001 from the sub 10kDa intact samples, as discussed in section 3.4.2.1.  
From visual examination of the profiles it is demonstrated that 7 show expression profile as 
predicted by figure 3.2 C and 25 show expression profile as predicted by figure 3.2 D. 
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Expression profile from significant feature 2 from sub 10kDa intact samples 
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Expression profile from significant feature 3 from sub 10kDa intact samples 
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Expression profile from significant feature 4 from sub 10kDa intact samples 
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Expression profile from significant feature 5 from sub 10kDa intact samples 
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Expression profile from significant feature 6 from sub 10kDa intact samples 
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Expression profile from significant feature 7 from sub 10kDa intact samples 
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Expression profile from significant feature 8 from sub 10kDa intact samples 
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Expression profile from significant feature 9 from sub 10kDa intact samples 
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Expression profile from significant feature 10 from sub 10kDa intact samples 
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Expression profile from significant feature 11 from sub 10kDa intact samples 
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Expression profile from significant feature 12 from sub 10kDa intact samples  
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Expression profile from significant feature 13 from sub 10kDa intact samples  
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Expression profile from significant feature 14 from sub 10kDa intact samples  
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Expression profile from significant feature 15 from sub 10kDa intact samples  
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Expression profile from significant feature 16 from sub 10kDa intact samples  
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Expression profile from significant feature 17 from sub 10kDa intact samples  
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Expression profile from significant feature 18 from sub 10kDa intact samples  
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Expression profile from significant feature 19 from sub 10kDa intact samples  
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Expression profile from significant feature 20 from sub 10kDa intact samples  
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Expression profile from significant feature 21 from sub 10kDa intact samples  
 
16
16.5
17
17.5
18
18.5
19
19.5
20
20.5
21
D0 D5 D10 F0 F5 F10
A
ve
ra
ge
 L
og
2 I
nt
en
si
ty
 
Expression profile from significant feature 22 from sub 10kDa intact samples  
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Expression profile from significant feature 23 from sub 10kDa intact samples  
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Expression profile from significant feature 24 from sub 10kDa intact samples  
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Expression profile from significant feature 25 from sub 10kDa intact samples  
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Expression profile from significant feature 26 from sub 10kDa intact samples  
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Expression profile from significant feature 28 from sub 10kDa intact samples  
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Expression profile from significant feature 30 from sub 10kDa intact samples  
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Expression profile from significant feature 32 from sub 10kDa intact samples  
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Expression profile from significant feature 33 from sub 10kDa intact samples  
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Expression profile from significant feature 34 from sub 10kDa intact samples  
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Expression profile from significant feature 35 from sub 10kDa intact samples  
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Expression profile from significant feature 36 from sub 10kDa intact samples  
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Expression profile from significant feature 38 from sub 10kDa intact samples  
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Expression profile from significant feature 39 from sub 10kDa intact samples  
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Expression profile from significant feature 40 from sub 10kDa intact samples  
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Expression profile from significant feature 41 from sub 10kDa intact samples  
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Expression profile from significant feature 42 from sub 10kDa intact samples  
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Expression profile from significant feature 43 from sub 10kDa intact samples  
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Expression profile from significant feature 44 from sub 10kDa intact samples  
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Expression profile from significant feature 45 from sub 10kDa intact samples  
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Expression profile from significant feature 46 from sub 10kDa intact samples  
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Expression profile from significant feature 47 from sub 10kDa intact samples  
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Expression profile from significant feature 48 from sub 10kDa intact samples  
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Expression profile from significant feature 49 from sub 10kDa intact samples  
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Appendix 4 – Assessment of Heat Treatment for 
Prevention of Proteomic Sample Degradation 
using Label Free Relative Quantitation 
The figures shown below demonstrate the expression profiles exhibited by the 50 features 
with p-values ≤ 0.001 from the sub 10kDa digested samples, as discussed in section 
3.4.2.2.  From visual examination of the profiles it is demonstrated that 6 show expression 
profile as predicted by figure 3.2 C and 5 show expression profile as predicted by figure 
3.2 D. 
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Expression profile from significant feature 1 from sub 10kDa digested samples  
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Expression profile from significant feature 2 from sub 10kDa digested samples  
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Expression profile from significant feature 4 from sub 10kDa digested samples  
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Expression profile from significant feature 5 from sub 10kDa digested samples  
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Expression profile from significant feature 6 from sub 10kDa digested samples  
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Expression profile from significant feature 7 from sub 10kDa digested samples  
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Expression profile from significant feature 8 from sub 10kDa digested samples  
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Expression profile from significant feature 9 from sub 10kDa digested samples  
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Expression profile from significant feature 11 from sub 10kDa digested samples  
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Expression profile from significant feature 12 from sub 10kDa digested samples  
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Expression profile from significant feature 15 from sub 10kDa digested samples  
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Expression profile from significant feature 16 from sub 10kDa digested samples  
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Expression profile from significant feature 18 from sub 10kDa digested samples  
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Expression profile from significant feature 19 from sub 10kDa digested samples  
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13
13.5
14
14.5
15
15.5
16
16.5
17
17.5
18
D0 D5 D10 F0 F5 F10
A
ve
ra
ge
 L
og
2 I
nt
en
si
ty
 
Expression profile from significant feature 21 from sub 10kDa digested samples  
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225 
10
12
14
16
18
20
22
D0 D5 D10 F0 F5 F10
A
ve
ra
ge
 L
og
2 I
nt
en
si
ty
 
Expression profile from significant feature 32 from sub 10kDa digested samples  
 
10
12
14
16
18
20
22
D0 D5 D10 F0 F5 F10
A
ve
ra
ge
 L
og
2 I
nt
en
si
ty
 
Expression profile from significant feature 33 from sub 10kDa digested samples  
 
226 
4
6
8
10
12
14
16
D0 D5 D10 F0 F5 F10
A
ve
ra
ge
 L
og
2 I
nt
en
si
ty
 
Expression profile from significant feature 34 from sub 10kDa digested samples  
 
10
11
12
13
14
15
16
17
18
D0 D5 D10 F0 F5 F10
A
ve
ra
ge
 L
og
2 I
nt
en
si
ty
 
Expression profile from significant feature 35 from sub 10kDa digested samples  
 
227 
12
13
14
15
16
17
18
19
D0 D5 D10 F0 F5 F10
A
ve
ra
ge
 L
og
2 I
nt
en
si
ty
 
Expression profile from significant feature 36 from sub 10kDa digested samples  
 
10
11
12
13
14
15
16
17
18
19
D0 D5 D10 F0 F5 F10
A
ve
ra
ge
 L
og
2 I
nt
en
si
ty
 
Expression profile from significant feature 37 from sub 10kDa digested samples  
 
228 
13
13.5
14
14.5
15
15.5
16
16.5
17
17.5
18
D0 D5 D10 F0 F5 F10
A
ve
ra
ge
 L
og
2 I
nt
en
si
ty
 
Expression profile from significant feature 38 from sub 10kDa digested samples  
 
15
16
17
18
19
20
21
22
23
24
25
D0 D5 D10 F0 F5 F10
A
ve
ra
ge
 L
og
2 I
nt
en
si
ty
 
Expression profile from significant feature 39 from sub 10kDa digested samples  
229 
Reference List 
 
 (1)  Persidis A. Proteomics - An ambitious drug development platform attempts to link gene 
sequence to expressed phenotype under various physiological states. Nature 
Biotechnology 1998; 16(4):393-394. 
 (2)  Supratim Choudhuri. The Path from Nuclein to Human Genome: A Brief History of DNA 
with a Note on Human Genome. Bulletin of Science, Technology and Society 2003; 
291(5507):1195. 
 (3)  Collins FS, Lander ES, Rogers J, Waterston RH, Int Human Genome Sequencing Conso. 
Finishing the euchromatic sequence of the human genome. Nature 2004; 431(7011):931-
945. 
 (4)  James P. Protein identification in the post-genome era: the rapid rise of proteomics. 
Quarterly Reviews of Biophysics 1997; 30(4):279-331. 
 (5)  Wasinger VC, Cordwell SJ, Cerpapoljak A, Yan JX, Gooley AA, Wilkins MR et al. Progress 
with Gene-Product Mapping of the Mollicutes - Mycoplasma-Genitalium. Electrophoresis 
1995; 16(7):1090-1094. 
 (6)  Jones MB, Krutzsch H, Shu HJ, Zhao YM, Liotta LA, Kohn EC et al. Proteomic analysis 
and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. 
Proteomics 2002; 2(1):76-84. 
 (7)  Wu W, Hu W, Kavanagh JJ. Proteomics in cancer research. International Journal of 
Gynecological Cancer 2002; 12(5):409-423. 
 (8)  Anderson NL, Anderson NG. The human plasma proteome - History, character, and 
diagnostic prospects. Molecular & Cellular Proteomics 2002; 1(11):845-867. 
 (9)  Veenstra TD, Conrads TP, Hood BL, Avellino AM, Ellenbogen RG, Morrison RS. 
Biomarkers: Mining the biofluid proteome. Molecular & Cellular Proteomics 2005; 4(4):409-
418. 
 (10)  Ma YF, Liu GS, Du M, Stayton I. Recent developments in the determination of urinary 
cancer biomarkers by capillary electrophoresis. Electrophoresis 2004; 25(10-11):1473-
1484. 
 (11)  Theodorescu D, Mischak H. Mass spectrometry based proteomics in urine biomarker 
discovery. World Journal of Urology 2007; 25:435-443. 
 (12)  Han WK, Waikar SS, Johnson A, Betensky RA, Dent CL, Devarajan P et al. Urinary 
biomarkers in the early diagnosis of acute kidney injury (vol 73, pg 863, 2008). Kidney 
International 2009; 76(3):348-349. 
 (13)  Vestergaard P, Leverett R. Constancy of Urinary Creatinine Excretion. Journal of 
Laboratory and Clinical Medicine 1958; 51(2):211-218. 
 (14)  Schiffer E, Mischak H, Novak J. High resolution proteome/peptidome analysis of body 
fluids by capillary electrophoresis coupled with MS. Proteomics 2006; 6(20):5615-5627. 
 (15)  Kussmann M, Raymond F, Affolter M. OMICS-driven biomarker discovery in nutrition and 
health. Journal of Biotechnology 2006; 124(4):758-787. 
 (16)  Schaub S, Wilkins J, Weiler T, Sangster K, Rush D, Nickerson P. Urine protein profiling 
with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney 
International 2004; 65(1):323-332. 
230 
 (17)  Mischak H, Apweiler R, Banks RE, Conaway M, Coon J, Dominiczak A et al. Clinical 
proteomics: A need to define the field and to begin to set adequate standards. Proteomics 
Clinical Applications 2007; 1(2):148-156. 
 (18)  Dayarathna MKDR, Hancock WS, Hincapie M. A two step fractionation approach for 
plasma proteomics using immunodepletion of abundant proteins and multi-lectin affinity 
chromatography: Application to the analysis of obesity, diabetes, and hypertension 
diseases. Journal of Separation Science 2008; 31(6-7):1156-1166. 
 (19)  Abdul-Salam VB, Paul GA, Ali JO, Gibbs SR, Rahman D, Taylor GW et al. Identification of 
plasma protein biomarkers associated with idiopathic pulmonary arterial hypertension. 
Proteomics 2006; 6(7):2286-2294. 
 (20)  Berhane BT, Zong CG, Liem DA, Huang A, Le S, Edmondson RD et al. Cardiovascular-
related proteins identified in human plasma by the HUPO Plasma Proteome Project pilot 
Phase. Proteomics 2005; 5(13):3520-3530. 
 (21)  Anderson L. Candidate-based proteomics in the search for biomarkers of cardiovascular 
disease. Journal of Physiology-London 2005; 563(1):23-60. 
 (22)  Donahue MP, Rose K, Vonderscher J, Bougueleret L, Nelson CL, Cohen D et al. 
Proteomic discovery of coronary artery disease proteins using industrial scale analysis of 
pooled plasma: Results from the pooled plasma proteomics project. Circulation 2004; 
110(17):1011. 
 (23)  Florian-Kujawski M, Hussain W, Chyna B, Kahn S, Hoppensteadt D, Leya E et al. 
Biomarker profiling of plasma from acute coronary syndrome patients - Application of 
ProteinChip Array analysis. International Angiology 2004; 23(3):246-254. 
 (24)  Hoffman SA, Joo WA, Echan LA, Speicher DW. Higher dimensional (Hi-D) separation 
strategies dramatically improve the potential for cancer biomarker detection in serum and 
plasma. Journal of Chromatography B-Analytical Technologies in the Biomedical and Life 
Sciences 2007; 849(1-2):43-52. 
 (25)  Pietrowska M. Tumor markers studied with proteomic methods in blood and serum plasma. 
Biotechnologia (Poznan) 2009;(2):39-53. 
 (26)  Schaub NP, Jones KJ, Nyalwidhe JO, Cazares LH, Karbassi ID, Semmes OJ et al. Serum 
Proteomic Biomarker Discovery Reflective of Stage and Obesity in Breast Cancer Patients. 
Journal of the American College of Surgeons 2009; 208(5):970-978. 
 (27)  Vasudev NS, Ferguson RE, Cairns DA, Stanley AJ, Selby PJ, Banks RE. Serum biomarker 
discovery in renal cancer using 2-DE and prefractionation by immunodepletion and 
isoelectric focusing; increasing coverage or more of the same? Proteomics 2008; 8(23-
24):5074-5085. 
 (28)  Grote T, Siwak DR, Fritsche HA, Joy C, Mills GB, Simeone D et al. Validation of reverse 
phase protein array for practical screening of potential biomarkers in serum and plasma: 
Accurate detection of CA19-9 levels in pancreatic cancer. Proteomics 2008; 8(15):3051-
3060. 
 (29)  Omenn GS, States DJ, Adamski M, Blackwell TW, Menon R, Hermjakob H et al. Overview 
of the HUPO Plasma Proteome Project: Results from the pilot phase with 35 collaborating 
laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and 
a publicly-available database. Proteomics 2005; 5(13):3226-3245. 
 (30)  Shi M, Caudle WM, Zhang J. Biomarker discovery in neurodegenerative diseases: A 
proteomic approach. Neurobiology of Disease 2009; 35(2):157-164. 
 (31)  de Roos B. Proteomic analysis of human plasma and blood cells in nutritional studies: 
development of biomarkers to aid disease prevention. Expert Review of Proteomics 2008; 
5(6):819-826. 
 (32)  Ahmed FE. Laser microdissection: Application to carcinogenesis. Cancer Genomics & 
Proteomics 2006; 3(3-4):217-225. 
231 
 (33)  Chaurand P, Sanders ME, Jensen RA, Caprioli RM. Proteomics in diagnostic pathology - 
Profiling and imaging proteins directly in tissue sections. American Journal of Pathology 
2004; 165(4):1057-1068. 
 (34)  Vincek V, Nassiri M, Nadji M, Morales AR. A tissue fixative that protects macromolecules 
(DNA, RNA, and protein) and histomorphology in clinical samples. Laboratory Investigation 
2003; 83(10):1427-1435. 
 (35)  Ahram M, Flaig MJ, Gillespie JW, Duray PH, Linehan WM, Ornstein DK et al. Evaluation of 
ethanol-fixed, paraffin-embedded tissues for proteomic applications. Proteomics 2003; 
3(4):413-421. 
 (36)  Griffin TJ, Lock CM, Li XJ, Patel A, Chervetsova L, Lee H et al. Abundance ratio-
dependent proteomic analysis by mass spectrometry. Analytical Chemistry 2003; 
75(4):867-874. 
 (37)  Wright ME, Han DK, Aebersold R. Mass spectrometry-based expression profiling of clinical 
prostate cancer. Molecular & Cellular Proteomics 2005; 4(4):545-554. 
 (38)  Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B et al. The case for early 
detection. Nature Reviews Cancer 2003; 3(4):243-252. 
 (39)  Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment 
selection. Nature Reviews Cancer 2005; 5(11):845-856. 
 (40)  Kiga C, Sakurai H, Goto H, Hayashi K, Shimada Y, Saiki I. Proteomic identification of 
haptoglobin as a stroke plasma biomarker in spontaneously hypertensive stroke-prone 
rats. Life Sciences 2008; 83(17-18):625-631. 
 (41)  Silbiger V, Luchessi A, Hirata R, Neto L, Pastorelli C, Ueda E et al. Time course proteomic 
profiling of human myocardial infarction plasma samples: An approach to new biomarker 
discovery. Clinica Chimica Acta 412[11-12], 1086-1093. 12-5-2011.  
 (42)  Hsieh SY, Chen RK, Pan YH, Lee HL. Systematical evaluation of the effects of sample 
collection procedures on low-molecular-weight serum/plasma proteome profiling. 
Proteomics 2006; 6(10):3189-3198. 
 (43)  Rai AJ, Gelfand CA, Haywood BC, Warunek DJ, Yi JZ, Schuchard MD et al. HUPO 
Plasma Proteome Project specimen collection and handling: Towards the standardization 
of parameters for plasma proteome samples. Proteomics 2005; 5(13):3262-3277. 
 (44)  Sampson M, Ruddel M, Albright S, Elin RJ. Positive interference in lithium determinations 
from clot activator in collection container. Clinical Chemistry 1997; 43(4):675-679. 
 (45)  Drake SK, Bowen RAR, Remaley AT, Hortin GL. Potential interferences from blood 
collection tubes in mass spectrometric analyses of serum polypeptides. Clinical Chemistry 
2004; 50(12):2398-2401. 
 (46)  Villanueva J, Philip J, Chaparro CA, Li YB, Toledo-Crow R, DeNoyer L et al. Correcting 
common errors in identifying cancer-specific serum peptide signatures. Journal of 
Proteome Research 2005; 4(4):1060-1072. 
 (47)  Baumann S, Ceglarek U, Fiedler GM, Lembcke J, Leichtle A, Thiery J. Standardized 
approach to proteome profiling of human serum based on magnetic bead separation and 
matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clinical 
Chemistry 2005; 51(6):973-980. 
 (48)  Capila I, Linhardt RJ. Heparin - Protein interactions. Angewandte Chemie-International 
Edition 2002; 41(3):391-412. 
 (49)  White JG. EDTA-induced changes in platelet structure and function: clot retraction. 
Platelets 2000; 11(1):49-55. 
232 
 (50)  Marshall J, Kupchak P, Zhu WM, Yantha J, Vrees T, Furesz S et al. Processing of serum 
proteins underlies the mass spectral fingerprinting of myocardial infarction. Journal of 
Proteome Research 2003; 2(4):361-372. 
 (51)  West-Hielsen M, Hogdall EV, Marchiori E, Hogdall CK, Schou C, Heegaard NHH. Sample 
handling for mass spectrometric proteomic investigations of human sera. Analytical 
Chemistry 2005; 77(16):5114-5123. 
 (52)  Kolch W, Mischak H, Pitt AR. The molecular make-up of a tumour: proteomics in cancer 
research. Clinical Science 2005; 108(5):369-383. 
 (53)  Koomen J, Hawke D, Kobayashi R. Developing an understanding an introduction to 
biological of proteomics: Mass spectrometry. Cancer Investigation 2005; 23(1):47-59. 
 (54)  Stephens WE. A Pulsed Mass Spectrometer with Time Dispersion. Physical Review 1946; 
69(11-1):691. 
 (55)  Hays EE, Richards PI, Goudsmit SA. Mass Measurements with A Magnetic Time-Of-Flight 
Mass Spectrometer. Physical Review 1951; 84(4):824-829. 
 (56)  Wiley WC, Mclaren IH. Time-Of-Flight Mass Spectrometer with Improved Resolution. 
Review of Scientific Instruments 1955; 26(12):1150-1157. 
 (57)  Cotter RJ. Time-Of-Flight Mass-Spectrometry for the Structural-Analysis of Biological 
Molecules. Analytical Chemistry 1992; 64(21):A1027-A1039. 
 (58)  Paul W, Steinwedel H. *Ein Neues Massenspektrometer Ohne Magnetfeld. Zeitschrift fur 
Naturforschung Section A-A Journal of Physical Sciences 1953; 8(7):448-450. 
 (59)  Stafford GC, Kelley PE, Syka JEP, Reynolds WE, Todd JFJ. Recent Improvements in and 
Analytical Applications of Advanced Ion Trap Technology. International Journal of Mass 
Spectrometry and Ion Processes 1984; 60(SEP):85-98. 
 (60)  Louris JN, Cooks RG, Syka JEP, Kelley PE, Stafford GC, Todd JFJ. Instrumentation, 
Applications, and Energy Deposition in Quadrupole Ion-Trap Tandem Mass-Spectrometry. 
Analytical Chemistry 1987; 59(13):1677-1685. 
 (61)  Jonscher K, Currie G, Mccormack AL, Yates JR. Matrix-Assisted Laser Desorption of 
Peptides and Proteins on A Quadrupole Ion Trap Mass-Spectrometer. Rapid 
Communications in Mass Spectrometry 1993; 7(1):20-26. 
 (62)  Pappin DJC, Hojrup P, Bleasby AJ. Rapid Identification of Proteins by Peptide-Mass Finger 
Printing (Vol 3, Pg 327, 1993). Current Biology 1993; 3(7):487. 
 (63)  Henry KD, Williams ER, Wang BH, Mclafferty FW, Shabanowitz J, Hunt DF. Fourier-
Transform Mass-Spectrometry of Large Molecules by Electrospray Ionization. Proceedings 
of the National Academy of Sciences of the United States of America 1989; 86(23):9075-
9078. 
 (64)  Beu SC, Senko MW, Quinn JP, Mclafferty FW. Improved Fourier-Transform Ion-Cyclotron-
Resonance Mass-Spectrometry of Large Biomolecules. Journal of the American Society for 
Mass Spectrometry 1993; 4(2):190-192. 
 (65)  Fenn JB, Mann M, Meng CK, Wong SF, Whitehouse CM. Electrospray Ionization for Mass-
Spectrometry of Large Biomolecules. Science 1989; 246(4926):64-71. 
 (66)  Fenn JB, Mann M, Meng CK, Wong SF, Whitehouse CM. Electrospray Ionization-
Principles and Practice. Mass Spectrometry Reviews 1990; 9(1):37-70. 
 (67)  Wilm M, Mann M. Analytical properties of the nanoelectrospray ion source. Analytical 
Chemistry 1996; 68(1):1-8. 
 (68)  Korner R, Wilm M, Morand K, Schubert M, Mann M. Nano electrospray combined with a 
quadrupole ion trap for the analysis of peptides and protein digests. Journal of the 
American Society for Mass Spectrometry 1996; 7(2):150-156. 
233 
 (69)  Valaskovic GA, Kelleher NL, Mclafferty FW. Attomole protein characterization by capillary 
electrophoresis mass spectrometry. Science 1996; 273(5279):1199-1202. 
 (70)  Wilm M, Shevchenko A, Houthaeve T, Breit S, Schweigerer L, Fotsis T et al. Femtomole 
sequencing of proteins from polyacrylamide gels by nano-electrospray mass spectrometry. 
Nature 1996; 379(6564):466-469. 
 (71)  Lebrilla CB, Wang DTS, Hunter RL, Mciver RT. Detection of Mass 31830 Ions with An 
External Ion-Source Fourier-Transform Mass-Spectrometer. Analytical Chemistry 1990; 
62(8):878-880. 
 (72)  Huang XH, Shear JB, Zare RN. Quantitation of Ribonucleotides from Base-Hydrolyzed 
Rna Using Capillary Zone Electrophoresis. Analytical Chemistry 1990; 62(18):2049-2051. 
 (73)  Loo JA, Williams ER, Amster IJ, Furlong JJP, Wang BH, Mclafferty FW et al. Cf-252 
Plasma Desorption with Fourier-Transform Mass-Spectrometry. Analytical Chemistry 1987; 
59(14):1880-1882. 
 (74)  Bowers WD, Delbert SS, Hunter RL, Mciver RT. Fragmentation of Oligopeptide Ions Using 
Ultraviolet-Laser Radiation and Fourier-Transform Mass-Spectrometry. Journal of the 
American Chemical Society 1984; 106(23):7288-7289. 
 (75)  Mccrery DA, Gross ML. Laser Desorption Fourier-Transform Mass-Spectrometry for the 
Study of Nucleosides, Oligosaccharides, and Glycosides. Analytica Chimica Acta 1985; 
178(1):91-103. 
 (76)  Karas M, Hillenkamp F. Laser Desorption Ionization of Proteins with Molecular Masses 
Exceeding 10000 Daltons. Analytical Chemistry 1988; 60(20):2299-2301. 
 (77)  Chapman S. Carrier mobility spectra of spray electrified liquids. Physical Review 1937; 
52(3):0184-0190. 
 (78)  Dole M, Mack LL, Hines RL. Molecular Beams of Macroions. Journal of Chemical Physics 
1968; 49(5):2240-&. 
 (79)  Yamashita M, Fenn JB. Electrospray Ion-Source - Another Variation on the Free-Jet 
Theme. Journal of Physical Chemistry 1984; 88(20):4451-4459. 
 (80)  Yamashita M, Fenn JB. Negative-Ion Production with the Electrospray Ion-Source. Journal 
of Physical Chemistry 1984; 88(20):4671-4675. 
 (81)  Ikonomou MG, Blades AT, Kebarle P. Investigations of the Electrospray Interface for 
Liquid-Chromatography Mass-Spectrometry. Analytical Chemistry 1990; 62(9):957-967. 
 (82)  Cahn JW. Stability of Electrically Charged Conducting Droplets. Physics of Fluids 1962; 
5(12):1662-1663. 
 (83)  Gomez A, Tang KQ. Charge and Fission of Droplets in Electrostatic Sprays. Physics of 
Fluids 1994; 6(1):404-414. 
 (84)  Cole RB. Some tenets pertaining to electrospray ionization mass spectrometry. Journal of 
Mass Spectrometry 2000; 35(7):763-772. 
 (85)  Smith RD, Lightwahl KJ. The Observation of Noncovalent Interactions in Solution by 
Electrospray-Ionization Mass-Spectrometry - Promise, Pitfalls and Prognosis. Biological 
Mass Spectrometry 1993; 22(9):493-501. 
 (86)  Dulcks T, Juraschek R. Electrospray as an ionisation method for mass spectrometry. 
Journal of Aerosol Science 1999; 30(7):927-943. 
 (87)  Juraschek R, Dulcks T, Karas M. Nanoelectrospray - More than just a minimized-flow 
electrospray ionization source. Journal of the American Society for Mass Spectrometry 
1999; 10(4):300-308. 
234 
 (88)  Iribarne JV, Thomson BA. Evaporation of Small Ions from Charged Droplets. Journal of 
Chemical Physics 1976; 64(6):2287-2294. 
 (89)  Kebarle P, Tang L. From Ions in Solution to Ions in the Gas-Phase - the Mechanism of 
Electrospray Mass-Spectrometry. Analytical Chemistry 1993; 65(22):A972-A986. 
 (90)  Gamero-Castano M, de la Mora JF. Mechanisms of electrospray ionization of singly and 
multiply charged salt clusters. Analytica Chimica Acta 2000; 406(1):67-91. 
 (91)  Wilm MS, Mann M. Electrospray and Taylor-Cone Theory, Doles Beam of Macromolecules 
at Last. International Journal of Mass Spectrometry 1994; 136(2-3):167-180. 
 (92)  Emmett MR, Caprioli RM. Micro-Electrospray Mass-Spectrometry - Ultra-High-Sensitivity 
Analysis of Peptides and Proteins. Journal of the American Society for Mass Spectrometry 
1994; 5(7):605-613. 
 (93)  Andren PE, Emmett MR, Caprioli RM. Micro-Electrospray - Zeptomole-Attomole Per 
Microliter Sensitivity for Peptides. Journal of the American Society for Mass Spectrometry 
1994; 5(9):867-869. 
 (94)  Davis MT, Stahl DC, Hefta SA, Lee TD. A Microscale Electrospray Interface for Online, 
Capillary Liquid-Chromatography Tandem Mass-Spectrometry of Complex Peptide 
Mixtures. Analytical Chemistry 1995; 67(24):4549-4556. 
 (95)  Gatlin CL, Kleemann GR, Hays LG, Link AJ, Yates JR. Protein identification at the low 
femtomole level from silver-stained gels using a new fritless electrospray interface for liquid 
chromatography microspray and nanospray mass spectrometry. Analytical Biochemistry 
1998; 263(1):93-101. 
 (96)  de la Mora JF. Electrospray ionization of large multiply charged species proceeds via 
Dole's charged residue mechanism. Analytica Chimica Acta 2000; 406(1):93-104. 
 (97)  Scott RPW. Modern Liquid-Chromatography. Chemical Society Reviews 1992; 21(2):137-
145. 
 (98)  van Deemter J.J., Zuiderweg F.J., Klinkenberg A. Longitudinal diffusion and resistance to 
mass transfer as causes of nonideality in chromatography. Chemical Engineering Science 
5, 271-289. 1956.  
 (99)  Schneiderheinze J, Walden Z, Dufleld R, Demarest C. Rapid online proteolytic mapping of 
PEGylated rhGH for identity confirmation, quantitation of methionine oxidation and 
quantitation of UnPEGylated N-terminus using HPLC with UV detection. Journal of 
Chromatography B 2009; 877(31):4065-4070. 
 (100)  Eggink M, Romero W, Vreuls RJ, Lingeman H, Niessen WMA, Irth H. Development and 
optimization of a system for comprehensive two-dimensional liquid chromatography with 
UV and mass spectrometric detection for the separation of complex samples by multi-step 
gradient elution. Journal of Chromatography A 2008; 1188(2):216-226. 
 (101)  Qiao XQ, Wang L, Ma JF, Deng QL, Liang Z, Zhang LH et al. High sensitivity analysis of 
water-soluble, cyanine dye labeled proteins by high-performance liquid chromatography 
with fluorescence detection. Analytica Chimica Acta 2009; 640(1-2):114-120. 
 (102)  Hirter P, Walther HJ, Datwyler P. Micro Column Liquid-Chromatography Mass-
Spectrometry Using A Capillary Interface. Journal of Chromatography 1985; 323(1):89-98. 
 (103)  Apffel JA, Brinkman UAT, Frei RW, Evers EAIM. Gas-Nebulized Direct Liquid Introduction 
Interface for Liquid-Chromatography Mass-Spectrometry. Analytical Chemistry 1983; 
55(14):2280-2284. 
 (104)  Erni F. Liquid Chromatography-Mass Spectrometry in the Pharmaceutical-Industry - 
Objectives and Needs. Journal of Chromatography 1982; 251(2):141-151. 
 (105)  Noga M, Sucharski F, Suder P, Silberring J. A practical guide to nano-LC troubleshooting. 
Journal of Separation Science 2007; 30:2179-2189. 
235 
 (106)  Wolters DA, Washburn MP, Yates JR. An automated multidimensional protein identification 
technology for shotgun proteomics. Analytical Chemistry 2001; 73(23):5683-5690. 
 (107)  Huang YF, Huang CC, Hu CC, Chang HT. Capillary electrophoresis-based separation 
techniques for the analysis of proteins. Electrophoresis 2006; 27(18):3503-3522. 
 (108)  Jabeen R, Payne D, Wiktorowcz J, Mohammad A, Petersen J. Capillary electrophoresis 
and the clinical laboratory. Electrophoresis 2006; 27(12):2413-2438. 
 (109)  Hutterer K, Dolnik V. Capillary electrophoresis of proteins 2001-2003. Electrophoresis 
2003; 24(22-23):3998-4012. 
 (110)  Hapuarachchi S, Janaway GA, Aspinwall CA. Capillary electrophoresis with a UV light-
emitting diode source for chemical monitoring of native and derivatized fluorescent 
compounds. Electrophoresis 2006; 27(20):4052-4059. 
 (111)  Kolch W, Neususs C, Peizing M, Mischak H. Capillary electrophoresis - Mass spectrometry 
as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrometry 
Reviews 2005; 24(6):959-977. 
 (112)  Mischak H, Kaiser T, Walden M, Hillmann M, Wittke S, Herrmann A et al. Proteomic 
analysis for the assessment of diabetic renal damage in humans. Clinical Science 2004; 
107(5):485-495. 
 (113)  Wittke S, Haubitz M, Walden M, Rohde F, Schwarz A, Mengel M et al. Detection of acute 
tubulointerstitial rejection by proteomic analysis of urinary samples in renal transplant 
recipients. American Journal of Transplantation 2005; 5(10):2479-2488. 
 (114)  Kolch W, Neususs C, Peizing M, Mischak H. Capillary electrophoresis - Mass spectrometry 
as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrometry 
Reviews 2005; 24(6):959-977. 
 (115)  Meier M, Kaiser T, Herrmann A, Knueppel S, Hillmann M, Koester P et al. Identification of 
urinary protein pattern in Type 1 diabetic adolescents with early diabetic nephropathy by a 
novel combined proteome analysis. Journal of Diabetes and Its Complications 2005; 
19(4):223-232. 
 (116)  Ramstrom M, Bergquist J. Miniatuized proteomics and pepitdomics using capillary liquid 
separation and high mass spectrometry. Febs Letters 2004; 567(1):92-95. 
 (117)  Marouga R, David S, Hawkins E. The development of the DIGE system: 2D fluorescence 
difference gel analysis technology. Analytical and Bioanalytical Chemistry 2005; 
382(3):669-678. 
 (118)  Shaw J, Rowlinson R, Nickson J, Stone T, Sweet A, Williams K et al. Evaluation of 
saturation labelling two-dimensional difference gel electrophoresis fluorescent dyes. 
Proteomics 2003; 3(7):1181-1195. 
 (119)  Steinberg TH, Jones LJ, Haugland RP, Singer VL. SYPRO Orange and SYPRO Red 
protein gel stains: One-step fluorescent staining of denaturing gels for detection of 
nanogram levels of protein. Analytical Biochemistry 1996; 239(2):223-237. 
 (120)  Tonge R, Shaw J, Middleton B, Rowlinson R, Rayner S, Young J et al. Validation and 
development of fluorescence two-dimensional differential gel electrophoresis proteomics 
technology. Proteomics 2001; 1(3):377-396. 
 (121)  Wheelock AM, Morin D, Bartosiewicz M, Buckpitt AR. Use of a fluorescent internal protein 
standard to achieve quantitative two-dimensional gel electrophoresis. Proteomics 2006; 
6(5):1385-1398. 
 (122)  Chen DY, Dovichi NJ. Yoctomole Detection Limit by Laser-Induced Fluorescence in 
Capillary Electrophoresis. Journal of Chromatography B-Biomedical Applications 1994; 
657(2):265-269. 
236 
 (123)  Zhao JY, Chen DY, Dovichi NJ. Low-Cost Laser-Induced Fluorescence Detector for 
Micellar Capillary Zone Electrophoresis - Detection at the Zeptomol Level of 
Tetramethylrhodamine Thiocarbamyl Amino-Acid Derivatives. Journal of Chromatography 
1992; 608(1-2):117-120. 
 (124)  Wu SO, Dovichi NJ. Capillary Zone Electrophoresis Separation and Laser-Induced 
Fluorescence Detection of Zeptomole Quantities of Fluorescein Thiohydantoin Derivatives 
of Amino-Acids. Talanta 1992; 39(2):173-178. 
 (125)  Weiss S. Fluorescence spectroscopy of single biomolecules. Science 1999; 
283(5408):1676-1683. 
 (126)  Kinsey JL. Laser-Induced Fluorescence. Annual Review of Physical Chemistry 1977; 
28:349-372. 
 (127)  Vrabel P, Taborsky P, Ryvolova M, Havel J, Preisler J. Sensitive detection and separation 
of fluorescent derivatives using capillary electrophoresis with laser-induced fluorescence 
detection with 532 nm Nd : YAG laser. Journal of Luminescence 2006; 118(2):283-292. 
 (128)  Mujumdar SR, Mujumdar RB, Grant CM, Waggoner AS. Cyanine-labeling reagents: 
Sulfobenzindocyanine succinimidyl esters. Bioconjugate Chemistry 1996; 7(3):356-362. 
 (129)  Holler MG, Campo LF, Brandelli A, Stefani V. Synthesis and spectroscopic characterisation 
of 2-(2 '-hydroxyphenyl)benzazole isothiocyanates as new fluorescent probes for proteins. 
Journal of Photochemistry and Photobiology A-Chemistry 2002; 149(1-3):217-225. 
 (130)  Smith SN, Steer RP. The photophysics of Lissamine rhodamine-B sulphonyl chloride in 
aqueous solution: implications for fluorescent protein-dye conjugates. Journal of 
Photochemistry and Photobiology A-Chemistry 2001; 139(2-3):151-156. 
 (131)  Zhao SL, Yuan HY, Xiao D. Optical fiber light-emitting diode-induced fluorescence 
detection for capillary electrophoresis. Electrophoresis 2006; 27(2):461-467. 
 (132)  McKeon J, Khaledi MG. Quantitative nuclear and cytoplasmic localization of antisense 
oligonucleotides by capillary electrophoresis with laser-induced fluorescence detection. 
Electrophoresis 2001; 22(17):3765-3770. 
 (133)  Khan HA. Detection and semi-quantitative determination of low abundance GFAP mRNA in 
mouse brain by capillary electrophoresis coupled with laser-induced fluorescence. Brain 
Research Protocols 2004; 14(1):13-17. 
 (134)  Roe MR, Griffin TJ. Gel-free mass spectrometry-based high throughput proteomics: Tools 
for studying biological response of proteins and proteomes. Proteomics 2006; 6(17):4678-
4687. 
 (135)  Kolkman A, Dirksen EHC, Slijper M, Heck AJR. Double standards in quantitative 
proteomics - Direct comparative assessment of difference in gel electrophoresis and 
metabolic stable isotope labeling. Molecular & Cellular Proteomics 2005; 4(3):255-266. 
 (136)  Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of 
complex protein mixtures using isotope-coded affinity tags. Nature Biotechnology 1999; 
17(10):994-999. 
 (137)  Gygi SP, Rist B, Griffin TJ, Eng J, Aebersold R. Proteome analysis of low-abundance 
proteins using multidimensional chromatography and isotope-coded affinity tags. Journal of 
Proteome Research 2002; 1(1):47-54. 
 (138)  Smolka MB, Zhou HL, Purkayastha S, Aebersold R. Optimization of the isotope-coded 
affinity tag-labeling procedure for quantitative proteome analysis. Analytical Biochemistry 
2001; 297(1):25-31. 
 (139)  Thompson A, Schafer J, Kuhn K, Kienle S, Schwarz J, Schmidt G et al. Tandem mass 
tags: A novel quantification strategy for comparative analysis of complex protein mixtures 
by MS/MS. Analytical Chemistry 2003; 75(8):1895-1904. 
237 
 (140)  Bottari P, Aebersold R, Turecek F, Gelb MH. Design and synthesis of visible isotope-coded 
affinity tags for the absolute quantification of specific proteins in complex mixtures. 
Bioconjugate Chemistry 2004; 15(2):380-388. 
 (141)  Jenkins RE, Kitteringham NR, Hunter CL, Webb S, Hunt TJ, Elsby R et al. Relative and 
absolute quantitative expression profiling of cytochromes P450 using isotope-coded affinity 
tags. Proteomics 2006; 6(6):1934-1947. 
 (142)  Qu J, Straubinger RM. Improved sensitivity for quantification of proteins using triply 
charged cleavable isotope-coded affinity tag peptides. Rapid Communications in Mass 
Spectrometry 2005; 19(19):2857-2864. 
 (143)  Wu WW, Wang GH, Baek SJ, Shen RF. Comparative study of three proteomic quantitative 
methods, DIGE, cICAT, and iTRAQ, using 2D gel- or LC-MALDI TOF/TOF. Journal of 
Proteome Research 2006; 5(3):651-658. 
 (144)  Ross PL, Huang YLN, Marchese JN, Williamson B, Parker K, Hattan S et al. Multiplexed 
protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging 
reagents. Molecular & Cellular Proteomics 2004; 3(12):1154-1169. 
 (145)  Zieske LR. A perspective on the use of iTRAQ (TM) reagent technology for protein 
complex and profiling studies. Journal of Experimental Botany 2006; 57(7):1501-1508. 
 (146)  Mann M. Functional and quantitative proteomics using SILAC. Nature Reviews Molecular 
Cell Biology 2006; 7(12):952-958. 
 (147)  Blagoev B, Kratchmarova I, Ong SE, Nielsen M, Foster LJ, Mann M. A proteomics strategy 
to elucidate functional protein-protein interactions applied to EGF signaling. Nature 
Biotechnology 2003; 21(3):315-318. 
 (148)  Ong SE, Kratchmarova I, Mann M. Properties of C-13-substituted arginine in stable isotope 
labeling by amino acids in cell culture (SILAC). Journal of Proteome Research 2003; 
2(2):173-181. 
 (149)  Ong SE, Foster LJ, Mann M. Mass spectrometric-based approaches in quantitative 
proteomics. Methods 2003; 29(2):124-130. 
 (150)  Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A et al. Stable 
isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach 
to expression proteomics. Molecular & Cellular Proteomics 2002; 1(5):376-386. 
 (151)  Molina H, Parmigiani G, Pandey A. Assessing reproducibility of a protein dynamics study 
using in vivo labeling and liquid chromatography tandem mass spectrometry. Analytical 
Chemistry 2005; 77(9):2739-2744. 
 (152)  Bantscheff M, Dumpelfeld B, Kuster B. Femtomol sensitivity post-digest O-18 labeling for 
relative quantification of differential protein complex composition. Rapid Communications in 
Mass Spectrometry 2004; 18(8):869-876. 
 (153)  Sakai J, Kojima S, Yanagi K, Kanaoka M. O-18-labeling quantitative proteomics using an 
ion trap mass spectrometer. Proteomics 2005; 5(1):16-23. 
 (154)  Lee YH, Han H, Chang SB, Lee SW. Isotope-coded N-terminal sulfonation of peptides 
allows quantitative proteomic analysis with increased de novo peptide sequencing 
capability. Rapid Communications in Mass Spectrometry 2004; 18(24):3019-3027. 
 (155)  Wienkoop S, Larrainzar E, Niemann M, Gonzalez EM, Lehmann U, Weckwerth W. Stable 
isotope-free quantitative shotgun proteomics combined with sample pattern recognition for 
rapid diagnostics. Journal of Separation Science 2006; 29(18):2793-2801. 
 (156)  Roy SM, Anderle M, Lin H, Becker CH. Differential expression profiling of serum proteins 
and metabolites for biomarker discovery. International Journal of Mass Spectrometry 2004; 
238(2):163-171. 
238 
 (157)  Silva JC, Denny R, Dorschel CA, Gorenstein M, Kass IJ, Li GZ et al. Quantitative 
proteomic analysis by accurate mass retention time pairs. Analytical Chemistry 2005; 
77(7):2187-2200. 
 (158)  Schmidt A, Karas M, Dulcks T. Effect of different solution flow rates on analyte ion signals 
in nano-ESI MS, or: When does ESI turn into nano-ESI? Journal of the American Society 
for Mass Spectrometry 2003; 14(5):492-500. 
 (159)  Shen YF, Zhao R, Berger SJ, Anderson GA, Rodriguez N, Smith RD. High-efficiency 
nanoscale liquid chromatography coupled on-line with mass spectrometry using 
nanoelectrospray ionization for proteomics. Analytical Chemistry 2002; 74(16):4235-4249. 
 (160)  Old WM, Meyer-Arendt K, Aveline-Wolf L, Pierce KG, Mendoza A, Sevinsky JR et al. 
Comparison of label-free methods for quantifying human proteins by shotgun proteomics. 
Molecular & Cellular Proteomics 2005; 4(10):1487-1502. 
 (161)  America AHP, Cordewener JHG, van Geffen MHA, Lommen A, Vissers JPC, Bino RJ et al. 
Alignment and statistical difference analysis of complex peptide data sets generated by 
multidimensional LC-MS. Proteomics 2006; 6(2):641-653. 
 (162)  Liu T, Qian WJ, Strittmatter EF, Camp DG, Anderson GA, Thrall BD et al. High-throughput 
comparative proteome analysis using a quantitative cysteinyl-peptide enrichment 
technology. Analytical Chemistry 2004; 76(18):5345-5353. 
 (163)  Wang GH, Wu WW, Zeng WH, Chou CL, Shen RF. Label-free protein quantification using 
LC-coupled ion trap or FT mass spectrometry: Reproducibility, linearity, and application 
with complex proteomes. Journal of Proteome Research 2006; 5(5):1214-1223. 
 (164)  America AHP, Cordewener JHG. Comparative LC-MS: A landscape of peaks and valleys. 
Proteomics 2008; 8(4):731-749. 
 (165)  Simpson KL, Whetton AD, Dive C. Quantitative mass spectrometry-based techniques for 
clinical use: Biomarker identification and quantification. Journal of Chromatography B-
Analytical Technologies in the Biomedical and Life Sciences 2009; 877(13):1240-1249. 
 (166)  Ru QHC, Zhu LWA, Silberman J, Shriver CD. Label-free semiquantitative peptide feature 
profiling of human breast cancer and breast disease sera via two-dimensional liquid 
chromatography-mass spectrometry. Molecular & Cellular Proteomics 2006; 5(6):1095-
1104. 
 (167)  Patwardhan AJ, Strittmatter EF, David GC, Smith RD, Pallavicini MG. Quantitative 
proteome analysis of breast cancer cell lines using O-18-labeling and an accurate mass 
and time tag strategy. Proteomics 2006; 6(9):2903-2915. 
 (168)  Vissers JPC, Langridge JI, Aerts JMFG. Analysis and quantification of diagnostic serum 
markers and protein signatures for Gaucher disease. Molecular & Cellular Proteomics 
2007; 6(5):755-766. 
 (169)  Kemperman RFJ, Horvatovich PL, Hoekman B, Reijmers TH, Muskiet FAJ, Bischoff R. 
Comparative urine analysis by liquid chromatography-mass spectrometry and multivariate 
statistics: Method development, evaluation, and application to proteinuria. Journal of 
Proteome Research 2007; 6(1):194-206. 
 (170)  Huang JTJ, McKenna T, Hughes C, Leweke FM, Schwarz E, Bahn S. CSF biomarker 
discovery using label-free nano-LC-MS based proteomic profiling: Technical aspects. 
Journal of Separation Science 2007; 30(2):214-225. 
 (171)  Metz TO, Qian WJ, Jacobs JM, Gritsenko MA, Moore RJ, Polpitiya AD et al. Application of 
proteomics in the discovery of candidate protein biomarkers in a diabetes autoantibody 
standardization program sample subset. Journal of Proteome Research 2008; 7(2):698-
707. 
 (172)  Canas B, Pineiro C, Calvo E, Lopez-Ferrer D, Gallardo JM. Trends in sample preparation 
for classical and second generation proteomics. Journal of Chromatography A 2007; 
1153(1-2):235-258. 
239 
 (173)  Tantipaiboonwong P, Sinchaikul S, Sriyam S, Phutrakul S, Chen ST. Different techniques 
for urinary protein analysis of normal and lung cancer patients. Proteomics 2005; 
5(4):1140-1149. 
 (174)  Zellner M, Winkler W, Hayden H, Diestinger M, Eliasen M, Gesslbauer B et al. Quantitative 
validation of different protein precipitation methods in proteome analysis of blood platelets. 
Electrophoresis 2005; 26(12):2481-2489. 
 (175)  Huber LA, Pfaller K, Vietor I. Organelle proteomics - Implications for subcellular 
fractionation in proteomics. Circulation Research 2003; 92(9):962-968. 
 (176)  Klose J, Link A. Fractionated extraction of total tissue proteins from mouse and human for 
2-D electrophoresis. Methods in Molecular Biology; 2-D proteome analysis protocols 
1999;67-85. 
 (177)  Pasquali C, Fialka I, Huber LA. Subcellular fractionation, electromigration analysis and 
mapping of organelles. Journal of Chromatography B-Analytical Technologies in the 
Biomedical and Life Sciences 1999; 722(1-2):89-102. 
 (178)  Stasyk T, Huber LA. Zooming in: Fractionation strategies in proteomics. Proteomics 2004; 
4(12):3704-3716. 
 (179)  Wu CC, MacCoss MJ, Mardones G, Finnigan C, Mogelsvang S, Yates JR et al. Organellar 
proteomics reveals Golgi arginine dimethylation. Molecular Biology of the Cell 2004; 
15(6):2907-2919. 
 (180)  Rice GE, Georgiou HM, Ahmed N, Shi G, Kruppa G. Translational proteomics: Developing 
a predictive capacity - A review. Placenta 2006; 27:S76-S86. 
 (181)  Zhang X, Leung SM, Morris CR, Shigenaga MK. Evaluation of a Novel, Integrated 
Approach Using Functionalized Magnetic Beads, Bench-Top MALDI-TOF-MS with 
Prestructured Sample Supports, and Pattern Recognition Software for Profiling Potential 
Biomarkers in Human Plasma. J Biomol Tech 2004; 15(3):167-175. 
 (182)  Merchant M, Weinberger SR. Recent advancements in surface-enhanced laser 
desorption/ionization-time of flight-mass spectrometry. Electrophoresis 2000; 21(6):1164-
1177. 
 (183)  Luque-Garcia JL, Neubert TA. Sample preparation for serum/plasma profiling and 
biomarker identification by mass spectrometry. Journal of Chromatography A 2007; 
1153(1-2):259-276. 
 (184)  Tammen H, Schulte L, Hess R, Menzel C, Kellmann M, Mohring T et al. Peptidomic 
analysis of human blood specimens: Comparison between plasma specimens and serum 
by differential peptide display. Proteomics 2005; 5(13):3414-3422. 
 (185)  Tirumalai RS, Chan KC, Prieto DA, Issaq HJ, Conrads TP, Veenstra TD. Characterization 
of the low molecular weight human serum proteome. Molecular & Cellular Proteomics 
2003; 2(10):1096-1103. 
 (186)  Whiteaker JR, Zhang HD, Eng JK, Fang RH, Piening BD, Feng LC et al. Head-to-head 
comparison of serum fractionation techniques. Journal of Proteome Research 2007; 
6(2):828-836. 
 (187)  Granger J, Siddiqui J, Copeland S, Remick D. Albumin depletion of human plasma also 
removes low abundance proteins including the cytokines. Proteomics 2005; 5(18):4713-
4718. 
 (188)  Zhang H, Yi EC, Li XJ, Mallick P, Kelly-Spratt KS, Masselon CD et al. High throughput 
quantitative analysis of serum proteins using glycopeptide capture and liquid 
chromatography mass spectrometry. Molecular & Cellular Proteomics 2005; 4(2):144-155. 
 (189)  Zhang H, Li XJ, Martin DB, Aebersold R. Identification and quantification of N-linked 
glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. 
Nature Biotechnology 2003; 21(6):660-666. 
240 
 (190)  Roth J. Protein N-glycosylation along the secretory pathway: Relationship to organelle 
topography and function, protein quality control, and cell interactions. Chemical Reviews 
2002; 102(2):285-303. 
 (191)  Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of 
Disease Study. Lancet 1997; 349(9061):1269-1276. 
 (192)  Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet 2008; 371(9624):1612-1623. 
 (193)  Bonita R. Epidemiology of Stroke. Lancet 1992; 339(8789):342-344. 
 (194)  Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL. Global and regional burden of 
disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 
367(9524):1747-1757. 
 (195)  Heart and Stroke Facts Statistics: Dallas: American Heart Association. American Heart 
Association . 1997.  
 
 (196)  Rothwell PM. The high cost of not funding stroke research: a comparison with heart 
disease and cancer. Lancet 2001; 357(9268):1612-1616. 
 (197)  Whisnant JP. Modeling of risk factors for ischemic stroke - The Willis Lecture. Stroke 1997; 
28(9):1840-1844. 
 (198)  Yusuf S, Hawken S, Ounpuu S. Effect of potentially modifiable risk factors associated with 
myocardial infarction in 52 countries (the INTERHEART study): case-control study (vol 
364, pg 937, 2004). Lancet 2004; 364(9449):1938. 
 (199)  Fiebach JB, Schellinger PD, Jansen O, Meyer M, Wilde P, Bender J et al. CT and 
diffusion-weighted MR imaging in randomized order - Diffusion-weighted imaging results in 
higher accuracy and lower interrater variability in the diagnosis of hyperacute ischemic 
stroke. Stroke 2002; 33(9):2206-2210. 
 (200)  Auer RN, Sutherland GR. Primary intracerebral hemorrhage: Pathophysiology. Canadian 
Journal of Neurological Sciences 2005; 32:S3-S12. 
 (201)  Mead GE, Wardlaw JM, Dennis MS, Lewis SC. Extensive haemorrhagic transformation of 
infarct: might it be an important cause of primary intracerebral haemorrhage? Age and 
Ageing 2002; 31(6):429-433. 
 (202)  Thrift AG, Donnan GA, Mcneil JJ. Epidemiology of intracerebral hemorrhage. 
Epidemiologic Reviews 1995; 17(2):361-381. 
 (203)  Thrift AG, Dewey HM, Macdonell RAL, Mcneil JJ, Donnan GA. Incidence of the major 
stroke subtypes - Initial findings from the North East Melbourne Stroke Incidence Study 
(NEMESIS). Stroke 2001; 32(8):1732-1738. 
 (204)  Fisher M, Garcia JH. Evolving stroke and the ischemic penumbra. Neurology 1996; 
47(4):884-888. 
 (205)  Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated 
view. Trends in Neurosciences 1999; 22(9):391-397. 
 (206)  Fisher M. The ischemic penumbra: Identification, evolution and treatment concepts. 
Cerebrovascular Diseases 2004; 17:1-6. 
 (207)  Hankey GJ, Jamrozik K, Broadhurst RJ, Forbes S, Burvill PW, Anderson CS et al. Long-
term risk of first recurrent stroke in the Perth Community Stroke Study. Stroke 1998; 
29(12):2491-2500. 
 (208)  Weimar C, Ziegler A, Konig IR, Diener HC, German Stroke SC. Predicting functional 
outcome and survival after acute ischemic stroke. Journal of Neurology 2002; 249(7):888-
895. 
241 
 (209)  Donnan GA, Omalley HM, Quang L, Hurley S, Bladin PF. The Capsular Warning 
Syndrome - Pathogenesis and Clinical-Features. Neurology 1993; 43(5):957-962. 
 (210)  Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency 
department diagnosis of TIA. Jama-Journal of the American Medical Association 2000; 
284(22):2901-2906. 
 (211)  Coull AJ, Lovett JK, Rothwell PM, Oxford VS. Population based study of early risk of stroke 
after transient ischaemic attack or minor stroke: implications for public education and 
organisation of services. British Medical Journal 2004; 328(7435):326-328. 
 (212)  Rothwell PM, Buchan A, Johnston SC. Recent advances in management of transient 
ischaemic attacks and minor ischaemic strokes. Lancet Neurology 2006; 5(4):323-331. 
 (213)  Coutts SB, Simon JE, Eliasziw M, Sohn CH, Hill MD, Barber PA et al. Triaging transient 
ischemic attack and minor stroke patients using acute magnetic resonance imaging. 
Annals of Neurology 2005; 57(6):848-854. 
 (214)  Bonita R, Beaglehole R. Does treatment of hypertension explain the decline in mortality 
from stroke? British Medical Journal 292, 191-192. 1986.  
 (215)  Bornstein N, Silvestrelli G, Caso V, Parnetti L. Arterial hypertension and stroke prevention: 
An update. Clinical and Experimental Hypertension 2006; 28(3-4):317-326. 
 (216)  Bonita R, Beaglehole R. The Decline in Stroke Mortality - the Limited Role of 
Antihypertensive Therapy. New Zealand Medical Journal 1987; 100(828):454-456. 
 (217)  Neal B, MacMahon S, Chapman N, Cutler J, Fagard R, Neal B et al. Effects of ACE 
inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of 
prospectively designed overviews of randomised trials. Lancet 2000; 356(9246):1955-
1964. 
 (218)  Lawes CMM, Bennett DA, Feigin VL, Rodgers A. Blood pressure and stroke - An overview 
of published reviews (vol 35, pg 776, 2004). Stroke 2004; 35(4):1024-1033. 
 (219)  Taylor FC, Cohen H, Ebrahim S. Systematic review of long term anticoagulation or 
antiplatelet treatment in patients with non-rheumatic atrial fibrillation. British Medical 
Journal 2001; 322(7282):321-326. 
 (220)  Amarenco P, Labreuche J, Lavallee P, Touboul PJ. Statins in stroke prevention and carotid 
atherosclerosis - Systematic review and up-to-date meta-analysis. Stroke 2004; 
35(12):2902-2909. 
 (221)  Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE et al. A randomized trial 
of low-dose aspirin in the primary prevention of cardiovascular disease in women. New 
England Journal of Medicine 2005; 352(13):1293-1304. 
 (222)  A randomized trial of aspirin and sulfinpyrazone in threatened stroke. The Canadian 
Cooperative Study Group. New England Journal of Medicine 299, 53-59. 1978.  
 (223)  Sandercock P, Collins R, Counsell C, Farrell B, Peto R, Slattery J et al. The International 
Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither 
among 19 435 patients with acute ischaemic stroke. Lancet 1997; 349(9065):1569-1581. 
 (224)  CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with 
acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet 
1997; 349(9066):1641-1649. 
 (225)  Gilligan AK, Thrift AG, Sturm JW, Dewey HM, Macdonell RAL, Donnan GA. Stroke units, 
tissue plasminogen activator, aspirin and neuroprotection: Which stroke intervention could 
provide the greatest community benefit? Cerebrovascular Diseases 2005; 20(4):239-244. 
 (226)  De Cristobal J, Moro MA, Davalos A, Castillo J, Leza JC, Camarero J et al. 
Neuroprotective effect of aspirin by inhibition of glutamate release after permanent focal 
cerebral ischaemia in rats. Journal of Neurochemistry 2001; 79(2):456-459. 
242 
 (227)  Eur Stroke Prev Study Group. The European Stroke Prevention Study Esps Principal End-
Points. Lancet 1987; 2(8572):1351-1354. 
 (228)  Koudstaal PJ, Dehaene I, Dhooghe M, Marchau M, Vanzandijcke M, Delwaide C et al. 
Secondary Prevention in Nonrheumatic Atrial-Fibrillation After Transient Ischemic Attack 
Or Minor Stroke. Lancet 1993; 342(8882):1255-1262. 
 (229)  Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid 
stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl 
J Med 1991; 325(7):445-453. 
 (230)  Eur Carotid Surg Trialists' Collab Group. Mrc European Carotid Surgery Trial Interim 
Results for Symptomatic Patients with Severe 70-99 Percent Or with Mild 0-29 Percent 
Carotid Stenosis. Lancet 1991; 337(8752):1235-1243. 
 (231)  Gent M, Beaumont D, Blanchard J, Bousser MG, Coffman J, Easton JD et al. A 
randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic 
events (CAPRIE). Lancet 1996; 348(9038):1329-1339. 
 (232)  Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 
individuals with previous stroke or transient ischaemic attack. Lancet 2001; 
358(9287):1033-1041. 
 (233)  Heart Outcomes PE. Effects of ramipril on cardiovascular and microvascular outcomes in 
people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy (vol 
355, pg 253, 2000). Lancet 2000; 356(9232):860. 
 (234)  Amarenco P, Bogousslavsky J, Callahan A, Goldstein LB, Hennerici M, Rudolph AE et al. 
High-dose atorvastatin after stroke or transient ischemic attack. New England Journal of 
Medicine 2006; 355(6):549-559. 
 (235)  Ringleb PA, Allenberg J, Berger J, Bruckmann H, Eckstein HH, Fraedrich G et al. 30 day 
results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy 
in symptomatic patients: a randomised non-inferiority trial. Lancet 2006; 368(9543):1239-
1247. 
 (236)  Brown MM, Rogers J, Bland JM, CAVATAS I. Endovascular versus surgical treatment in 
patients with carotid stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty 
Study (CAVATAS): a randomised trial. Lancet 2001; 357(9270):1729-1737. 
 (237)  Mas J, Chatellier G, Beyssen B, Branchereau A, Moulin T, Becquemin JP et al. 
Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. New 
England Journal of Medicine 2006; 355(16):1660-1671. 
 (238)  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional 
treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK 
Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131):837-853. 
 (239)  Donnan GA, Adena MA, Omalley HM, Mcneil JJ, Doyle AE, Neill GC. Smoking As A Risk 
Factor for Cerebral-Ischemia. Lancet 1989; 2(8664):643-647. 
 (240)  Reynolds K, Lewis LB, Nolen JDL, Kinney GL, Sathya B, He J. Alcohol consumption and 
risk of stroke - A meta-analysis. Jama-Journal of the American Medical Association 2003; 
289(5):579-588. 
 (241)  He FJ, Nowson CA, MacGregor GA. Fruit and vegetable consumption and stroke: meta-
analysis of cohort studies. Lancet 2006; 367(9507):320-326. 
 (242)  Wendel-Vos GCW, Schuit AJ, Feskens EJM, Boshuizen HC, Verschuren WMM, Saris 
WHM et al. Physical activity and stroke. A meta-analysis of observational data. 
International Journal of Epidemiology 2004; 33(4):787-798. 
 (243)  Langhorne P, Williams BO, Gilchrist W, Howie K. Do Stroke Units Save Lives. Lancet 
1993; 342(8868):395-398. 
243 
 (244)  Langhorne P, Dey P, Woodman M, Kalra L, Wood-Dauphinee S, Patel N et al. Is stroke 
unit care portable? A systematic review of the clinical trials. Age and Ageing 2005; 
34(4):324-330. 
 (245)  Indredavik B, Bakke F, Slordahl SA, Rokseth R, Haheim LL. Treatment in a combined 
acute and rehabilitation stroke unit - Which aspects are most important? Stroke 1999; 
30(5):917-923. 
 (246)  Cadilhac DA, Ibrahim J, Pearce DC, Ogden KJ, McNeill J, Davis SM et al. Multicenter 
comparison of processes of care between Stroke Units and conventional care wards in 
Australia. Stroke 2004; 35(5):1035-1040. 
 (247)  Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP et al. Association 
of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS 
rt-PA stroke trials. Lancet 2004; 363(9411):768-774. 
 (248)  Frank JI. Large Hemispheric Infarction, Deterioration, and Intracranial-Pressure. Neurology 
1995; 45(7):1286-1290. 
 (249)  Davis SM, Broderick J, Hennerici M, Brun NC, Diringer MN, Mayer SA et al. Hematoma 
growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. 
Neurology 2006; 66(8):1175-1181. 
 (250)  Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN et al. Recombinant 
activated factor VII for acute intracerebral hemorrhage. New England Journal of Medicine 
2005; 352(8):777-785. 
 (251)  Smith WS, Sung G, Starkman S, Saver JL, Kidwell CS, Gobin YP et al. Safety and efficacy 
of mechanical embolectomy in acute ischemic stroke - Results of the MERCI trial. Stroke 
2005; 36(7):1432-1438. 
 (252)  Furlan AJ, Fisher M. Devices, drugs, and the Food and Drug Administration - Increasing 
implications for ischemic stroke. Stroke 2005; 36(2):398-399. 
 (253)  Fisher M, Stroke Therapy Acad Ind Roundtable. Enhancing the development and approval 
of acute stroke therapies - Stroke Therapy Academic Industry Roundtable. Stroke 2005; 
36(8):1808-1813. 
 (254)  Chaurand P, Stoeckli M, Caprioli RM. Direct profiling of proteins in biological tissue 
sections by MALDI mass spectrometry. Analytical Chemistry 1999; 71(23):5263-5270. 
 (255)  Stoeckli M, Chaurand P, Hallahan DE, Caprioli RM. Imaging mass spectrometry: A new 
technology for the analysis of protein expression in mammalian tissues. Nature Medicine 
2001; 7(4):493-496. 
 (256)  Chaurand P, Schwartz SA, Caprioli RM. Imaging mass spectrometry: a new tool to 
investigate the spatial organization of peptides and proteins in mammalian tissue sections. 
Current Opinion in Chemical Biology 2002; 6(5):676-681. 
 (257)  Chaurand P, Caprioli RM. Direct profiling and imaging of peptides and proteins from 
mammalian cells and tissue sections by mass spectrometry. Electrophoresis 2002; 
23(18):3125-3135. 
 (258)  Murphy RC, Hankin JA, Barkley RM. Imaging of lipid species by MALDI mass 
spectrometry. Journal of Lipid Research 2009; 50:S317-S322. 
 (259)  Andren P. Frontier and perspectives - Specific and sensitive identification of peptides using 
peptidomics and MALDI imaging mass spectrometry. Journal of Peptide Science 2008; 
14(8):40. 
 (260)  Goodwin RJA, Pennington SR, Pitt AR. Protein and peptides in pictures: Imaging with 
MALDI mass spectrometry. Proteomics 2008; 8(18):3785-3800. 
 (261)  Cornett DS, Mobley JA, Dias EC, Andersson M, Arteaga CL, Sanders ME et al. A novel 
histology-directed strategy for MALDI-MS tissue profiling that improves throughput and 
244 
cellular specificity in human breast cancer. Molecular & Cellular Proteomics 2006; 
5(10):1975-1983. 
 (262)  Meistermann H, Norris JL, Aerni HR, Cornett DS, Friedlein A, Erskine AR et al. Biomarker 
discovery by imaging mass spectrometry - Transthyretin is a biomarker for gentamicin-
induced nephrotoxicity in rat. Molecular & Cellular Proteomics 2006; 5(10):1876-1886. 
 (263)  Skold K, Svensson M, Nilsson A, Zhang XQ, Nydahl K, Caprioli RM et al. Decreased 
striatal levels of PEP-19 following MPTP lesion in the mouse. Journal of Proteome 
Research 2006; 5(2):262-269. 
 (264)  Chaurand P, Rahman MA, Hunt T, Mobley JA, Gu G, Latham JC et al. Monitoring mouse 
prostate development by profiling and imaging mass spectrometry. Molecular & Cellular 
Proteomics 2008; 7(2):411-423. 
 (265)  Shimma S, Sugiura Y, Hayasaka T, Hoshikawa Y, Noda T, Setou M. MALDI-based 
imaging mass spectrometry revealed abnormal distribution of phospholipids in colon 
cancer liver metastasis. Journal of Chromatography B-Analytical Technologies in the 
Biomedical and Life Sciences 2007; 855(1):98-103. 
 (266)  Reyzer ML, Caprioli RM. MALDI mass spectrometry for direct tissue analysis: A new tool 
for biomarker discovery. Journal of Proteome Research 2005; 4(4):1138-1142. 
 (267)  Meistermann H, Norris JL, Aerni HR, Cornett DS, Friedlein A, Erskine AR et al. Biomarker 
discovery by imaging mass spectrometry - Transthyretin is a biomarker for gentamicin-
induced nephrotoxicity in rat. Molecular & Cellular Proteomics 2006; 5(10):1876-1886. 
 (268)  Schwartz SA, Weil RJ, Thompson RC, Shyr Y, Moore JH, Toms SA et al. Proteomic-based 
prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption 
ionization mass spectrometry. Cancer Research 2005; 65(17):7674-7681. 
 (269)  Roepstorff P, Fohlman J. Proposal for A Common Nomenclature for Sequence Ions in 
Mass-Spectra of Peptides. Biomedical Mass Spectrometry 1984; 11(11):601. 
 (270)  Barton SJ, Whittaker JC. Review of Factors That Influence the Abundance of Ions 
Produced in A Tandem Mass Spectrometer and Statistical Methods for Discovering These 
Factors. Mass Spectrometry Reviews 2009; 28(1):177-187. 
 (271)  Chen R, Brentnall TA, Pan S, Cooke K, Moyes KW, Lane Z et al. Quantitative proteomics 
analysis reveals that proteins differentially expressed in chronic pancreatitis are also 
frequently involved in pancreatic cancer. Molecular & Cellular Proteomics 2007; 6(8):1331-
1342. 
 (272)  Kikuchi T, Carbone DP. Proteomics analysis in lung cancer: Challenges and opportunities. 
Respirology 2007; 12(1):22-28. 
 (273)  Lemhire R, Menguellet SA, Stauber J, Marchaudon V, Lucot JP, Collinet P et al. Specific 
MALDI imaging and profiling for biomarker hunting and validation: Fragment of the 11S 
proteasome activator complex, reg alpha fragment, is a new potential ovary cancer 
biomarker. Journal of Proteome Research 2007; 6(11):4127-4134. 
 (274)  Pan S, Shi M, Jin JH, Albin RL, Lieberman A, Gearing M et al. Proteomics identification of 
proteins in human cortex using multidimensional separations and MALDI tandem mass 
spectrometer. Molecular & Cellular Proteomics 2007; 6(10):1818-1823. 
 (275)  Goodwin RJA, Dungworth JC, Cobb SR, Pitt AR. Time-dependent evolution of tissue 
markers by MALDI-MS imaging. Proteomics 2008; 8(18):3801-3808. 
 (276)  Skold K, Svensson M, Norrman M, Sjogren B, Svenningsson P, Andren PE. The 
significance of biochemical and molecular sample integrity in brain proteomics and 
peptidomics: Stathmin 2-20 and peptides as sample quality indicators. Proteomics 2007; 
7(24):4445-4456. 
 (277)  Galli C, Racagni G. Use of Microwave Techniques to Inactivate Brain-Enzymes Rapidly. 
Methods in Enzymology 1982; 86:635-642. 
245 
 (278)  O'Callaghan JP, Sriram K. Focused microwave irradiation of the brain preserves in vivo 
protein phosphorylation: comparison with other methods of sacrifice and analysis of 
multiple phosphoproteins. Journal of Neuroscience Methods 2004; 135(1-2):159-168. 
 (279)  Theodorsson E, Stenfors C, Mathe AA. Microwave Irradiation Increases Recovery of 
Neuropeptides from Brain-Tissues. Peptides 1990; 11(6):1191-1197. 
 (280)  Mathe AA, Stenfors C, Brodin E, Theodorsson E. Neuropeptides in Brain - Effects of 
Microwave Irradiation and Decapitation. Life Sciences 1990; 46(4):287-293. 
 (281)  Nylander I, Stenfors C, Tanno K, Mathe AA, Terenius L. A comparison between microwave 
irradiation and decapitation: basal levels of dynorphin and enkephalin and the effect of 
chronic morphine treatment on dynorphin peptides. Neuropeptides 1997; 31(4):357-365. 
 (282)  Svensson M, Skold K, Svenningsson P, Andren PE. Peptidomics-based discovery of novel 
neuropeptides. Journal of Proteome Research 2003; 2(2):213-219. 
 (283)  Che FY, Lim J, Pan H, Biswas R, Fricker LD. Quantitative neuropeptidomics of microwave-
irradiated mouse brain and pituitary. Molecular & Cellular Proteomics 2005; 4(9):1391-
1405. 
 (284)  Mikesh LM, Ueberheide B, Chi A, Coon JJ, Syka JEP, Shabanowitz J et al. The utility of 
ETD mass spectrometry in proteomic analysis. Biochimica et Biophysica Acta-Proteins and 
Proteomics 2006; 1764(12):1811-1822. 
 (285)  Bakhtiar R, Guan ZQ. Electron capture dissociation mass spectrometry in characterization 
of peptides and proteins. Biotechnology Letters 2006; 28(14):1047-1059. 
 (286)  Goodwin RJA, Lang AM, Allingham H, Boren M, Pitt AR. Stopping the clock on proteomic 
degradation by heat treatment at the point of tissue excision. Proteomics 2010; 10(9):1751-
1761. 
 (287)  Olsen JV, Ong SE, Mann M. Trypsin cleaves exclusively C-terminal to arginine and lysine 
residues. Molecular & Cellular Proteomics 2004; 3(6):608-614. 
 (288)  Bensadek D, Monigatti F, Steen JAJ, Steen H. Why b, y's? Sodiation-induced tryptic 
peptide-like fragmentation of non-tryptic peptides. International Journal of Mass 
Spectrometry 2007; 268(2-3):181-189. 
 (289)  Mikesh LM, Ueberheide B, Chi A, Coon JJ, Syka JEP, Shabanowitz J et al. The utility of 
ETD mass spectrometry in proteomic analysis. Biochimica et Biophysica Acta-Proteins and 
Proteomics 2006; 1764(12):1811-1822. 
 (290)  Sun RX, Dong MQ, Chi H, Yang B, Xiu LY, Wang LH et al. ECD/ETD-based Tandem Mass 
Spectrometry in Proteomics. Progress in Biochemistry and Biophysics 2010; 37(1):94-102. 
 (291)  Jansson M, Moller M, Hederstedt L, James P. Charge-directed fragmentation of non-tryptic 
peptides. Molecular & Cellular Proteomics 2005; 4(8):S322. 
 (292)  Elliott WI. Systemic hypertension. Current Problems in Cardiology 2007; 32(4):201-259. 
 (293)  Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of 
hypertension: analysis of worldwide data. Lancet 2005; 365:217-223. 
 (294)  Kannel WB. Blood pressure as a cardiovascular risk factor - Prevention and treatment. 
Jama-Journal of the American Medical Association 1996; 275(20):1571-1576. 
 (295)  Lee MLT, Rosner BA, Weiss ST. Relationship of blood pressure to cardiovascular death: 
The effects of pulse pressure in the elderly. Annals of Epidemiology 1999; 9(2):101-107. 
 (296)  Staessen JA, Wang YG, Thijs L. Cardiovascular protection and blood pressure reduction: a 
meta-analysis. Lancet 2001; 358(9290):1305-1315. 
246 
 (297)  Kannel WB. Risk stratification in hypertension: New insights from the Framingham Study. 
American Journal of Hypertension 2000; 13(1):3S-10S. 
 (298)  Cheung BMY, Ong KL, Man YB, Lam KSL, Lau CP. Prevalence, awareness, treatment, 
and control of hypertension: United States National Health and Nutrition Examination 
Survey 2001-2002. J Clin Hypertens (Greenwich) 2006; 8(2):93-98. 
 (299)  Aram V.Chobanian M, George L.Bakris M, Henry R.Black M, William C.Cushman M, Lee 
A.Green MM, Joseph L.Izzo JM et al. The Seventh Report of the Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Journal of Americal 
Medical Association. In press. 
 (300)  Oparil S, Zaman A, Calhoun DA. Pathogenesis of hypertension. Annals of Internal 
Medicine 2003; 139(9):761-776. 
 (301)  De Wardener HE, Macgregor GA. Sodium and blood pressure. Current Opinion in 
Cardiology 2002; 17(4):360-367. 
 (302)  Mayer G. An update on the relationship between the kidney, salt and hypertension. Wien 
Med Wochenschr 2008; 158(13-14):365-369. 
 (303)  Meneton P, Jeunemaitre X, De Wardener HE, Macgregor GA. Links between dietary salt 
intake, renal salt handling, blood pressure, and cardiovascular diseases. Physiological 
Reviews 2005; 85(2):679-715. 
 (304)  Koga Y, Hirooka Y, Araki S, Nozoe M, Kishi T, Sunagawa K. High Salt Intake Enhances 
Blood Pressure Increase during Development of Hypertension via Oxidative Stress in 
Rostral Ventrolateral Medulla of Spontaneously Hypertensive Rats. Hypertension 
Research 2008; 31(11):2075-2083. 
 (305)  Sanders PW. Dietary Salt Intake, Salt Sensitivity, and Cardiovascular Health. Hypertension 
2009; 53(3):442-445. 
 (306)  Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell 
2001; 104(4):545-556. 
 (307)  Blaustein MP, Zhang J, Chen L, Hamilton BP. How does salt retention raise blood 
pressure? American Journal of Physiology-Regulatory Integrative and Comparative 
Physiology 2006; 290(3):R514-R523. 
 (308)  Lohmeier TE, Hildebrandt DA, Warren S, May PJ, Cunningham JT. Recent insights into the 
interactions between the baroreflex and the kidneys in hypertension. American Journal of 
Physiology-Regulatory Integrative and Comparative Physiology 2005; 288(4):R828-R836. 
 (309)  Guyton AC, Coleman TG. Quantitative Analysis of Pathophysiology of Hypertension. 
Circulation Research 1969; 24(5S1):I1-&. 
 (310)  Hamlyn JM, Blaustein MP. Sodium-Chloride, Extracellular Fluid Volume, and Blood-
Pressure Regulation. American Journal of Physiology 1986; 251(4):F563-F575. 
 (311)  Freis ED. Mechanism of the Antihypertensive Effects of Diuretics Possible Role of Salt in 
Hypertension. Clinical Pharmacology & Therapeutics 1960; 1(3):337-344. 
 (312)  Curtis JJ, Luke RG, Dustan HP, Kashgarian M, Whelchel JD, Jones P et al. Remission of 
Essential-Hypertension After Renal-Transplantation. New England Journal of Medicine 
1983; 309(17):1009-1015. 
 (313)  Guidi E, Menghetti D, Milani S, Montagnino G, Palazzi P, Bianchi G. Hypertension may be 
transplanted with the kidney in humans: A long-term historical prospective follow-up of 
recipients grafted with kidneys coming from donors with or without hypertension in their 
families. Journal of the American Society of Nephrology 1996; 7(8):1131-1138. 
 (314)  Rettig R, Grisk O. The kidney as a determinant of genetic hypertension - Evidence from 
renal transplantation studies. Hypertension 2005; 46(3):463-468. 
247 
 (315)  Nakasaki Y, Iwamoto T, Hanada H, Imagawa T, Shigekawa M. Cloning of the Rat Aortic 
Smooth-Muscle Na+/Ca-2+ Exchanger and Tissue-Specific Expression of Isoforms. 
Journal of Biochemistry 1993; 114(4):528-534. 
 (316)  O'Shaughnessy KM, Karet FE. Salt handling and hypertension. Journal of Clinical 
Investigation 2004; 113(8):1075-1081. 
 (317)  Takahashi N, Smithies O. Gene targeting approaches to analyzing hypertension. Journal of 
the American Society of Nephrology 1999; 10(7):1598-1605. 
 (318)  Feinleib M, Garrison RJ, Fabsitz R, Christian JC, Hrubec Z, Borhani NO et al. Nhlbi Twin 
Study of Cardiovascular-Disease Risk-Factors - Methodology and Summary of Results. 
American Journal of Epidemiology 1977; 106(4):284-295. 
 (319)  Longini IM, Higgins MW, Hinton PC, Moll PP, Keller JB. Environmental and Genetic 
Sources of Familial Aggregation of Blood-Pressure in Tecumseh, Michigan. American 
Journal of Epidemiology 1984; 120(1):131-144. 
 (320)  Johnson RJ, Rodriguez-Iturbe B, Nakagawa T, Kang DH, Feig DI, Herrera-Acosta J. Subtle 
renal injury is likely a common mechanism for salt-sensitive essential hypertension. 
Hypertension 2005; 45(3):326-330. 
 (321)  Sutherla DJ, Ruse JL, Laidlaw JC. Hypertension Increased Aldosterone Secretion and Low 
Plasma Renin Activity Relieved by Dexamethasone. Canadian Medical Association Journal 
1966; 95(22):1109-&. 
 (322)  Pascoe L, Curnow KM, Slutsker L, Rosler A, White PC. Mutations in the Human Cyp11B2 
(Aldosterone Synthase) Gene Causing Corticosterone Methyloxidase-Ii Deficiency. 
Proceedings of the National Academy of Sciences of the United States of America 1992; 
89(11):4996-5000. 
 (323)  New MI, Levine LS, Biglieri EG, Pareira J, Ulick S. Evidence for An Unidentified Steroid in 
A Child with Apparent Mineralocorticoid Hypertension. Journal of Clinical Endocrinology 
and Metabolism 1977; 44(5):924-933. 
 (324)  Mune T, Rogerson FM, Nikkila H, Agarwal AK, White PC. Human Hypertension Caused by 
Mutations in the Kidney Isozyme of 11-Beta-Hydroxysteroid Dehydrogenase. Nature 
Genetics 1995; 10(4):394-399. 
 (325)  Geller DS, Farhi A, Pinkerton N, Fradley M, Moritz M, Spitzer A et al. Activating 
mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 
2000; 289(5476):119-123. 
 (326)  Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and 
the risk of developing hypertension. Jama-Journal of the American Medical Association 
2003; 290(22):2945-2951. 
 (327)  Vasan RS, Evans JC, Larson MG, Wilson PWF, Meigs JB, Rifai N et al. Serum aldosterone 
and the incidence of hypertension in nonhypertensive persons. New England Journal of 
Medicine 2004; 351(1):33-41. 
 (328)  Wang TJ, Evans JC, Meigs JB, Rifai N, Fox CS, D'Agostino RB et al. Low-grade 
albuminuria and the risks of hypertension and blood pressure progression - Response. 
Circulation 2005; 112(9):E121. 
 (329)  Freitag MH, Larson MG, Levy D, Benjamin EJ, Wang TJ, Leip EP et al. Plasma brain 
natriuretic peptide levels and blood pressure tracking in the Framingham Heart Study. 
Hypertension 2003; 41(4):978-983. 
 (330)  Wang TJ, Gona P, Larson MG, Levy D, Benjamin EJ, Tofler GH et al. Multiple biomarkers 
and the risk of incident hypertension. Hypertension 2007; 49(3):432-438. 
 (331)  Carty DM, Siwy J, Brennand JE, Zurbig P, Mullen W, Franke J et al. Urinary Proteomics for 
Prediction of Preeclampsia. Hypertension 2011; 57(3):561-U387. 
248 
 (332)  Dayarathna MKDR, Hancock WS, Hincapie M. A two step fractionation approach for 
plasma proteomics using immunodepletion of abundant proteins and multi-lectin affinity 
chromatography: Application to the analysis of obesity, diabetes, and hypertension 
diseases. Journal of Separation Science 2008; 31(6-7):1156-1166. 
 (333)  Graham D, McBride MW, Gaasenbeek M, Gilday K, Beattie E, Miller WH et al. Candidate 
genes that determine response to salt in the stroke-prone spontaneously hypertensive rat - 
Congenic analysis. Hypertension 2007; 50:1134-1141. 
 (334)  Clark JS, Jeffs B, Davidson AO, Lee WK, Anderson NH, Bihoreau MT et al. Quantitative 
trait loci in genetically hypertensive rats - Possible sex specificity. Hypertension 1996; 
28(5):898-906. 
 (335)  Kerr S, Brosnan MJ, McIntyre M, Reid JL, Dominiczak AF, Hamilton CA. Superoxide anion 
production is increased in a model of genetic hypertension - Role of the endothelium. 
Hypertension 1999; 33(6):1353-1358. 
 (336)  Jeffs B, Negrin CD, Graham D, Clark JS, Anderson NH, Gauguier D et al. Applicability of a 
"speed" congenic strategy to dissect blood pressure quantitative trait loci on rat 
chromosome 2. Hypertension 2000; 35(1):179-187. 
 (337)  McBride MW, Carr FJ, Graham D, Anderson NH, Clark JS, Lee WK et al. Microarray 
analysis of rat chromosome 2 congenic strains. Hypertension 2003; 41(3):847-853. 
 (338)  McBride MW, Brosnan MJ, Mathers J, McLellan LI, Miller WH, Graham D et al. Reduction 
of Gstm1 expression in the stroke-prone spontaneously hypertension rat contributes to 
increased oxidative stress. Hypertension 2005; 45(4):786-792. 
 (339)  Lander ES, Schork NJ. Genetic Dissection of Complex Traits. Science 1994; 
265(5181):2037-2048. 
 (340)  Ransohoff DF. Opinion - Bias as a threat to the validity of cancer molecular-marker 
research. Nature Reviews Cancer 2005; 5(2):142-149. 
 (341)  Ransohoff DF. Opinion - Rules of evidence for cancer molecular-marker discovery and 
validation. Nature Reviews Cancer 2004; 4(4):309-314. 
 (342)  Pepe MS, Etzioni R, Feng ZD, Potter JD, Thompson ML, Thornquist M et al. Phases of 
biomarker development for early detection of cancer. Journal of the National Cancer 
Institute 2001; 93(14):1054-1061. 
 (343)  Anderson NL, Anderson NG. The human plasma proteome - History, character, and 
diagnostic prospects. Molecular & Cellular Proteomics 2002; 1(11):845-867. 
 (344)  Tam SW, Pirro J, Hinerfeld D. Depletion and fractionation technologies in plasma 
proteomic analysis. Expert Review of Proteomics 2004; 1(4):411-420. 
 (345)  Veenstra TD, Conrads TP, Hood BL, Avellino AM, Ellenbogen RG, Morrison RS. 
Biomarkers: Mining the biofluid proteome. Molecular & Cellular Proteomics 2005; 4(4):409-
418. 
 (346)  Echan LA, Tang HY, Ali-Khan N, Lee K, Speicher DW. Depletion of multiple high-
abundance proteins improves protein profiling capacities of human serum and plasma. 
Proteomics 2005; 5(13):3292-3303. 
 (347)  Ahmed N, Barker G, Oliva K, Garfin D, Talmadge K, Georgiou H et al. An approach to 
remove albumin for the proteomic analysis of low abundance biomarkers in human serum. 
Proteomics 2003; 3(10):1980-1987. 
 (348)  Steel LF, Trotter MG, Nakajima PB, Mattu TS, Gonye G, Block T. Efficient and specific 
removal of albumin from human serum samples. Molecular & Cellular Proteomics 2003; 
2(4):262-270. 
249 
 (349)  Adkins JN, Varnum SM, Auberry KJ, Moore RJ, Angell NH, Smith RD et al. Toward a 
human blood serum proteome - Analysis by multidimensional separation coupled with 
mass spectrometry. Molecular & Cellular Proteomics 2002; 1(12):947-955. 
 (350)  Bjorhall K, Miliotis T, Davidsson P. Comparison of different depletion strategies for 
improved resolution in proteomic analysis of human serum samples. Proteomics 2005; 
5(1):307-317. 
 (351)  Whiteaker JR, Zhang HD, Eng JK, Fang RH, Piening BD, Feng LC et al. Head-to-head 
comparison of serum fractionation techniques. Journal of Proteome Research 2007; 6:828-
836. 
 (352)  Castronovo V, Kischel P, Guillonneau F, de Leval L, Defechereux T, De Pauw E et al. 
Identification of specific reachable molecular targets in human breast cancer using a 
versatile ex vivo proteomic method. Proteomics 2007; 7(8):1188-1196. 
 (353)  Gronwall C, Sjoberg A, Ramstrom M, Hoidn-Guthenberg I, Hober S, Jonasson P et al. 
Affibody-mediated transferrin depletion for proteomics applications. Biotechnology Journal 
2007; 2(11):1389-1398. 
 (354)  Zolotarjova N, Martosella J, Nicol G, Bailey J, Boyes BE, Barrett WC. Differences among 
techniques for high-abundant protein depletion. Proteomics 2005; 5(13):3304-3313. 
 (355)  Brand J, Haslberger T, Zolg W, Pestlin G, Palme S. Depletion efficiency and recovery of 
trace markers from a multiparameter immunodepletion column. Proteomics 2006; 
6(11):3236-3242. 
 (356)  Gong Y, Li X, Yang B, Ying WT, Li D, Zhang YJ et al. Different immunoaffinity fractionation 
strategies to characterize the human plasma proteome. Journal of Proteome Research 
2006; 5(6):1379-1387. 
 (357)  Pernemalm M, Orre LM, Lengqvist J, Wikstrom P, Lewensohn R, Lehtio J. Evaluation of 
three principally different intact protein prefractionation methods for plasma biomarker 
discovery. Journal of Proteome Research 2008; 7(7):2712-2722. 
 (358)  Liu T, Qian WJ, Mottaz HM, Gritsenko MA, Norbeck AD, Moore RJ et al. Evaluation of 
multiprotein immunoaffinity subtraction for plasma proteomics and candidate biomarker 
discovery using mass spectrometry. Molecular & Cellular Proteomics 2006; 5(11):2167-
2174. 
 (359)  Huang L, Fang X. Immunoaffinity fractionation of plasma proteins by chicken IgY 
antibodies. Methods in Molecular Biology 2008;41-51. 
 (360)  Zolotarjova N, Mrozinski P, Chen H, Martosella J. Combination of affinity depletion of 
abundant proteins and reversed-phase fractionation in proteomic analysis of human 
plasma/serum. Journal of Chromatography A 2008; 1189(1-2):332-338. 
 (361)  Levin Y, Schwarz E, Wang L, Leweke FM, Bahn S. Label-free LC-MS/MS quantitative 
proteomics for large-scale biomarker discovery in complex samples. Journal of Separation 
Science 2007; 30:2198-2203. 
 (362)  Gao MX, Deng CH, Yu WJ, Zhang Y, Yang PY, Zhang XM. Large scale depletion of the 
high-abundance proteins and analysis of middle- and low-abundance proteins in human 
liver proteome by multidimensional liquid chromatography. Proteomics 2008; 8(5):939-947. 
 (363)  Sennels L, Salek M, Lomas L, Boschetti E, Righetti PG, Rappsilber J. Proteomic analysis 
of human blood serum using peptide library beads. Journal of Proteome Research 2007; 
6:4055-4062. 
 (364)  Jonasson T, Ohlin AK, Gottsater A, Hultberg B, Ohlin H. Plasma homocysteine and 
markers for oxidative stress and inflammation in patients with coronary artery disease - a 
prospective randomized study of vitamin supplementation. Clinical Chemistry and 
Laboratory Medicine 2005; 43(6):628-634. 
250 
 (365)  Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nature Reviews Cancer 
2003; 3(4):276-285. 
 (366)  Shi QL, Gibson GE. Oxidative stress and transcriptional regulation in Alzheimer disease. 
Alzheimer Disease & Associated Disorders 2007; 21(4):276-291. 
 (367)  Dalle-Donne I, Giustarini D, Colombo R, Rossi R, Milzani A. Protein carbonylation in 
human diseases. Trends in Molecular Medicine 2003; 9(4):169-176. 
 (368)  Mirzaei H, Baena B, Barbas C, Regnier F. Identification of oxidized proteins in rat plasma 
using avidin chromatography and tandem mass spectrometry. Proteomics 2008; 8(7):1516-
1527. 
 (369)  Liu T, Qian WJ, Strittmatter EF, Camp DG, Anderson GA, Thrall BD et al. High-throughput 
comparative proteome analysis using a quantitative cysteinyl-peptide enrichment 
technology. Analytical Chemistry 2004; 76(18):5345-5353. 
 (370)  Qiu RQ, Regnier FE. Comparative glycoproteomics of N-linked complex-type glycoforms 
containing sialic acid in human serum. Analytical Chemistry 2005; 77(22):7225-7231. 
 (371)  Kobata A, Amano J. Altered glycosylation of proteins produced by malignant cells, and 
application for the diagnosis and immunotherapyof tumours. Immunology and Cell Biology 
2005; 83(4):429-439. 
 (372)  Zhao J, Simeone DM, Heidt D, Anderson MA, Lubman DM. Comparative serum 
glycoproteomics using lectin selected sialic acid glycoproteins with mass spectrometric 
analysis: Application to pancreatic cancer serum. Journal of Proteome Research 2006; 
5(7):1792-1802. 
 (373)  Zhang H, Li XJ, Martin DB, Aebersold R. Identification and quantification of N-linked 
glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. 
Nature Biotechnology 2003; 21(6):660-666. 
 (374)  Larsen MR, Jensen SS, Jakobsen LA, Heegaard NHH. Exploring the sialiome using 
titanium dioxide chromatography and mass spectrometry. Molecular & Cellular Proteomics 
2007; 6:1778-1787. 
 (375)  Zhang QB, Tang N, Schepmoes AA, Phillips LS, Smith RD, Metz TO. Proteomic profiling of 
nonenzymatically glycated proteins in human plasma and erythrocyte membranes. Journal 
of Proteome Research 2008; 7(5):2025-2032. 
 (376)  Sun XS, Chiu JF, He QY. Application of immobilized metal affinity chromatography in 
proteomics. Expert Review of Proteomics 2005; 2(5):649-657. 
 (377)  Cheng AJ, Chen LC, Chien KY, Chen YJ, Chang JTC, Wang HM et al. Oral cancer plasma 
tumor marker identified with bead-based affinity-fractionated proteomic technology. Clinical 
Chemistry 2005; 51(12):2236-2244. 
 (378)  Navare A, Zhou M, McDonald J, Noriega FG, Sullards MC, Fernandez FM. Serum 
biomarker profiling by solid-phase extraction with particle-embedded micro tips and matrix-
assisted laser desorption/ionization mass spectrometry. Rapid Communications in Mass 
Spectrometry 2008; 22(7):997-1008. 
 (379)  Gatlin-Bunai CL, Cazares LH, Cooke WE, Semmes OJ, Malyarenko DI. Optimization of 
MALDI-TOF MS detection for enhanced sensitivity of affinity-captured proteins spanning a 
100 kDa mass range. Journal of Proteome Research 2007; 6:4517-4524. 
 (380)  Granger J, Siddiqui J, Copeland S, Remick D. Albumin depletion of human plasma also 
removes low abundance proteins including the cytokines. Proteomics 2005; 5(18):4713-
4718. 
 (381)  Tukey JW. Some Thoughts on Clinical-Trials, Especially Problems of Multiplicity. Science 
1977; 198(4318):679-684. 
251 
 (382)  Greenhalgh T. How to read a paper - Statistics for the non-statistician .2. ''significant'' 
relations and their pitfalls. British Medical Journal 1997; 315(7105):422-425. 
 (383)  Bland JM, Altman DG. Multiple Significance Tests - the Bonferroni Method .10. British 
Medical Journal 1995; 310(6973):170. 
 (384)  Perneger TV. What's wrong with Bonferroni adjustments. BMJ 1998; 316(7139):1236-
1238. 
 (385)  Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1990; 
1(1):43-46. 
 (386)  Pawitan Y, Michiels S, Koscielny S, Gusnanto A, Ploner A. False discovery rate, sensitivity 
and sample size for microarray studies. Bioinformatics 2005; 21(13):3017-3024. 
 (387)  Benjamini Y, Hochberg Y. Controlling the False Discovery Rate - A Practical and Powerful 
Approach to Multiple Testing. Journal of the Royal Statistical Society Series B-
Methodological 1995; 57(1):289-300. 
 (388)  Benjamini Y, Hochberg Y. On the adaptive control of the false discovery fate in multiple 
testing with independent statistics. Journal of Educational and Behavioral Statistics 2000; 
25(1):60-83. 
 (389)  Keselman HJ, Cribbie R, Holland B. Controlling the rate of Type I error over a large set of 
statistical tests. British Journal of Mathematical & Statistical Psychology 2002; 55:27-39. 
 (390)  Grant GR, Liu JM, Stoeckert CJ. A practical false discovery rate approach to identifying 
patterns of differential expression in microarray data. Bioinformatics 2005; 21(11):2684-
2690. 
 (391)  Hu JH, Zou F, Wright FA. Practical FDR-based sample size calculations in microarray 
experiments. Bioinformatics 2005; 21(15):3264-3272. 
 (392)  Jung SH. Sample size for FDR-control in microarray data analysis. Bioinformatics 2005; 
21(14):3097-3104. 
 (393)  Jung SH, Jang W. How accurately can we control the FDR in analyzing microarray data? 
Bioinformatics 2006; 22(14):1730-1736. 
 (394)  Li QB, Roxas BAP. An assessment of false discovery rates and statistical significance in 
label-free quantitative proteomics with combined filters. Bmc Bioinformatics 2009; 10. 
 (395)  Maurer MH, Feldmann RE, Bromme JO, Kalenka A. Comparison of statistical approaches 
for the analysis of proteome expression data of differentiating neural stem cells. Journal of 
Proteome Research 2005; 4(1):96-100. 
 (396)  Roxas BAP, Li QB. Significance analysis of microarray for relative quantitation of LC/MS 
data in proteomics. Bmc Bioinformatics 2008; 9. 
 (397)  Choi H, Fermin D, Nesvizhskii AI. Significance Analysis of Spectral Count Data in Label-
free Shotgun Proteomics. Molecular & Cellular Proteomics 2008; 7(12):2373-2385. 
 (398)  Breitling R, Herzyk P. Rank-based methods as a non-parametric alternative of the T-
statistic for the analysis of biological microarray data. Journal of Bioinformatics and 
Computational Biology 2005; 3(5):1171-1189. 
 (399)  Breitling R, Armengauda P, Amtmann A, partial-least square discriminant analysis Herzyk 
P. Rank products: a simple, yet powerful, new method to detect differentially regulated 
genes in replicated microarray experiments. FEBS letters 573, 83-92. 11-8-2004.  
 
 (400)  Nikkila H, Gitlin JD, Mullereberhard U. Rat Hemopexin - Molecular-Cloning, Primary 
Structural Characterization, and Analysis of Gene-Expression. Biochemistry 1991; 
30(3):823-829. 
 (401)  Mullereberhard U. Hemopexin. Methods in Enzymology 1988; 163:536-565. 
252 
 (402)  Lecam A, Pages G, Auberger P, Lecam G, Leopold P, Benarous R et al. Study of A 
Growth Hormone-Regulated Protein Secreted by Rat Hepatocytes - Cdna Cloning, Anti-
Protease Activity and Regulation of Its Synthesis by Various Hormones. Embo Journal 
1987; 6(5):1225-1232. 
 (403)  Ohkubo K, Ogata S, Misumi Y, Takami N, Ikehara Y. Molecular-Cloning and 
Characterization of Rat Contrapsin-Like Protease Inhibitor and Related Proteins. Journal of 
Biochemistry 1991; 109(2):243-250. 
 (404)  Chao J, Chai KX, Chen LM, Xiong W, Chao S, Woodleymiller C et al. Tissue Kallikrein-
Binding Protein Is A Serpin .1. Purification, Characterization, and Distribution in 
Normotensive and Spontaneously Hypertensive Rats. Journal of Biological Chemistry 
1990; 265(27):16394-16401. 
 (405)  Yoon JB, Towle HC, Seelig S. Growth-Hormone Induces 2 Messenger-Rna Species of the 
Serine Protease Inhibitor Gene Family in Rat-Liver. Journal of Biological Chemistry 1987; 
262(9):4284-4289. 
 (406)  Wang JY, Cheng KI, Yu FJ, Tsai HL, Huang TJ, Hsieh JS. Analysis of the correlation of 
plasma NO and ET-1 levels in rats with acute mesenteric ischemia. Journal of Investigative 
Surgery 2006; 19(3):155-161. 
 (407)  Huang JTJ, McKenna T, Hughes C, Leweke FM, Schwarz E, Bahn S. CSF biomarker 
discovery using label-free nano-LC-MS based proteomic profiling: Technical aspects. 
Journal of Separation Science 2007; 30(2):214-225. 
 
 
